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The purpose of this thesis was to investigate visual dysfunction arising from 
vigabatrin (VGB) toxicity: structural investigation utilising optical coherence 
tomography (OCT) and functional investigation using multifocal electrophysiology.
OCT of the retinal nerve fibre layer (RNFL) based upon a fixed diameter circle scan 
and enabling reference to the manufacturers’ large proprietary normative database, 
revealed a specific finding associated with vigabatrin-attributed visual field loss 
(VAVFL); namely, a characteristic pattern of nasal quadrant attenuation with a 
normal temporal quadrant thickness. This was present in all 11 individuals (including 
2 learning-disabled adults) with VAVFL. A further 4 of 16 (including 3 learning- 
disabled adults and three children) VGB-exposed individuals with normal visual 
fields (VGB-E) also manifested this pattern as did two of three individuals (one 
learning-disabled adult and two children) exposed to VGB but unable to undertake 
perimetry. The pattern was absent in all 13 individuals treated with non-gabaergic 
anti-epileptic drugs manifesting normal fields and in 9 normal children.
OCT is readily achievable in children as young as 3 years and in learning-disabled 
adults and should be essential for identifying VAVFL.
A re-analysis of RNFL thickness for quadrant/sector differences by OCT and by 
scanning laser ophthalmoscopy (Heidelberg Retinal Tomography (HRT)) on 13 
individuals with VAVFL, 8 VGB-E and 21 normal individuals previously published 
(Wild et al., 2006) confirmed the abnormal nasal/normal temporal pattern of 
attenuation.
Four children, exposed to VGB in utero, from three mothers (two with VAVFL and 
nasal RNFL attenuation) yielded normal visual fields and RNFL thicknesses.
The amplitudes and implicit times of the mfERG waveform were normal in all 5 
VAVFL and in 9 VGB-E, when compared to 13 normal individuals. This suggests 
that neither bipolar cell nor photoreceptor cell dysfunction, respectively, is implicated 
in VGB toxicity.
The mfVEP amplitudes were normal in all 5 VAVFL and in all 9 VGB-E, when 
compared to 16 normal individuals. The lack of abnormality may arise from the 
mismatch between cortical functional topography and the characteristics of VAVFL 
and the technical limitations associated with the monocular analysis of the mfVEP.
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Chapter 1: Vigabatrin In A Clinical Context
1.1. Clinical indications for the use of vigabatrin
Vigabatrin (VGB) was first licensed in the UK in 1989 as add-on therapy for partial- 
onset epilepsy. At that time, the drug was welcomed as a new treatment for refractory 
epilepsy and was quickly used far beyond the original licensing applications. VGB 
rapidly acquired a reputation as an effective, well-tolerated drug in competent adults. 
(Marson et al., 1996, Cramer et al., 1999) Prescription of VGB spread into paediatric 
use and was variably reported as effective in the majority of epilepsy types affecting 
this population. Particularly, it was hailed as the treatment of choice for West 
Syndrome. VGB was also readily prescribed for learning- disabled adults where the 
perceived advantage of minimal adverse effects was paramount particularly with 
respect to cognitive impairment.
The first report of vigabatrin-attributed visual field loss (VAVFL) appeared in 1997. 
(Eke et al., 1997) The characteristics of the field loss, a concentric constriction with 
nasal predominance and relative temporal sparing (Wild et al., 1999), are such that it 
is asymptomatic until the defect is advanced. (Hardus et al., 2000a) VAVFL is 
irreversible. (Johnson et al., 2000) Due to the predominantly asymptomatic nature of 
the field loss, screening for VAVFL with perimetry is therefore mandatory. However, 
a developmental age of 9 years is required for perimetry and many children and 
approximately 25% of adults are unable to appreciate the requirements of perimetry. 
(Wild et al., 1999)
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As a consequence of the visual field loss, VGB lost its place in mainstream adult 
epilepsy and has never been licensed for use in the USA. VGB is still occasionally 
prescribed in learning-disabled individuals and is also used in paediatric practice; the 
development of guidelines for examination of the latter group anticipated the ongoing 
usage. (2000) Paradoxically, the patients who are receiving VGB, and who are 
considered to benefit the most from the drug, are the very patients who cannot 
undergo perimetry and cannot therefore be monitored for the development of 
VAVFL.
Many clinicians mourn the loss of VGB and others continue to prescribe it in 
restricted practice. However, is the argument for the use of VGB really that 
compelling?
A potential use of VGB is for addiction treatment of cocaine and amphetamine. The 
reviving commercial interest in VGB is likely to renew interest in the mechanism of 
the visual dysfunction. At present, there are many unanswered questions concerning 
the pathogenesis of VGB toxicity. Whilst it is conceivable that biomarkers could be 
developed to identify individuals who could safely be prescribed VGB, no such safety 
net currently exists.
1.1.1 The evidence for VGB efficacy in adults
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Numerous trials have reported the efficacy of VGB in adults. (Gram et al., 1983, 
Rimmer and Richens, 1984, Gram et al., 1985, Loiseau et al., 1986, Browne et al., 
1987, Sivenius et al., 1987, Tassinari et al., 1987, Cocito et al., 1989, Dam, 1989, 
Remy and Beaumont, 1989, Tartara et al., 1989, Sander et al., 1990) (Reynolds et al., 
1991) The most robust information comes from short-term double blind add-on trials 
of VGB versus placebo in refractory epilepsy. The short-term add-on studies of VGB 
demonstrate reasonably consistent results with a 42- 49% reduction in the frequently 
quoted * 50% seizure rate reduction in focal onset epilepsy. (Tassinari et al., 1987, 
Tartara et al., 1986, Loiseau et al., 1986)
The limitations of short-term studies in severe refractory epilepsy are well 
documented. (Leach and Brodie, 1995) However, due to ethical limitations and 
market driven reasons of time constraints, this study design is the most frequently 
undertaken and often provides the only available evidence base for new anti-epileptic 
drugs (AEDs).
In order to achieve a monotherapy license, any new drug must be shown to be either 
better than the standard drug, or equally efficacious and better tolerated. In the 
absence of direct comparative head-to-head trials of VGB, one approach is to 
compare separate trial data. There have been two main attempts to use the Cochrane 
meta-analyses to compare eight newly developed drugs with each other.
The first comparison of gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin and
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zonisamide found no significant difference between the six drugs in terms of the 50% 
seizure reduction rates. VGB did not emerge as significantly better tolerated than the 
other five drugs. (Marson et al., 1996) The second study compared available data 
from each trial to assess absolute success rates, based on a calculation of success of 
the antiepileptic drug minus the success of placebo. (Cramer et al., 1999) Trends 
emerged which favoured vigabatrin and levetiracetam versus lamotrigine, but placebo 
data were highly variable across the different studies, highlighting the difficulty of 
comparing results across studies. No clear differences emerged between the new 
antiepileptic drugs from either of these analyses. Prior to the SANAD study, (Marson 
et al., 2007a, Marson et al., 2007b) it might be reasonably claimed that in adults with 
partial-onset epilepsy there was equivalent evidence for the adjunctive use of VGB as 
for any other AED.
Two direct attempts were made to assess whether VGB could justifiably be used as a 
first line drug. One open label trial in adults with partial epilepsy reported very 
favourable results (57.7% seizure free after one month, and 39.8% seizure free during 
the fourth month) in patients with moderate epilepsy defined as a maximum of 7 
seizures per month. (Arzimanoglou et al., 1997) Following this promising report, a 
double-blind monotherapy study randomising 459 patients to either CBZ or VGB 
confirmed that VGB was better tolerated than CBZ, but less effective, and thus should 
not be considered a first-line agent. (Chadwick, 1999)
In summary, notwithstanding recent data for the other newer AEDs, there is indeed
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reasonable evidence for the efficacy of VGB as an adjunctive therapy but no good 
evidence to justify using it as monotherapy.
1.1.2 Vigabatrin: the evidence for efficacy in children with partial 
and generalised seizures
There is a dearth of high-quality data assessing VGB efficacy in children, and, in part, 
this arises from difficulty in obtaining ethical approval for paediatric trials.
Open-label monotherapy trial
A study of 42 children reported similar efficacy for VGB and CBZ monotherapies. 
(Gobbi et al., 1999) Children with cryptogenic partial epilepsy demonstrated seizure 
response rates of 82% and 100% in VGB and CBZ, respectively, whilst children with 
symptomatic partial epilepsy demonstrated seizure response rates of 50% and 55% 
respectively though, as in the adult monotherapy studies, VGB was slightly better 
tolerated.
Single Blind Placebo Add-On Trials
The first of two studies reported a dose-response relationship and recommended dose 
escalation in those who seemed to show a partial response after 1 month. (Arteaga et 
al., 1992) However, this study was limited to 16 children (12 of whom had either 
symptomatic or cryptogenic partial onset epilepsy, with only 4 having idiopathic 
generalised epilepsy) over a one-month period.
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The second trial reported high rates of seizure reduction from 97 per month on 
placebo to 9 per month after 6 months of treatment with VGB. (Dalla Bemardina et 
al., 1995) At 7 months, 8 of the 46 study patients were seizure free on VGB, 
compared with none rendered seizure free during one month of placebo. Thirty-nine 
of 46 patients completed the study, again supporting high tolerability.
Open-label Add On Trials
Three trials reported varying success of VGB in open label trials. One multi-centre 
trial reported a significant reduction compared with baseline for both partial and 
generalised seizures, in a study that excluded patients with IGE or West syndrome. 
(Gherpelli et al., 1997) A second trial, running for 24 months, reported 23% and 9% 
seizure freedom in cryptogenic partial epilepsies and symptomatic partial epilepsies 
respectively, (Coppola et al., 1997) but found that VGB was ineffective in 
myocolonic epilepsies and in LGS. In patients with intractable epilepsy, the rate of 
seizure response (defined as 50 -75% reduction in seizures) over 2-24 months was 
43%. (Wong, 1995)
VGB Withdrawal Study
A unique study assessing withdrawal from VGB used the number of patients 
remaining in the study as the primary endpoint.(Chiron et al., 1996) This measure 
reflects a combined perception of both efficacy and tolerability. 93% of patients
6
randomised to stay on VGB remained in the study, compared with 46% of those who 
were randomised to placebo.
Retrospective Studies
VGB was considered to be effective in 43 children for complex partial seizures with 
or without secondary generalisation. In contrast, children with atonic seizures and 
myoclonic epilepsies responded badly. (Gibbs et al., 1992) Further support for VGB 
came from 73 patients treated with VGB, including 12 on VGB monotherapy, where 
high rates of >90% seizure reduction were found (30 of 73, including 7 rendered 
seizure free). ((Prasad et al., 2001)) The cohort constituted predominantly 
symptomatic epilepsy (50 of 73) although no difference was found in seizure response 
according to epilepsy type. Interestingly, long-term follow-up study of VGB in partial 
epilepsies in children showed persistent efficacy in 40% of patients. (Uldall et al., 
1995)
LTG and VGB showed similar rates of improved seizure control and similar rates of 
treatment maintenance in 109 children with a higher proportion with idiopathic 
generalised epilepsy (IGE); 8 of 20 children with IGE responded to VGB. (Schapel et 
al., 1997) Similar results for efficacy and tolerability for both VGB and LTG across 
children with partial and generalised patients have also been found. (Dimova and 
Korinthenberg, 1999)
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However, a comparison of VGB and Lamotrigine (LTG) as add-on therapy in a case 
series review of 105 children (Belanger et al., 1998) found that VGB was more 
effective than lamotrigine in partial epilepsies; however LTG was more effective for 
generalised epilepsies. Nevertheless, LTG has been shown to be better retained in 
patients with either partial or generalised epilepsy than VGB due to perceptions of 
lack of efficacy of VGB. (McDonald et al., 2005)
A review (Schmidt and Bourgeois, 2000) of therapies for Lennox-Gastaut Syndrome 
does not recommend VGB, even as a third-line agent. Only one study ((Feucht and 
Brantner-Inthaler, 1994) has reported high rates of response of VGB add-on therapy 
to VALP monotherapy in patients with Lennox-Gastaut Syndrome.
In summary, the literature suggests that the efficacy of VGB in children follows a 
similar pattern to that in adults. There is a consensus that VGB is a well-tolerated 
drug, effective as an adjunctive therapy in partial onset epilepsies both in the short 
term and also in the long term. Evidence regarding efficacy in idiopathic generalised 
epilepsies is more limited and does not support VGB as being highly efficacious in 
this group. However, as in adults, there is no data to support the use of VGB as a 
monotherapy over CBZ.
8
1.1.2.1 Vigabatrin and Infantile Spasms (IS)
The effectiveness of VGB for infantile spasms (IS) has been much vaunted and 
currently VGB remains arguably the drug of first choice. (2000). However, the use of 
VGB over alternative treatments is not supported in the literature.
Systematic Reviews
A Cochrane review of the treatment of infantile spasms (Hancock et al., 2003) 
included 11 randomised controlled trials (RCTs) but concluded all studies 
demonstrated poor methodology to varying degrees, rendering comparison and 
interpretation difficult. No treatment was found to be more efficacious than any other. 
For VGB specifically, high-dose VGB seemed to be more effective than low-dose 
VGB in controlling IS.
A more recent systematic review similarly concluded that no long term therapy could 
be recommended over another. (Mackay et al., 2004) This review included 14 studies 
of VGB and IS and 7 studies assessing VGB in Tuberous Sclerosis (TS). Again, 
problems in methodology hampered interpretation and the authors’ supported the 
prescription of VGB but advised that the evidence was of low grade only.
Riikonen (Riikonen, 2000) reviewed all published trial data despite differences in 
methodology and, in common with the other systematic reviews, failed to demonstrate
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improved efficacy of one drug over another but considered that ACTH should be used 
ahead of VGB due to the risk of developing VAVFL.
Randomised Double Blind Controlled Study
In the only randomised placebo controlled study of VGB as first-line treatment of 
infantile spasms, which after 5 days became an open label extension for up to 24 
weeks. (Appleton et al., 1999) found a significantly higher percentage reduction in 
spasms in the VGB group compared with the placebo group at the end of the double 
blind period (77.9% cf 25.9%). At the end of the open-label extension period, 42% of 
the original 36 children were spasm free on VGB monotherapy. Those with cerebral 
dysplasia were most responsive to VGB. Overall, VGB was well tolerated despite 
rapid escalation of dosage, with no withdrawals due to adverse events.
Single Blind Randomised Studies
Two RCTs comparing VGB with ACTH and Hydrocortisone, respectively, (Vigevano 
and Cilio, 1997) Chiron and Dulac, 2002) found a much more rapid response rate to 
VGB than to steroid and better tolerability to VGB. However, at 14 days and beyond, 
rates of response were similar across the various groups. VGB was more effective in 
cerebral dysplasia and other cerebral malformations compared to ACTH. (Vigevano 
and Cilio, 1997)
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A single blind two-week trial of low-dose versus high-dose VGB, with an open label 
follow-up study of 142 children, found similar rates of early response to VGB 
(defined as 7 consecutive days spasm free in the first 14 days) and showed high-dose 
VGB yielded a faster time to respond than low-dose VGB. (Elterman et al., 2001) 
Efficacy was prolonged, with 65 % of patients remaining spasm free at 3 months.
Open Label Randomised Studies
In contrast, either of prednisolone or tetracosactide was found to be more effective 
than VGB in the open-label randomised trial UKISS (Lux et al., 2005) which, 
interestingly excluded patients with TS since it was felt that the evidence for VGB use 
was already conclusive.
The primary outcome in the UKISS study was cessation of spasms, but this was only 
measured on days 13 and 14, in contrast to the RCTs of Vigevano and associates 
(Vigevano and Cilio, 1997) and Chiron and associates (Chiron and Dulac, 2002), 
described in Section 1.1.2.1 above It is notable that whilst UKISS used comparable 
maximum dosages of VGB to the two RCTs, UKISS was unable to confirm in almost 
half the study subjects that the full dosing protocol had been followed. The starting 
dose of VGB was proportionately low, whilst the doses of both ACTH and 
prednisolone were proportionately high. The lack of perceived efficacy of VGB may 
have been due to the low dosage. The UKISS study stands alone in reporting 
hormonal treatments as more effective than VGB.
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Retrospective studies
An open label trial found that only 2 of 8 children with IS showed an improvement on 
VGB. However, this was sustained, with 1 child remaining seizure free for the 24 
months of study period, and the other maintaining a seizure reduction of >50% for 30 
months. (Coppola et al., 1997)
A case series review (Belanger et al., 1998) showed that 12 of 23 children with IS 
were rendered seizure free on VGB, either as monotherapy or as adjunctive therapy to 
ACTH. No difference was found between children with symptomatic IS and children 
with cryptogenic IS.
A similar proportion of children with IS responded positively to VGB, including 2 
with TS as the underlying cause, who became seizure free. The most common 
diagnosis amongst non-responders was hypoxic-encephalopathy. (Prasad et al., 2001) 
However, all these retrospective studies involved small numbers of patients, who 
exhibited mixed treatment methodologies and therefore the evidence must be 
considered to be low-grade.
1.1.2.2 Vigabatrin and Tuberous Sclerosis (TS)
Only three studies have investigated the efficacy of VGB in individuals with TS 
manifesting seizures other than IS. Numbers are, not surprisingly, small and are
12
underpowered to draw any firm conclusions; however, all report in favour of VGB. 
One retrospective study reported seizure reduction in three of five patients (Prasad et 
al., 2001) whilst an open label study reported seizure freedom in 2 of 4 children on 
therapy with VGB, and seizure reduction in a third child, and good seizure response 
to VGB in 5 of 8 adults with TS. (Laan, 2004) The VGB withdrawal study discussed 
in section 1.1.2 also reported good results in TS (Chiron et al., 1996) but all of these 
studies involve very small numbers,
1.1.3 Vigabatrin and Learning Disability
One of the perceived advantages of VGB is the relatively low rate of associated 
cognitive impairment, an important consideration in all patient groups, but of 
particular functional significance when treating people with pre-existing cognitive 
impairment.
The best evidence for the impact of VGB on cognitive function in competent adults is 
that provided by Dodrill. (Dodrill et al., 1995) In a randomised, double-blind, 
placebo-controlled, add-on study evaluating cognitive and Quality of Life (QoL) 
scores in adults with focal onset epilepsy, receiving appropriate doses of VGB and 
who were seizure responders, Dodrill and associates found similar cognitive and QoL 
scores at the end of treatment to those at baseline. Only one test, the Digit 
Cancellation Test showed any deterioration with escalating doses of VGB.
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An earlier double blind randomised crossover study in 10 healthy volunteers assessed 
cognitive scores on a fixed dose of VGB of 2g/day; only one individual performed 
worse on VGB. (Thomas and Trimble, 1996)
In a notably larger cohort of 111 patients (53 on placebo, 58 VGB exposed), no 
difference was found in cognitive performance compared with placebo. (Bruni et al.,
2000) and these findings were sustained after 12 months, although the group treated 
with VGB showed a trend towards improvement. (Guberman and Bruni, 2000)
A unique study of efficacy and cognitive performance in 36 learning-disabled adults 
treated with VGB, involved follow-up at 3 months, 2 years, and 5 years. Forty-two 
percent showed a >50% seizure reduction at 3 months, falling to 22% after 5 years. 
Those patients with partial seizures responded best to VGB. Psychological 
performance was maintained throughout the study period.
A single open label trial of add-on therapy of VGB in 22 adults with severe epilepsy 
and learning disability found a reduction in mean seizures of 49%, overall, compared 
with baseline. (Armour et al., 1992) No adults were withdrawn from VGB due to 
adverse effects. In keeping with the findings of (Pitkanen et al., 1993) and those 
reported in adults and children, a trend was seen towards better seizure reduction in 
partial compared with generalised seizures.
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In conclusion, VGB is effective in the learning-disabled population, where efficacy 
varies depending on epilepsy type mirroring that seen in children and competent 
adults. Further, in the learning-disabled population, VGB does not impact upon 
cognitive function.
1.1.4 A New Clinical Indication for Vigabatrin
VCB has been studied as a potential short-term anti-addiction drug; specifically for 
use in cocaine and methamphetamine dependence. Even tobacco dependency has 
been cited as a potential future use for VGB. (Dewey et al., 1999) Initial reports that 
vigabatrin may be useful in addiction date back to 1998. (Dewey et al., 1998) Animal 
studies measuring in vivo concentrations of dopamine in the nucleus accumbens 
(DANA) of rats pre- and post- cocaine administration demonstrated, on average, an 
increase of 482%. The increase in DANA concentration was 365% following VGB 
administered 2 hours prior to cocaine intake. The attenuation of increased DANA 
levels was sustained in ongoing VGB administration, in a dose dependent manner. 
(Morgan and Dewey, 1998) Anticipatory cues associated with cocaine administration 
in rats also produce a 25% increase in DANA, which is abolished by VGB. 
(Gerasimov et al., 2001)
To date, only two studies have investigated VGB as an anti-addiction agent in 
humans. In the first, 30 individuals were recruited into a 9-week open-label safety 
study, which investigated vigabatrin in methamphetamine (‘crystal meth’) and/or
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cocaine addiction. Only 18 individuals completed the study, of which 16 tested 
negative for stimulant drugs in urinary screening in the final 6 weeks. No long-term 
data regarding sustained abstinence are available. (Brodie et al., 2005) An attempt to 
assess ocular safety of VGB when used as an anti-addiction agent found no ocular 
involvement in 18 individuals exposed to 137g of cumulative VGB over 9 weeks. 
(Fechtner et al., 2006) Only 18 of 28 individuals completed the study, of which 16 
tested negative in final urinary screening. Visual testing comprised visual acuity, and 
peripheral visual field investigation (Humphrey Field Analyzer Program 60-4) at 
baseline, weeks 1, 4, 8 and at 4 weeks or more post completion. No significant 
changes in visual acuity and visual field from baseline were reported.
Clearly, major uncertainties remain regarding both the efficacy and the safety of VGB 
in this setting. Given that VGB has a dose-dependent effect on DANA concentration, 
high levels of VGB might be required. No data is available regarding efficacy of VGB 
in the face of escalating intakes of cocaine or methamphetamine, and users may be 
able to overcome the inhibition with increased drug intake. Drug withdrawal 
programmes often last several months to years and this could result in considerable 
VGB dosing. The ocular safety data, therefore, represents an extremely idealised and 
minimal VGB exposure. Calls for licensing of VGB as an anti-addiction drug should 
be regarded as premature.
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1.1.5 Summary and Conclusions
Epilepsy is currently the sole clinical indication for vigabatrin.
In adults, there is good evidence for its clinical efficacy as add-on treatment for focal 
epilepsy. The only study exploring its potential as first line monotherapy suggests that 
it is less effective than carbamazepine. There is no robust evidence for the efficacy of 
VGB in idiopathic generalised epilepsy in adults and there is even some suggestion 
that it may be less effective in this group.
In children, the data are limited, but sufficient to support VGB being effective and 
well-tolerated; as in adults, seizure control appears to be better in partial-onset 
compared with generalised seizures. The sole open-label monotherapy study 
comparing carbamazepine to VGB shows no difference in efficacy. Despite several 
studies using VGB for IS, three reviews have concluded that there is no definite 
advantage for VGB. One review advocates against VGB in IS despite current UK 
paediatric guidelines.
In learning-disabled adults, the limited data confirm the effectiveness of VGB as 
add-on therapy in focal-onset epilepsy and indicate that VGB is well-tolerated with no 
adverse effects on cognition.
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1.2 Vigabatrin Attributed Visual Field Loss: Characteristics 
And Pathogenesis
The first report of VAVFL appeared in 1997 (Eke et al., 1997) with a case series of 
three individuals exposed to VGB for a minimum of 28 months. The field loss in each 
case was a bilateral constriction. There are now nearly 200 publications discussing 
VAVFL.
1.2.1 Topographic Characteristics O f The Field Defect
The characteristics of the field defect associated with VGB (Lawden et al., 1999, 
Wild et al., 1999) are now well accepted. (Daneshvar et al., 1999) The field loss is a 
bilateral ‘concentric’ constriction which preferentially affects the nasal field, both in 
terms of area and depth, resulting in a characteristic pattern of binasal attenuation 
which, within the central field (i.e. within 30° from fixation) manifests by static 
threshold perimetry as a steep-sided binasal annulus extending vertically across the 
horizontal midline and also centripetally. Initially, the temporal field is spared to 
varying extents, but in advanced cases, becomes concentric within the central field.
The propensity for nasal visual field loss is more apparent by static perimetry than by 
kinetic perimetry. (Lawden et al., 1999, Wild et al., 1999, Wild et al., 2007) Only one 
study has attempted to quantify the nasal preferential loss. Patients were assessed with 
the 120 point screening test protocol of the HFA. The visual field loss in the nasal
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hemifield was more severe than in the temporal hemifield in 75% of 21 individuals 
with VAVFL. (Manuchehri et al., 2000)
1.2.1.1 Is this purely a peripheral disorder?
Whilst the visual field loss is predominantly peripheral, there is both structural and 
functional evidence of retinal dysfunction. Central retinal abnormalities have been 
observed on ophthalmoscopy including reports of retinopathy (Krauss et al., 1998, 
Beran et al., 1996) along with optic nerve pallor (Eke et al., 1997, Lawden et al., 
1999, Crofts et al., 1997). The first report of reduced peripapillary nerve fibre layer 
was in 1999, (Miller et al., 1999) and since that report there has been growing 
evidence to confirm this as an important finding even in early VAVFL (Wild et al., 
2006, Buncic et al., 2004).
Central clinical abnormalities have been identified including subtle colour-vision 
defects and irregularities of the macula reflex. (Krauss et al., 1998) Similarly, 
abnormalities in colour vision have also been reported along with reduced contrast 
sensitivity by (Nousiainen et al., 2000) although, confusingly, these abnormalities 
have also been reported in Carbamazepine-exposed individuals. Manuchehri 
(Manuchehri et al., 2000) also found a higher rate of incorrectly read Ishihara pseudo- 
isochromatic plates in VAVFL compared with CBZ-exposed controls, but were 
unable to demonstrate evidence of reduced visual acuity. One case of severely 
impaired visual acuity and 5 cases of impaired colour vision were identified in a
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group of 22 VGB exposed individuals, which, it was felt, was attributable to VGB. 
However, the proportion of these cases with VAVFL is not clear. (Paul et al., 2001)
1.2.2 The Asymptomatic Nature of VAVFL
The characteristics of the field loss in VAVFL are such that the patient is unaware of 
the field loss until the defect is advanced. The asymptomatic nature in the early stages 
is most likely to arise from the normal or near normal visual acuity associated with 
the relative sparing of the temporal field compensating for the nasal loss in the 
contralateral eye. (Wild et al., 1999)
Most authors agree that VAVFL changes are asymptomatic.(Lawden et al., 1999, Eke 
et al., 1997, Wild et al., 1999) However, one study (Schmidt et al., 2004) described a 
positive predictive correlation between the response to two questions on a 
questionnaire relating to vision and the presence of VAVFL. Nevertheless, the 
severity of the field loss was not described.
1.2.3 The Scale of the Problem
It is difficult to determine accurately the prevalence estimate of VAVFL. This is due 
to a number of factors, including the sensitivity and specificity of the given visual 
field protocol to identify VAVFL; the performance of the patient during the visual 
field examination; the experience of the clinician interpreting the result of the
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examination and the sampling bias present in the given cohort with particular 
reference to the duration, daily and cumulative dose of VGB; and the small numbers 
of patients associated with many cohorts. Furthermore, approximately 25% of adult 
patients exposed to VGB are unable to cooperate with the demands of perimetry. 
(Wild et al., 1999)
The highest estimate of prevalence of VAVFL is 90% derived from a cohort of 20 
individuals. (Besch et al., 2002) A further 9 studies yield a wide range of prevalence 
estimates from 17 to 73%. (Daneshvar et al., 1999, Arndt et al., 1999, Hardus et al., 
2000c, Gross-Tsur et al., 2000, Kalviainen et al., 1999, Lawden et al., 1999, Miller et 
al., 1999, Wild et al., 1999, Wohlrab et al., 1999, Rao et al., 1998) A pooled analysis 
of 528 patients from all available studies resulted in a prevalence estimate of 32% (95 
% Cl 28% -36%). (Kalviainen and Nousiainen, 2001)
The prevalence of VAVFL in children and adolescents is generally lower than that 
reported in adults. (Vanhatalo et al., 2002, Wild et al., 2007) (You et al., 2006) The 
lower prevalence in children may reflect increased retinal plasticity, although this is 
unsubstantiated, but may also reflect difficulties in the visual field examination of 
children. Indeed, three studies have shown prevalence estimates in children that are 
generally higher than those found in adult cohorts. One study (Wohlrab et al., 1999) 
reported a prevalence estimate of 42% for asymptomatic VAVFL in a paediatric 
group, however, only 12 of 153 could undertake the visual filed examination. The 
second (Luchetti et al., 2000) and third studies (Gross-Tsur et al., 2000) reported
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VAVFL in 8 of 13 children (62%), and in 11 of 17 children (65%) respectively. These 
latter two prevalence estimates may also reflect difficulties associated with the visual 
field examination of children.
1.2.4 Is VAVFL Stable?
No Improvement In VAVFL Following Withdrawal From VGB
Despite some reports to the contrary (Versino and Veggiotti, 1999, Krakow et al., 
2000, Giordano et al., 2000, Fledelius, 2003), it is clear that VAVFL persists after 
withdrawal of VGB.(Johnson et al., 2000, Kjellstrom et al., 2008a, Paul et al., 2001)
The most frequently cited report of reversibility was that of an eleven-year-old child 
with rapidly improving fields after VGB withdrawal.(Versino and Veggiotti, 1999) 
Further paediatric cases followed amid suggestions that reversibility of VAVFL 
represented physiological differences and capacity for retinal plasticity in children. 
The more likely explanation is that of improved compliance with the visual field 
examination with age. Indeed, improved visual field performance in paediatric 
patients exposed to VGB is well documented. (Vanhatalo et al., 2002) These cases of 
apparent reversibility exemplify the limitations of perimetry, particularly in children. 
The non-reversibility of VAVFL, following withdrawal, was confirmed in 8 
paediatric patients. (Luchetti et al., 2000)
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Similarly, two adults with VAVFL exhibited an apparent improvement in the visual 
field after withdrawal of the drug.(Krakow et al., 2000) ERG abnormalities were cited 
as supportive evidence but, tellingly, the most striking ERG abnormality was that of 
reduced or absent oscillatory potentials; these have subsequently been shown to be 
associated with vigabatrin therapy rather than vigabatrin toxicity. (A fuller discussion 
of electrophysiology in Vigabatrin is contained in Section 1.3.3). Again, the most 
plausible explanation for the apparent improvement was that of the perimetric 
learning effect. (Wild et al., 1999)
The only study involving substantive numbers of patients to report improvement in 
VAVFL following withdrawal of VGB involved 26 patients with a mean follow-up of 
12 months post withdrawal. (Fledelius, 2003) In general, the illustrated fields prior to 
withdrawal were of poor quality and it is likely that the apparent improvement can 
again be attributed to the perimetric learning effect. Numerous studies have 
subsequently confirmed that VAVFL is non-reversible.(Wilson and Brodie, 1997, 
Paul et al., 2001, Nousiainen et al., 2001, Newman et al., 2002, Kjellstrom et al., 
2008b)
No Worsening Of VAVFL Following Withdrawal Of VGB
In addition, VAVFL also does not seemingly progress following withdrawal from 
VGB. (Nousiainen et al., 2001, Newman et al., 2002)
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On Continued VGB
The progressive nature, from detection, of VAVFL on continued therapy with VGB is 
widely clinically accepted but refuted by one research group. Two studies from one 
centre assert that VAVFL either does not deteriorate at all (Paul et al., 2001) or 
progresses in a small number of individuals. (Best and Acheson, 2005) In contrast, 
and in keeping with most clinicians’ findings, two studies from a Netherlands group 
(Hardus et al., 2000b, Hardus et al., 2003) report progression.
Visual stability was reported in 15 patients on continued VGB therapy over a 12- 
month period. (Paul et al., 2001) However, seven of the initial 22 patients withdrew 
from VGB either due to poor seizure control or concerns about visual progression, 
and therefore these patients were excluded from the analysis. The second study 
reported stability of VAVFL in 15 of 16 individuals who remained on VGB over a 
period of 18 -  43 months. (Best and Acheson, 2005) All had received vigabatrin for 
at least 5 years. The remaining patient demonstrated unequivocal deterioration of the 
VAVFL and discontinued treatment. The time periods over which potential 
progression has been studied may be insufficient to identify progression of VAVFL.
The group reporting progression from detection of VAVFL (Hardus et al., 2000b, 
Hardus et al., 2003) found that all 11 individuals remaining on VGB showed clear 
progressive loss with continuing medication over 3 7 -4 7  months.
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1.2.5 The Natural History of Vigabatrin Attributed Visual 
Dysfunction
Various factors, including smoking, age and male gender, have been suggested to 
increase the risk of developing VAVFL. Male preponderance is generally considered 
to be the major risk factor (Wild et al., 2007, Wild et al., 1999) (Hardus et al., 2000b, 
Hardus et al., 2001, Kalviainen and Nousiainen, 2001). In contrast, Manuchehri did 
not report any significant correlation with male gender in 20 cases of VAVFL and 11 
controls. (Manuchehri et al., 2000)
Age has been identified as a risk factor for VAVFL by univariate analysis in some 
studies (Wild et al., 2007, Schmitz et al., 2002 but not in others {Manuchehri, 2000) 
although many have not specifically addressed the issue of age. The potential 
association with increasing age is likely to reflect a vascular component in the 
pathogenesis of VAVFL.
1.2.6 The Relationship Between Dosing and VAVFL
The evidence regarding the dose-responsive nature of VAVFL is equivocal. The 
majority of studies have shown a relationship between cumulative doses and/or dose 
duration and the development of VAVFL. ((Arndt et al., 1999, Daneshvar et al., 1999, 
Eke et al., 1997, Krauss et al., 1998, Lawden et al., 1999, Mackenzie and Klistomer,
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1998, Vanhatalo et al., 1999, Wilson and Brodie, 1997) However, other studies have 
reported contrary findings. (Best and Acheson, 2005, Paul et al., 2001, Wild et al.,
1999)
Lawden and associates reported a mean cumulative dose of 4.4kg for those with 
VAVFL compared to 1.7kg in those exposed to VGB but with normal fields. (Lawden 
et al., 1999) The severity of VAVFL is moderately correlated with cumulative dose 
0.525 (p=0.002) (Manuchehri et al., 2000) and with duration. (Hardus et al., 2000c) In 
the latter study, which involved a cohort of 157 patients, of whom 118 had been 
exposed to VGB, a significant correlation was present between the severity of 
VAVFL and dose duration, with more extensive defects seen in those exposed for 2-4 
years, or 4-6 years, as compared to 0-2 years. Similarly, a moderate correlation was 
found between the extent of VAVFL and duration of exposure. (Toggweiler and 
Wieser, 2001) A recent attempt to quantify severity of visual field loss in VGB 
examined the relationship between maximum daily dosing, cumulative dose and dose 
duration with visual parameters.(Conway et al., 2008) Maximum daily dosing was 
found to be the single most reliable indicator of development of VGB.
Some studies have failed to demonstrate a definite relationship with VGB dosing and 
VAVFL ((Wild et al., 1999, Kalviainen et al., 1999). In the former study, no 
significant difference was found in occurrence of VAVFL in those treated for greater 
than 4 years compared to those treated for less than 4 years. Kalviainen and 
associates were also unable to demonstrate a relationship between dose duration or
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cumulative dose and VAVFL, despite a robust prospective study assessing VGB 
monotherapy of 32 patients over a mean duration of 69 months. It is possible 
however, that the prospective nature limited the duration and also the higher ranges of 
cumulative dose.
In the largest study to date, involving 563 patients of whom 421 were exposed to 
VGB, and based upon the 432 individuals able to produce a reliable outcome, the 
presence of VAVFL was associated with increasing duration (odds ratio 14.2; 95% Cl 
5.0 to 40.5) and increasing mean dose (odds ratio 8.5; 95% Cl 2.2 to 33.2). (Wild et 
al., 2007)
1.2.7 The Development of Paediatric Guidelines
Appleton (Appleton, 1998) published a consensus guideline from a paediatric 
advisory group addressing the prescription of vigabatrin in children. The 
recommendations included 6-12 monthly visual field examination in children with a 
cognitive age of greater than 9 years. No technique was recommended for children 
with a cognitive age of less than 9 years. The guidelines counselled against 
widespread withdrawal of the drug, and advised an individual risk/benefit analysis. It 
was advocated that VGB remain the drug of first choice in children with seizures 
caused by TS and the second or third choice in children with epilepsy due to 
symptomatic or cryptogenic partial epilepsies.
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The guidelines were revised in (2000) and again advised visual field examination 
which adhered to a specific protocol. It was accepted that electroretinography 
performed according to International Society for the Clinical Electrophysiology of 
Vision (ISCEV) standards would be useful in children. Vigabatrin was once again 
named as the drug of choice in children with IS.
1.2.8 Co-Medication
Some studies have implicated other AEDs in the pathogenesis of VAVFL. (Eke et al., 
1997, Wild et al., 1999). However, the large number of potential polytherapies 
combined with the small cohorts makes attribution difficult. (Hardus et al., 2001) The 
issue is further confounded by isolated reports in the literature of visual field loss 
seemingly attributable to a given AED.
Non GABA Drugs
CBZ has been considered to be associated with visual field loss. (Leach, 1998, 
Kalviainen et al., 1999) However, this finding has not been confirmed in subsequent 
studies. (Wild et al., 2007)
GABA D rugs
Valproate has been suggested to potentiate an increased prevalence of VAVFL. This 
theory is plausible given the mild GABA-ergic action of valproate.
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Arndt (Amdt et al., 1999) reported that polytherapy of VGB and valproate (VALP) 
was associated with the two most severe cases of VAVFL in a cohort of 52, where 
severity of visual field loss was also worse as a while in the VGB/VALP group 
compared with a VGB/CBZ group. Wild demonstrated attenuated retinal nerve fibre 
layer (RNFL) thickness in individuals with VAVFL. The cohort exposed to VGB and 
Valproate had relatively thinner RNFL. (Wild et al., 2006) Valproate, alone, and in 
appropriate dosing, does not cause detectable abnormalities of retinal dysfunction 
(Ozkul et al., 2002) (Wild et al., 2006)
Progabide was implicated in a single case report as causing ‘tunnel vision’ in an 
individual receiving progabide and Phenobarbital. (Baulac, 1998) Interestingly, 
replacement with valproic acid led to an improvement in the fields, which raises the 
possibility of an artefact due to the learning effect, rather than a true improvement in 
the field.
In general, it is felt that Tiagabine does not result in visual field loss, when used either 
as monotherapy (Collins, 1998, Kalviainen, 1999) or as adjunctive therapy. (Lawden, 
2003, Krauss et al., 2003) However, one single case report described apparent visual 
field defect attributable to tiagabine adjunctive therapy in an individual with bipolar 
disorder.(Kaufman et al., 2001) The field returned to normal on withdrawal of the 
drug, suggesting, once again, an artefact arising from the perimetric learning effect.
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1.2.9 Electrophysiology and Imaging In Vigabatrin Attributed Visual 
Dysfunction
1 . 2 . 9 . 1  E l e c t r o r e t i n o g r a m  ( E R G  )
The most widely used electrophysiological technique in the investigation of VGB 
toxicity is the ERG. Initially, the whole-field ERG was found to be normal in patients 
with VAVFL (Blackwell et al., 1997, Gross-Tsur et al., 2002, Harding, 1997, Lawden 
et al., 1999) suggesting that such ERGs are a relatively insensitive tool for the 
detection of VAVFL. However, the consensus opinion is that the photopic ERG 
exhibits a reduction in amplitude suggesting dysfunction of the cone receptor pathway 
and are irreversible after withdrawal (Arndt et al., 1999, Krauss et al., 1998, Coupland 
et al., 2001, Sills et al., 2001). Occasional reports of reduced scotopic b-waves in 
ERG implicate rod pathway dysfunction (Daneshvar et al., 1999, Coupland et al.,
2001) and may either be a treatment effect, or more likely reflect the end stage of 
VGB toxicity with catastrophic retinal destruction.
The 30 Hz flicker ERG has been suggested as the most effective electrophysiological 
tool for the detection of VGB dysfunction. Harding and associates (Harding et al., 
2000) reported that the 30Hz flicker response predicted VAVFL with 100% 
sensitivity and 75% specificity. However, at 100% sensitivity, Brigell and colleagues 
were only able to demonstrate a specificity of 50% for the same measure. (Brigell,
2000) Reduced photopic oscillatory potentials were initially reported to be indicative 
of VGB toxicity (Krauss et al., 1998) but this reduction has since been demonstrated
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to be a treatment effect. (Harding et al., 1998, Duckett, 1998, Westall et al., 2003)
Deterioration in the photopic ERG has been used as a measure for monitoring the 
progression of VGB dysfunction. (Brigell, 2000) Eleven of 14 patients with VAVFL 
showed progression of the photopic ERG over time. The sensitivity for progressive 
VAVFL was 78%. However, the specificity was low as 23 of 46 patients without 
VAVFL also showed such ERG changes. It is uncertain whether the reduced photopic 
ERG reflects treatment effects or is a marker for VGB dysfunction preceding overt 
clinical change.
1 . 2 . 9 . 2  M u l t i - F o c a l  E l e c t r o r e t i n o g r a m  ( m f E R G )
There have been few studies involving the mfERG in VGB-exposed individuals. Two 
patients with reduced peripheral amplitudes compared with central responses and no 
delay in implicit times were reported. (Lawden et al., 1999) An abnormal mfERG 
responses was also found in 2 patients; a reduction was present in the amplitude of 
summated action potentials, particularly those of what was termed the ‘b wave’, and 
were more pronounced peripherally. (Mackenzie and Klistomer, 1998) Abnormal 
mfERGs were also found in 6 of 12 patients with VAVFL, again with reduced 
amplitudes in the periphery, although there was no congruency with the visual field 
loss. (Ponjavic and Andreasson, 2001) However, a normal mfERG was present in one 
patient with VAVFL , who also exhibited abnormal full-field ERGs. (Reuther, 1998)
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The wide-field mfERG has been shown to exhibit a reduction in the peripheral 
amplitude response of particularly PI, compared to the central amplitude response in 
patients with VAVFL. (McDonagh et al., 2003) However, access to this application 
has not been made commercially available and the technique has not been 
investigated by other groups. An abstract from the same group found a delay in the PI 
implicit time in the peripheral response.
1 . 2 . 9 . 3  E l e c t r o - o c u l o g r a m  ( E O G )
A reduced Arden Index (Al) was found in 2 of the 3 patients comprising the original 
case series of VAVFL described by (Eke et al., 1997).However, following withdrawal 
of VGB, these patients exhibited an Al within the normal range. (Harding, 1997) The 
improvement of the Al following withdrawal of VGB has since been confirmed. 
(Harding et al., 1998) and indicates a metabolic effect of VGB on the retinal pigment 
epithelium and the retinal pigment epithelial-outer segment complex. (Coupland et al., 
2001, Comaish et al., 2002, Lawden et al., 1999, Arndt et al., 1999)
1 . 2 . 9 . 4  V i s u a l  E v o k e d  P o t e n t i a l  ( V E P )
A majority of studies report a normal VEP in adults with VAVFL. (Eke et al., 1997, 
Lawden et al., 1999, Liegeois-Chauvel et al., 1989, Mauguiere et al., 1997, Reuther, 
1998, Wilson and Brodie, 1997) and in children with VAVFL. (Uldall et al., 1995)
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However, an abnormal VEP was found in 1 of 4 VGB exposed patients (Krauss et al.,
1998), and in 22% of 32 patients exposed to VGB (including the 4 previously 
described by Krauss and associates). (Miller et al., 1999) A similar prevalence of 
abnormality has been found in a further adult cohort (30%), the majority of whom 
exhibited advanced VAVFL (Daneshvar et al., 1999) and also in children (33%). 
(Gross-Tsur et al., 2000) The reduction in the VEP reflects the central dominance of 
the traditional summed VEP responses and it can be postulated that mfVEP 
technology may identify VGB toxicity more peripherally.
1 . 2 . 9 . 5  F u n d a l  A b n o r m a l i t i e s  A s s o c i a t e d  w i t h  V A  V F L
The retinal abnormalities associated with VAVFL, visible by fundoscopy, if present, 
are subtle and include retinal nerve fibre layer (RNFL) attenuation, (Miller et al., 
1999, Buncic et al., 2004, Frisen and Malmgren, 2003) abnormalities of the macula 
(Krauss et al., 1998) including epi-retinal membrane formation,(Krauss et al., 1998, 
Buncic et al., 2004) peripheral vessel irregularity (Krauss et al., 1998, Wild et al.,
1999) and peripheral pigmentary disturbances.(Lawden et al., 1999, Wild et al., 1999) 
The optic nerve head exhibits a characteristic ‘inverse’ or nasal atrophy. (Buncic et 
al., 2004, Frisen and Malmgren, 2003) It seems likely that these manifestations, 
particularly that of the optic atrophy, are late presentations of VAVFL.
The first case report, by optical coherence tomography (OCT) of an attenuated RFNL 
layer in VAVFL was that of (Choi and Kim, 2004). An abnormally attenuated RNFL
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associated with VAVFL as measured by OCT (fast RNFL 3.4) in at least one quadrant 
was described in a further 12 eyes (75%) of a case series comprising a mixed-age 
cohort of 8 individuals, and outside of normal limits in at least 2 quadrants in 9 eyes 
(56.3%). Despite advanced VAVFL, no eye showed reduced RNFL thickness in the 
temporal quadrant. In each case, the visual field was congruent with the 
corresponding RNFL thickness. (Rebolleda et al., 2005)
In a case-controlled study (Wild et al., 2006), which was accepted for publication 
prior to publication of the commentary by Rebolleda and associates, an attenuated 
average retinal nerve fibre layer (RNFL) was reported in all 13 adults with VAVFL. 
Of the 8 individuals who were exposed to VGB but with normal fields, 3 exhibited an 
average RNFL thickness, which lay just beyond the 95% confidence interval. This 
latter finding may reflect either a precursor of functional abnormality, or may be an 
artefact due to the lack of statistical precision of the 95% confidence interval, which 
was derived from 20 age matched normal individuals. All but two of the 14 non- 
GABAergic controls and all 7 of the valproate controls exhibited an average RNFL 
thickness within the normal range.
An attenuated RNFL thickness associated with VAVFL has also been described in a 
single case report using scanning laser ophthalmoscopy (SLO). (Viestenz et al., 2003) 
This technique was also used in the case-control study of (Wild et al., 2006) although 
SLO exhibited less sensitivity (77%) than OCT for the identification of VAVFL. A 
third imaging modality, namely nerve fibre layer polarimetry, has also confirmed the
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association between an attenuated RNFL thickness and VAVFL: all 8 individuals 
manifested this finding. (Dumian and Clearkin, 2007)
1.2.10 Pathogenesis
A consensus view of the findings from visual electrophysiology implicates retinal 
dysfunction, possibly Amacrine and/or Muller cell dysfunction. The conclusion from 
the limited number of studies involving retinal imaging, namely an attenuated RNFL 
layer, is of course, compatible with retinal dysfunction. Post-mortem examination of 
the retinae of a patient with advanced VAVFL found profound atrophy of the 
peripheral retina including ganglion cell and nerve fibre layer loss. (Ravindran et al., 
2001).
A VGB dose-dependent disruption of the photoreceptor layer of the albino rat was 
demonstrated prior to VGB licensing. (Butler et al., 1987) Microvacuolation 
attributable to VGB was also found prior to licensing of the drug in beagle and 
monkey brain cortex. (John et al., 1987) Subsequent work in the rat showed that 
VGB crosses the blood-retinal barrier and accumulates at a concentration of five-fold 
compared to that measured in the brain. {Sills, 2001} Interestingly, a six-fold increase 
in GABA concentration has been found in the rat retina following VGB. (Neal et al., 
1989) VGB toxicity is seemingly light dependent: a dose-dependent relationship 
between retinal damage and VGB has been found in the albino rat at 20,000 lux in the 
albino rat but not in the dark. However, GABA accumulation plus light does not
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result in retinal damage. (Izumi et al., 2004) (Izumi et al., 2004)
Irreversible reduction in the photopic ERG, the flicker response and the OPs arising 
from VGB is associated with peripheral disorganisation of the outer retina in albino 
rat, in particular cone photoreceptor damage. (Duboc et al., 2004)
It is clear that the mechanism of VGB toxicity cannot be derived from 
electrophysiology or ocular imaging and has not yet been elucidated from animal 
toxicology studies.
1.2.11 Conclusion
VGB unequivocally causes irreversible visual field loss, which is initially 
asymptomatic. The severity of the field loss seems to vary between individuals. The 
principal risk factors for the development of VAVFL are male gender, mean dose and 
dose duration of VGB. Fundal abnormalities in VAVFL are subtle, if present at all. 
The findings from visual electrophysiology and retinal imaging studies are indicative 
of a retinal location for VGB toxicity. However, the precise pathogenesis of VGB 
visual dysfunction is not known.
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1.3 Assessing VGB Toxicity in Children and Learning 
Disabled Adults: General Considerations
Assessing VGB toxicity in children and learning disabled adults requires successful 
application of perimetry and electrophysiology. Traditionally, perimetry, in particular, 
has not been undertaken in children and learning disabled adults.
Perimetry: Challenges In Children And Learning Disabled Adults
It is generally considered that individuals require a developmental age of nine years in 
order to reliably perform perimetry. (Wild et al., 1999) Other factors that may affect 
ability to undertake perimetry include interest, levels of alertness, and fatigue.
In infants and children, clinical assessment of the visual field is often overlooked due 
to perceived difficulty. However, gross defects such as hemianopia or 
quandrantanopia may be apparent upon careful clinical observation. The usual 
approach is to look for a shift in the individual’s fixation from an object of interest in 
the central field to a newly introduced object in the peripheral field. A standardised 
method for use in infants and children has been described. (Mohn et al., 1988) It 
should be noted that the visual field of newborns extends only to approximately 30°, 
which then expands over 12 to 15 months to the extent of that in adults. (Suchoff, 
1979)
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In learning-disabled adults, a wide spectrum of ability is encountered; traditional 
confrontation assessment of the visual field may be possible, but in those individuals 
who do not possess language skills, the only clinical assessment involves watching for 
a shift in fixation towards an object induced into the visual field. (Mohn et al., 1988)
1.3.3 Electrophysiological techniques currently used in children and 
learning-disabled adults
Given the constraints in assessing the visual field of children and learning-disabled 
adults, attempts to quantify objectively VGB-attributed visual dysfunction have been 
made using electrophysiological techniques, namely Visual Evoked Potentials 
(VEPs), Electroretinograms (ERG) and the electro-oculogram (EOG).
Applications of The Visual Evoked Potential (VEP) In Children And Learning-Disabled 
Adults
VEP responses reach maturation at between four to six months of age and therefore 
represent a useful reference point for assessing vision, even in infants. (Brecelj, 2003) 
VEPs have been used to assess vision in pre-verbal children and in patients with 
developmental delay. (Spencer and Harding, 2003) Standard methods of recording 
ensure consistent results. A comprehensive account of VEP in ocular and neurological 
conditions in children is that of Westall and colleagues. (Westall et al., 2000)
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The VEP has a wide range of applications in paediatric practice, but is under-utilised 
in learning-disabled patients (Tables 1.3.1 and 1.3.2). The VEP is of particular benefit 
in neurological disease and in those exhibiting developmental delay. However, in the 
presence of optic nerve disease, the VEP is likely to be of small amplitude and to be 
delayed and therefore, in such cases, will be limited as a technique in monitoring any 
visual dysfunction posteriorly to the optic nerve.
Applications of The Electroretinogram In Children And Learning-Disabled Adults
The ERG represents a mass response from the retina and as such is useful in assessing 
retinal disorders and in localising the site of the visual dysfunction. However, ERG 
recording is relatively time consuming and invasive. In children less than 5 years of 
age, recording of the ERG typically requires the use of a contact lens electrode and 
sedation. (Fulton et al., 2006)
There are five types of ERG responses recommended for the standard ERG 
examination. (Marmor et al., 2008) The ERG can distinguish between outer, middle 
or inner retinal location dependent upon the type(s) of ERG being employed. ERG 
responses do not maturate to those present in adults until 3-5 years of age and age- 
matched reference values must be used for children less than 5 years of age in order to 
avoid over-diagnosis of retinal dysfunction. (Laget et al., 1984) The ERG remains the 
preferred method for assessing inherited retinal disorders and dystrophies (Table 
1.3.2). In cerebral causes of visual failure, the ERG is normal. (Laget et al., 1984) The
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30-Hz flicker ERG has been used in infants to identity VGB toxicity, and possibly to 
predict the development of VGB toxicity. (Westall et al., 2002)
The Multifocal ERG In Children And Learning-Disabled Adults
The mfERG has been successfully applied in those unable to perform perimetry 
(Hood et al., 2003a) and has been shown to have good repeatability (Mazinani et al., 
2007) making it an appropriate technique for monitoring disease progression. A 
summary of the potential utility of the mfERG is given in Table 5. A detailed 
discussion of mfERG in VGB toxicity was given in section 1.5.1.
Multi-focal VEP In Children And Learning-Disabled Adults
The mfVEP has been widely used in adults to study diseases both of the ganglion 
cells and the optic nerve, including optic neuritis and multiple sclerosis (Grover et al., 
2008, Klistomer et al., 2008) and glaucoma. (Hood and Greenstein, 2003, Grippo et 
al., 2006) This technology has already been successfully applied in those unable to 
perform perimetry (Hood et al., 2003b).
There are a number of potential clinical applications of mfVEP (Table 1.3.3). 
However, many protocols are time-consuming requiring in the region of half an hour. 
(Hood et al., 2003b) Fortunately, it is seemingly possible to achieve useful responses 
from as few as 4 recording cycles, with a recording time of a few minutes. (Hood et 
al., 2007)
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Field-specific VEPs
A novel use of the standard VEP (the field-specific VEP), which is applicable to 
children older than approximately 3 years of age, has been described. (Harding et al., 
2002b) This technique enables recording of separate central and peripheral responses 
by presenting a stimulus with both a central and peripheral stimulus of reversing 
checks that increase in size with eccentricity. The central and peripheral checks are 
separated by a blank annulus. The checks reverse at different rates, thus allowing 
identification of peripheral and central responses. In conditions where central vision is 
spared, such as in vigabatrin-attributed visual field loss (VAVFL), standard VEP 
responses remain normal. The recording of an attenuated or absent peripheral 
response in the presence of a normal central response is indicative of peripheral visual 
field loss.
In a paediatric study assessing VGB toxicity, 35 of 39 children (mean age 12.2 years) 
were able to undertake the field-specific VEP, whereas only 12 children were able to 
undergo perimetry. (Harding et al., 2002b) The field-specific VEP identified 3 of 4 
children with VAVFL identified by perimetry (75% sensitivity) and correctly 
designated 7 of 8 children with normal fields by perimetry (87.5% specificity).
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Retinal Imaging
A detailed discussion of retinal imaging in relation to VGB toxicity was given in 
section 1.2.12. Estimation of RNFL thickness has been quantified in children using 
OCT (Rebolleda et al., 2005) and SLO (Lundvall Nilsson A.E., 2007) where children 
as young as 6 years of age have been assessed. In particular, OCT has been shown to 
identify VGB toxicity in children.(Rebolleda et al., 2005)
1.3.5 Conclusion
The outcome of perimetry in children and learning-disabled adults is dependent upon 
developmental age, as well as alertness and concentration. It is generally accepted that 
perimetry is not possible in individuals exhibiting a developmental age of less than 9 
years.
ERG identifies VGB toxicity in infants, although sedation is required. However, both 
mfVEP and mfERG remain untried in children and learning disabled adults, and this 
may reflect restricted access to multifocal technology.
Estimation of RNFL thickness is possible in children with a chronological age of at 
least 6 years and, in older children at least, identifies VGB toxicity.
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Table 1.3 .1 Current Uses of VEP
Clinical Application Characteristics of VEP
Visual Acuity Decreasing check size until VEP 
responses not discernible correlate with 
acuity
Albinism Flash VEP asymmetry comparing right 
and left eyes due to abnormal decussation 
at the chiasm
Cerebral visual impairment Prognostic information; poor VEP 
responses correlate with poor visual 
outcome
Delayed Visual Maturation Progressive improvement in latency and 
amplitude
Ocular Motor Apraxia Normal age appropriate pattern VEP 
responses prior to developing head thrust
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Table 1.3.2 Current Applications of ERG
Inherited retinal degenerations and dystrophies e.g. retinitis pigmentosa (RP)
Lipopigment storage diseases e.g. Batten disease
Mucopolysaccharidoses
Inflammatory retinopathy incl. Cogan’s syndrome
Toxic retinopathies
RP-like dystrophies, e.g. Usher
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Table 1.3.3 Potential Clinical Applications of mfVEP
Clinical application Clinical conditions
Detecting visual field loss in subjects 
unable to perform perimetry
Toxic (e.g. vigabatrin)
Structural (e.g. post trauma, space 
occupying lesions)
Raised intracranial pressure (e.g. 
obstructive hydrocephalus, idiopathic 
intracranial hypertension or IIH)
Monitoring disease progression Optic neuritis, glaucoma, retinitis 
pigmentosa, IIH
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Table 1.3.4 Potential Clinical Applications of mfERG
Clinical Conditions
Inflammatory retinopathy
Toxic retinopathy e.g. vigabatrin
Malignant retinopathy e.g. melanoma
Glaucoma
Retinal dystrophies e.g. RP, Usher, Biedl
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Chapter 2: Rationale For Research
2.1 Clinical Reason For Study
The Welsh Epilepsy Unit at the University Hospital of Wales was a centre, during the 
1980s, for the Phase III trials of VGB. Following licencing of VGB, a large number of 
patients attending the Welsh Epilepsy Unit were treated with the drug. As a consequence, 
the local population has a far higher prevalence of patients with exposure to VGB than 
that of most, if not all, epilepsy services across the UK and worldwide.
The proportionately large numbers of patients exposed to VGB attracted research interest, 
and generated the acquisition of concomittant expertise, in the problem of vigabatrin- 
attributed visual dysfunction. My clinical neurology supervisor (PEMS) had recognized, 
at an early stage, the potential scale of the problem of VAVFL, had been rigorous in 
implementing a regular visual screening programme for patients exposed to VGB under 
his care at the University Hospital of Wales and has subsequently developed great 
awareness and experience of the clinical management of patients exhibiting VAVFL. My 
vision science supervisor (JMW), whilst in Birmingham, had acquired a reputation as an 
acknowledged international expert in the interpretation of VAVFL, and a productive 
collaboration between these two individuals was instituted on his appointment in Cardiff. 
A postgraduate student, Catherine Robson, had obtained her PhD in 2007 for a thesis 
which involved the investigation of VAVFL in patients attending the Welsh Epilpesy
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Unit (Chapter 3.1). The research reported in this thesis extends the previous research 
undertaken by the groups in Birmingham and Cardiff and is concerned with the 
identification of vigabatrin-attributed dysfunction in particular sub-groups of patients 
treated with VGB.
In the current context of a relative plethora of available anti-epileptic drugs, vigabatrin 
might appear to be a dinosaur: once suited to its environment but now categorically 
shown to be not fit for purpose due to a major flaw namely irreversible visual field loss. 
A pragmatic viewpoint is that the prescription of VGB is no longer justified, under any 
circumstances. However, when dealing with complex clinical issues, this hard-and-fast 
rule becomes less easy to apply, particularly when dealing with a patient with 
catastrophic epilepsy.
VGB, somewhat controversially, is still recommended as a first-line treatment for IS in 
West Syndrome (both with and without a causative diganosis of TS. (Appleton, 1998, 
Lux et al., 2001) Although the evidence for VGB as a superior agent to hormonal 
methods of treating IS is lacking, (Hancock et al., 2001) it is clear that VGB is 
nonetheless a highly effective agent, and some children respond better to VGB than to 
ACTH, or are better served by VGB because of the adverse effects associated with 
hormonal treatment. Therefore, it is immediately apparent that simply removing VGB 
from the prescribing inventory is not an appropriate response and will not best serve the
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epilepsy commnunity as a whole.
Learning-disabled adults are a particularly vulnerable group often living in delicately 
balanced social cirumstances. Altering an effective anti-epileptic regimen, in this case 
VGB, because of an unquantified risk of developing visual field loss, often proves to be 
an unpalatable option for all concerned. This, coupled with the relative lack of an effect 
on cognitive function of VGB compared to other anti-epileptic drugs results in high rates 
of retention of VGB in this group. (Dodrill et al., 1995)
Clinical pilot studies assesssing the utility of VGB as an anti-addiction drug for cocaine 
and crystal methamphetamine (with potential uses for alcohol and even smoking being 
suggested) have once again brought VGB to the fore (Brodie, 2005, Brodie et al., 2003, 
Fechtner et al., 2006). Whilst the planned short-term restricted use of VGB may reduce 
the risk of VAVFL in a given population, no individual predictive markers yet exist, and 
no definitive marker preceding irreversible damage has yet been determined.
Given the limitations of the visual field examination in patients with epilepsy and, in 
particular, those exposed to VGB (approximately 25-30% of the latter patients are unable 
to comply with the requirements of perimetry) and, also, armed with the knowledge that 
vigabatrin induces retinal damage; it seemed appropriate to utilise novel techniques
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which, a priori, seemed applicable to the study of vigabatrin associated visual dysfunction 
at a functional and structural level. Given the current set of circumstances, the pressing 
clinical question is how best to address the question of the surveillance of visual 
dysfunction in those individuals where VGB remains the only therapeutic intervention -  
namely, children and learning disabled adults. These populations are currently 
disadvantaged, largely because perimetry requires a developmental age of approximately 
9 years old and a reasonable degree of sustained alertness.
The research topic for this thesis continues the study of a technique that showed potential 
for identifying vigabatrin-attributed visual dysfunction in those incapable of perimetry 
namely, measurement of retinal nerve fibre layer (RNFL) thickness by optical coherence 
tomography. This previous research had suggested the possibility of the identification of 
damage to the RNFL that preceded clinical loss; a lofty ambition, but, clinically, a far 
more useful one. In addition, the research topic for this thesis also involves the 
investigation of the suitability of emerging multifocal visual electrophysiological 
techniques for the identification of vigabtrin-attributed visual dysfunction.
2.1.1 Previous Work
As part of her PhD thesis, Catherine Robson had, in particular, shown in a prospective 
cross sectional obervational study (Wild et al., 2006) that attenuation of the RNFL 
thickness, as estimated by optical coherence technology (OCT) and by scanning laser
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ophthalmoscopy (SLO), was a reliable biomarker for VAVFL, particularly that recorded 
by OCT. As described previously (Chapter 1.2.12.5.) such a finding was consistent with 
two previous single-patient case studies of VAVFL using SLO (Viestenz et al., 2003) 
and OCT (Choi and Kim, 2004) and a commentary on the RNFL thickness, derived by 
OCT, in 13 individuals exposed to VGB. (Rebolleda et al., 2005) The latter was 
published after our group’s manuscript had been accepted for publication. Subsequently, 
an attenuated RNFL associated with VAVFL was also found by a third imaging modality, 
namely scanning laser polarimetry (SLP). (Dumian and Clearkin, 2007) The attenutaed 
RNFL was also consistent with the post-mortem appearance of the retinae of an 
individual with advanced VAVFL. (Ravindran et al., 2001)
Interestingly, a characteristic clinical observation, labelled ‘inverse atrophy’, had been 
coined to highlight the differential pattern of optic nerve head atrophy present with 
VAVFL, compared to that of the normal manifestation of optic neuropathy. (Buncic et 
al., 2004) The retinal nerve fibre layer exhibited an atrophy which spared the temporal 
regions of the retina and optic nerve head, whilst showing attenuated nasal, superior and 
inferior sectors of the optic nerve head. This characteristic pattern of atrophy had also 
been identified in digitally-enhanced ocular fundus photography. (Frisen and Malmgren,
2003) The inverse pattern of atrophy had not been reported in any other ocular condition. 
The possibility of identifying this pattern using OCT, potentially and specifically 
manifested as a nasal sector attenuation at the optic nerve head would obviate the need 
for fundoscopy, with its inherent difficutlies and limitations, and would greatly enhance
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the ability of diagnostic imaging in the identification of VAVFL.
The notion of structural change pre-dating visual field loss is well-established in 
glaucoma, (Caprioli et al., 2006) and is seemingly predictive of the development of 
multiple sclerosis. (Sepulcre et al., 2007) Therefore, it was felt that attenuation of the 
RNFL layer potentially and specifically manifested as a nasal sector attenuation at the 
optic nerve head, might be a precursor of VGB-attributed functional damage. The 
possibility of nasal atrophy in eyes of individuals exposed to VGB manifesting normal 
visual fields was of particular interest. Notwithstanding the latter, and of paramount 
importance, was whether the OCT could be applied to children below a chronological age 
of 6 years, and to learning-disabled adults.
Thus, if a nasal sector optic nerve head RNFL abnormality could be identified as a 
specific finding to VAVFL, and OCT could be applied to children and learning-disabled 
adults, then such findings would be of major importance in the detection and monitoring 
of VGB visual dysfunction.
2.2.2 Multifocal Electrophysiology in VGB Visual Dysfunction
Multifocal visual electrophysiology has not been widely applied to VGB visual
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dysfunction. The development of this technology affords the potential to investigate 
regional change that standard electroretinography (ERG) and visual evoked potential 
(VEP) recording cannot provide. Furthermore, the mass response of each of these 
modalities, it is argued, may obscure the identification/presence of local abnormalities. 
(Poloschek and Sutter, 2002, Hood et al., 2003a) Given that VAVFL is, initially at least, 
a focal/ localised disease, predominantly affecting the nasal visual field and exhibiting 
varying degrees of sparing of the temporal field, and latterly producing a concentric 
defect, it was felt that these techniques seemed appealing.
It is noteworthy that, amid the conflicting human and animal electropysiological, 
structural and epidemiology reports, there is no clear theory underpinning the 
pathogenesis of VAVFL. One possible advantage of examining patients with both 
mfVEP and mfERG, might be the insight that could be afforded into cellular locations of 
vigabatrin toxicity. This combination has been considered to be clinically useful in a 
variety of clinical scenarios, including non-organic visual loss. (Renner et al., 2005)
Multifocal ERGs theoretically reflect integrity anywhere within the retina; in practice 
however, much of the electrical response is dominated by the bipolar cells, with the 
photoreceptors impacting on implicit times and the ganglion cells exerting subtle effects 
on the shape of the PI waveform. (Hood et al., 2002) However, the mfVEP reflects 
integrity anywhere from the ganglion cell through the optic nerve, chiasm, tracts, and
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visual cortical areas. Amidst this wealth of representation, it is postulated that cortical 
changes may dominate. (Hood, 2004)
In addition, the relatively short, and potentially interrupted examination time, with 
sequences requiring attention and fixation for as little as 15 seconds at a time, for a total 
recording time of 7 minutes, suggested that the multifocal techniques might be 
applicable to young children and learning-disabled adults.
2.3 Aims of the Thesis
The aim of the thesis was therefore two-fold. Firstly, to investigate the suitability, in 
competent adults, of RNFL measurement by OCT, referenced to a commercially 
available normative database, as a measure of VGB dysfunction. Secondly, to investigate 
the potential of mfERG and mfVEP, and if positive, RNFL measurement by OCT for the 
investigation of VAVFL in children and learning-disabled adults.
2.3 General Methodology
The development of an objective and rapid technique for the assessment of VGB 
dysfunction, with high sensitivity and specificity, would enable safe continued 
presciption of VGB as determined by clinical need. The fervent hope was that the
65
structural or electrophysiological techniques would reveal changes that pre-date 
irreversible visual loss. The ideal outcome of the study was the development of a 
clinically useful tool - one that is readily performed clinically - rather than a research 
tool, per se. Such a finding would enable VGB to be re-introduced into mainstream 
epilepsy practice.
The three techniques required validation in individuals able to perform static perimetry; 
perimetry is the only means of quantifying visual field loss in VGB toxicity and as such, 
must be considered the gold standard. As would be expected, the validation group largely 
comprised competent adults, although a few children and learning disabled adults proved 
able to undertake static perimetry.
Participants who volunteered to take part in the studies were drawn from patients 
attending either the tertiary epilepsy clinics or the paediatric neurology clinics at the 
University Hospital of Wales. The corresponding caring physician initially approached 
all potential participants and requested permission from the potential participant to 
provide me with their name and contact details.
It was anticipated that limited numbers of individuals with exposure to VGB would result 
in a corresponding limited number of children and to a lesser extent, learning-disabled
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adults being enrolled in the study. Therefore, for pragmatic reasons of time constraint, the 
three investigative techniques were simultaneously applied to the competent adults, 
children and learning-disabled adults. Ethical approval had been obtained from South 
East Wales Ethical Committee for all the studies described in this thesis. In addition the 
studies were approved by the Research and Development Office of the Cardiff and Vale 
NHS Trust.
The investigation of RNFL thickness soon became the focus for the majority of my work, 
as this seemed by far the most promising tool.
2.4 Study Logistics And Limitations
A number of logistical difficulties were encountered with this study, as is often the case 
in studies driven by clinical need. The major unknown associated with the development 
of the thesis was that it was not possible to predict whether the study participants 
(particularly children and learning-disabled adults) would be able to cooperate with the 
three investigative techniques.
Considerable time was invested in applying the techniques to competent adults in order to 
minimise operator error and to gain a clear idea of the intrinsic difficulties associated 
with the study cohort. There was a major time requirement involved in acquiring
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sufficient expertise in electrophysiology. Early on in the development of the thesis, a visit 
was made to Professor Colin Barber (Consultant Electrophysiologist at the Queens 
Medical Centre, Nottingham) to acquire expertise in multifocal electrophysiology 
recording. He and his unit provided a useful link for ongoing advice and assistance. The 
author also attended the practical course on visual electrophysiology recording preceding 
the annual meeting of ISCEV in 2005. The experience gained from this course was 
invaluable, but it was felt that considerable practice was required prior to commencing 
the study. Approximately 240 hours for mfERG, and 180 hours for mfVEP, were spent 
acquiring traces from normal individuals prior to undertaking the various studies.
There was a particular difficulty with the mfERG data. It emerged (see chapter 5) that a 
software upgrade of the VERIS system had resulted in an additive shift of approximately 
7 milliseconds in the PI implicit time. It was uncertain whether this shift was uniform, 
within and between participants and whether or not it was possible to predict what effect, 
if any, the software change exerted on the amplitude. This anomaly was noticed at the 
initial data analysis, and necessitated discarding of the entire normative database (23 
individuals) and the acquisition of a new, temporally correct database.
The other major logistical problem with the development of the thesis related to the 
requirement for reliable normative databases. Whilst robust normative databases exist for 
the Humphrey Visual Field Analyzer and for the StratusOCT systems, databases for the
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mfVEP and mfERG had to be acquired. The local ethical committee felt that the ethical 
constraints involved in exposing healthy children to invasive testing with mfERG, which 
requires the pupil to be dilated and the use of a DTL fibre (with a consequent small risk 
of corneal abrasion) outweighed the benefits of establishing an electrophysiology dataset 
for children.
A further difficulty was the access to the OCT. The OCT is housed in the Media 
Resources department at the University Hospital of Wales, in a room with general 
photography requirements. Staff of the department performs NHS clinical OCT scans, 
and clinical requests are prioritised over research use. This resulted in long delays (over 
an hour on several occasions) for some research participants, and led to individuals 
withdrawing from the study, or simply refusing to wait or to return for non-completed 
imaging studies. Out of hours access is not routinely available and this proved 
particularly problematic for testing children.
I am indebted to my colleagues for their prompt referral of suitable patients particularly 
my supervisor (PEMS) and the other members of the Epilepsy Unit, but also my 
Paediatric Neurology colleagues, Frances Gibbon and Johann te Water Naude. 
Agreement to participate in the study was approximately 70% of those individuals 
referred to me. Where possible, study visits were arranged for participants on days on 
which they had pre-existing or required clinical appointments. Unfortunately, the mean
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rate of non-attendance (38%) was disappointing, but understandable given the complex 
problems faced by the participants. In addition, illness often forced cancellation or 
unforeseen non-attendance.
Some individuals were either unable or failed, to attend for examination with all the 
various investigative modalities, even after re-booking of the failed appointments. Other 
individuals were unable to cooperate with one or more of the investigative modalities. 
Such failed appointments and/ or an inability to undertake an investigative modality 
necessitated the recruitment of additional patients, resulting in delays in data collection 
and yielding different datasets for the various studies, making comparison across studies 
difficult.
Despite these challenges, a total of 104 individuals attended for testing in at least one of 
the investigative modalities. The number of appointments totalled 395 and, on average, 
each appointment lasted one and a half hours. Thus, over 590 hours were spent in data 
collection, which yielded approximately 180 visual fields, 164 OCT measurements, 108 
mfERG trace arrays and 125 mfVEPs trace arrays. Following the software shift with the 
mfERG, 15 individuals were unavailable for repeat testing and so were not included in 
the subsequent analysis of the mfERG, but were included in the analysis of the mfVEP.
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Chapter 3: Utility of Retinal Nerve Fibre Layer 
Thickness as Measured by OCT in VGB-Attributed 
Visual Dysfunction
3.1.1 OCT: Introduction
OCT is a non-invasive imaging technique, which provides high-resolution cross- 
sectional images of the tissue in question. The technique first became commercially 
available for imaging the ocular fundus in the mid-1990s.
The current commercially available instruments utilise conventional standard 
interferometry. Advances on this technique include ultra high-resolution, adaptive 
optics and Fourier domain analysis in order to improve resolution. (Drexler and 
Fujimoto, 2008)
OCT has been used in a variety of clinical contexts including macular, vitreo-retinal, 
optic nerve head and retinal nerve fibre layer disorders. Measurement of the RNFL is 
usually provided by circular scans centred on the optic nerve head, generating, in the 
case of the Stratus OCT, a RNFL thickness regional map over 12 sectors of the optic 
disc. RNFL thickness attenuation has been detected by OCT in glaucoma and in 
ocular hypertension (Zangwill et al., 2000), where it seemingly precedes functional
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visual loss. (Caprioli et al., 2006) Of increasing interest in neurological disorders, 
RNFL thickness correlates with axonal loss as measured by brain MRI in multiple 
sclerosis, and this holds true for clinically unaffected eyes, as well as eyes with 
documented optic neuritis. Temporal RNFL attenuation may predict the development 
of relapses and deterioration in multiple sclerosis. (Sepulcre et al., 2007)
An attenuated RNFL has been reported in VAVFL. (Wild et al., 2006) (Choi and 
Kim, 2004, Rebolleda et al., 2005, Wild et al., 2006) Wild and associates (Wild et al.,
2006) also showed an attenuated mean RNFL in some individuals exposed to VGB 
but manifesting normal visual fields, suggesting that RNFL changes may also predate 
functional visual loss in VAVFL.
3.1.2 OCT: Principles, Acquisition and Interpretation
The Optical Coherence Tomography (OCT) is analogous to ultrasound, in that the 
image is based on differing reflecting properties of the tissues examined. However, 
the OCT image is created by reflection of light rather than sound. The intensity of the 
reflected light from the retina will vary depending upon the structure from which it 
has been reflected. (Chauhan and Marshall, 1999) In order to determine differential 
reflected light properties, the principle of interferometry is applied. Interferometry 
describes the superimposition of two or more waves. Measurement of the output wave 
is dependent upon the phase differences between the input waves (Figure 3.1.1). The 
Michelsen interferometer is widely applied in the commercially available OCT
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instruments (Figure 3.1.2) and essentially comprises a coherent light 
detector, two mirrors and one beam splitter.
source, a
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Wave
Input
Waves
Figure 3.1.1 The left-hand diagram illustrates constructive interference; two waves 
with coincident phase add to produce a larger amplitude output wave. The right-hand 
diagram illustrates destructive interference; two waves in opposite phase, and if of 
equal amplitude, cancel each other out.
mirror
half-silvered 
v  mirrorcoherent 
light source
□Zh
detector
Figure 3.1.2 The Michelson Interferometer
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The emitted light is split by the beam-splitter, one becoming the reference beam and 
the other, the test beam. The position of the mirror(s) may be altered, which change 
the resultant distance (path length) travelled by the light and creates a phase 
interference, measured by the detector. The position of the mirror in the reference arm 
is used as an interference signal, and, in turn, to determine the location of the sample 
mirror. OCT measures reflections at different depths, and the reflection mirror scans 
longitudinally, yielding different signal pulses at different depths. Plotting amplitude 
of the reflected light versus depth generates an axial scan. (A-Scan, Figure 3.1.3).
Figure 3 .1.3 A-Scan of the retina.
The amplitude of the reflected light 
is plotted against depth (ie the position 
of the tissue acting as a reflector).
Multiple A-scans are acquired as the OCT beam scans transversely across a tissue. 
Digital processing and digital smoothing techniques then align these images in order 
to improve the signal-to-noise ratio; these then form a two-dimensional cross- 
sectional image. One of the commercially available OCT systems, and that used in 
this thesis, the Stratus OCT, acquires 400 A-scans per second, totalling 512 
sequentially obtained A-Scans in 1.3 seconds, and generates an axial resolution of 9-
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10 microns. Numerous scan modes are available; primarily these are composed of 
circles or straight lines.
Standard interferometry applied by the Michelson interferometer measures 
interference in metres (fit for purpose measuring cosmic ether); clearly retinal 
imaging demands interferometry distances of micrometres. The vast shortening of the 
measurable distance is achieved by altering the type of light source. Conventional 
OCT uses a low-coherence light source. The axial resolution depends upon the 
wavelength and bandwidth of the incident light (Jaffe and Caprioli, 2004). In imaging 
the retina, shorter wavelength light (800nm) is used as this is less absorbed by the 
high-water content structure of the cornea and vitreous. Light with a broad spectral 
bandwidth produces a shorter coherence beam, which maximises the optical path 
length mismatch between the reference and sample mirror. A super-luminescent diode 
(SLD) is commonly used to generate a uniform, low-coherence light source centred at 
a wavelength of 830 nm. (Schuman et al., 1995). The Stratus OCT achieves higher 
axial resolution than the forerunners (OCT1 and OCT2) due to better equality 
between the optical dispersions in the reference pathway and the sample pathway 
(Jaffe and Caprioli, 2004). Transverse resolution is essentially independent of light 
source wavelength and is limited by pupillary aperture and optical quality of the eye 
to approximately 10pm (Drexler, 2004).
New advances in OCT technology (ultra-high resolution) utilise an ultrabroad- 
bandwidth femtosecond laser technology, which reduces axial resolution to 2-3pm.
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(Drexler et al., 2003) To date, this technology has been expensive and hence, has been 
restricted to research applications. Recently, multiplexed SLDs have been combined 
to synthesize a broadband spectrum, which has the potential for commercial 
development, being cheaper than femtosecond technology. (Unterhuber et al., 2004) 
However, the multiplexed SLD system generates a peak emission wavelength of 
900nm, overlapping with water absorption at 980nm, and hence limiting the 
resolution. Adler et al., 2004, Ko et al., 2005) At the time of writing, the newest 
comnmercial instruments use a single SLD and produce axial image resolutions of 5- 
8 pm.
3.1.3 OCT: Retinal Nerve Fibre Layer Detection
Retinal thickness is calculated as the distance between the vitreo-retinal interface and 
the anterior boundary of the reflectance layer (traditionally labelled red in the pseudo­
coloured bands) corresponding to the Retinal Pigment Epithelium (RPE) which is the 
choriocapillaris. (Schuman et al., 1996) Technical difficulties in identifying the 
appropriate boundaries are more common at the posterior boundary.
RNFL thickness is defined by the distance bounded by the first reflection off the 
retinal surface - one of the most consistent sources of reflectivity, (Chauhan and 
Marshall, 1999) and the RNFL posterior boundary. This latter boundary is an 
arbitrary definition based on the change in the refractive index in the retinal tissue, 
which is believed to indicate a change in the structure i.e. a movement from the RNFL
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into the more posterior layers. This definition for the boundary is not yet fully 
accepted. (Jaffe and Caprioli, 2004)
3.1.4 OCT Relationship between RNFL and Perimetry
The topographic relationship between the retinal nerve fibre layer and the visual field 
has been described, based upon retinal ganglion cell (RGC) loss in glaucoma. (Figure 
3.1.4). However, the number, separation and positioning of the stimulus locations in 
the clinically utilised visual field protocols are not ideal for investigating the 
relationship between reduction in the visual field and attenuation of the RNFL. For 
example, only one-sixth of the available stimulus locations correspond to the region in 
which those RGC axons in the nasal half of the retina enter the optic nerve head. 
Various topographical relationships between the given stimulus location and the 
corresponding RGC axon entry into the optic nerve head have been described. 
(Magacho et al., 2005, Boland et al., 2008, Garway-Heath et al., 2000)
3.2 The Application Of Imaging Techniques In VAVFL
Ophthalmoscopy, fundus photography and other imaging modalities have been 
scrutinised in the hope of identifying changes predictive or diagnostic of VAVFL 
(Frisen and Malmgren, 2003, Buncic et al., 2004, Wild et al., 2007). The fundal 
abnormalities associated with VAVFL are subtle when viewed by fundoscopy. The 
field loss can occur in the presence of a seemingly normal retina and/or normal optic 
nerve head. (Kalviainen et al., 1999, Newman et al., 2002) However, it can also
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occur with optic nerve atrophy (Daneshvar et al., 1999, Wild et al., 1999, Frisen and 
Malmgren, 2003, Buncic et al., 2004, Harding et al., 2002a) with or without one or 
more of a variety of retinal abnormalities including surface wrinkling retinopathy 
(Krauss et al., 1998, Buncic et al., 2004), peripheral retinal arterial narrowing, (Krauss 
et al., 1998, Wild et al., 1999), peripheral retinal hypopigmentation (Lawden et al., 
1999), irregular sheen at the macula (Krauss et al., 1998) and thinning of the retinal 
nerve fibre layer (Miller et al., 1999, Frisen and Malmgren, 2003, Buncic et al.,
2004). The attenuation of the retinal nerve fibre layer, both by fundoscopy (Buncic et 
al., 2004) and by image enhancement of fundus photographs (Frisen and Malmgren, 
2003), can show a nasal predilection which can frequently be associated with 
corresponding secondary nasal optic atrophy.
The subtlety and variation of the associated optic nerve head and retinal abnonnalities, 
nevertheless, precludes the use of fundal examination by ophthalmoscopy as a marker of 
VAVFL field loss. Visual electrophysiology has identified markers of VAVFL field loss, 
particularly the 30Hz flicker electroretinogram (ERG) (Harding et al., 2000, Coupland et 
al., 2001); however, no one stand-alone ERG criterion possesses a clinically acceptable 
sensitivity and specificity.
Measurement of the retinal nerve fibre layer thickness, using either scanning laser 
ophthalmoscopy, (Viestenz et al., 2003, Wild et al., 2006) OCT (Choi and Kim, 2004) 
(Rebolleda et al., 2005) (Wild et al., 2006) or nerve fibre layer polarimetry (Viestenz et al., 
2003, Dumian and Clearkin, 2007) shows considerable potential as a marker for VGB 
toxicity. However, such potential is based upon case histories (Viestenz et al.,
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2003, Choi and Kim, 2004), retrospective case analysis (Rebolleda et al., 2005) or 
uncontrolled studies of small numbers of individuals with field loss (Dumian and Clearkin,
2007). Only one case-controlled prospective study has been undertaken (Wild et al., 2006).
The case-controlled prospective study from the Cardiff group (Wild et al., 2006) measured 
retinal nerve fibre layer thickness using OCT with the StratusOCT and the Proportional 
Circle Scan set at a scan radius corresponding to the vertical diameter of the individual 
optic nerve head. At 100% specificity, based upon the 95% confidence limits derived from 
20 age-matched normal individuals, the mean of the retinal nerve fibre layer thickness over 
the circular scan yielded 100% sensitivity for 13 individuals with VAVFL visual field loss. 
However, 3 of 8 individuals exposed to VGB but with normal fields and 2 of 14 individuals 
receiving carbamazepine monotherapy (a non-GABAergic antiepileptic drug) and 
exhibiting normal fields also manifested mean retinal nerve fibre layer thicknesses outside 
the apparent normal range. The former raises the possibility of an earlier manifestation of 
vigabatrin toxicity than visual field loss, whilst the latter questions the validity of the 
confidence intervals.
The Proportional Circle Scan utilises a scan diameter based upon a function of the vertical 
diameter of the individual optic nerve head. This is in contrast to the more commonly used 
alternative; a fixed scan radius which does not account for variation in the optic nerve head 
size. The former has the advantage of overcoming the between-individual differences in 
the topographical variation of the normal nerve fibre layer thickness inherent with the use 
of a fixed scan radius and arising from between-individual variations in the size of the optic 
nerve head. However, only the fixed scan radius protocol benefits from the manufacturer’s
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standardised and substantive generic database of normal values contained within the 
instrument software and which is available to all users. Thus, there is a pressing need to 
validate the previous findings of retinal nerve fibre layer attenuation, obtained with the 
Proportionate Circle scan and the small proprietary database, (Wild et al., 2006) against the 
fixed scan radius and the corresponding generic database of normal values, as a marker of 
VGB toxicity, particularly nasally.
3.2.1 Aims
The purpose of the study, therefore, was two-fold. Firstly, to confirm the validity of 
retinal nerve fibre attenuation measured by OCT as a marker of VGB toxicity with 
particular reference to a standardised set of generic normal values (i.e. those of the 3.4 
RNFL thickness protocol of the StratusOCT). Secondly, to determine whether retinal 
nerve fibre attenuation within the nasal quadrant is a more sensitive marker of VGB 
toxicity than that for the remaining quadrants.
3.2.2.2 Methods
The study utilised a cross-sectional, prospective, observational design.
3.2.2.1 Cohorts
The cohort comprised 3 groups of individuals with focal onset epilepsy. Group 1 
comprised 11 individuals (4 males and 7 females; mean age 41.5 years, SD 11.1) 
exposed to VGB and who manifested VAVFL visual field loss. Group II comprised
81
16 individuals (3 males and 13 females; mean age 38.3 years, SD 16.1) exposed to 
VGB and who manifested normal visual fields. This latter group included 3 learning 
disabled adults and 3 adolescents aged 13, 13, and 15 years, respectively. Four 
individuals were receiving VGB at the time of the study, one in Group I and three in 
Group II. Four of the individuals in Group I and four in Group II had taken part in the 
previous study of retinal nerve fibre layer thickness using the Proportionate Circle 
scan (Wild et al., 2006). Group III comprised 13 individuals (4 males and 9 females; 
mean age 47.8 years SD 14.2) with no exposure to VGB or other GABA-ergic anti­
epileptic drugs and who were currently being treated with one or more non-GABA- 
ergic anti-epileptic drugs, primarily carbamazepine. Twelve of the thirteen 
individuals in Group III were drawn from the corresponding group (Group IV) 
described by Wild et al (Wild et al., 2006). The individuals in Group III provided a 
match in terms of age and of gender to the VGB-exposed individuals as far as 
possible.
The eight individuals exposed to VGB and the 12 individuals exposed to non- 
GABAergic AEDs were selected so as to provide some indication as to the 
consistency in the RNFL thickness measured by the two differing scan protocols.
The adults were recruited from the Welsh Epilepsy Unit, University Hospital of 
Wales, Cardiff, and the adolescents from the Paediatric Neurology and Adolescent 
services at the University Hospital of Wales, Cardiff. All individuals conformed to 
rigid inclusion criteria in each eye including a distance refractive error of less than or
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equal to 5 dioptres mean sphere and less than 2.5 dioptres cylinder; open angles, clear 
ocular media; no fundal or optic nerve head abnormalities characteristic of known 
disease other than VGB toxicity; no previous ocular surgery or trauma; no history of 
diabetes mellitus and no family history of glaucoma. All individuals exhibited a 
visual acuity of 6/9 or better in each eye.
The individuals exposed to VGB attended for two visits. Visual field examination of 
the right eye was undertaken at one visit and retinal nerve fibre layer imaging of the 
same eye at a second visit. The order of the perimetry and imaging visits was 
randomised between individuals. All individuals in the non-GABAergic epilepsy 
control group (Group III) exhibited normal fields and attended for retinal imaging of 
the right eye only.
3.2.2.2 Perimetry
Perimetry comprised two examinations: Three-Zone Age-Corrected suprathreshold 
perimetry undertaken with the Full Field 135 Screening Test followed by threshold 
perimetry undertaken with Program 30-2 and the FASTPAC strategy of the Humphrey 
Field Analyzer 750 (Carl Zeiss Meditec, Dublin, CA). Distance refraction corrected, where 
appropriate, for the viewing distance of the perimeter bowl was utilised for examination of 
the central field. No correction was utilised for examination of the peripheral field (i.e. that 
beyond 30° eccentricity). Individuals were given frequent rest periods, both throughout 
and between perimetric examinations, and occasionally required more than one visit to
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provide a conclusive visual field outcome.
All 27 individuals exposed to VGB were able to undertake suprathreshold perimetry 
and all exhibited incorrect responses to each of the three types of catch trials within 
the normal range. Two adolescents could not perform threshold perimetry. For 
threshold perimetry, one individual, exposed to VGB but with normal fields, 
exhibited incorrect-responses to the fixation loss catch trials which were outside of 
the normal range; and two individuals, both with VGB-attributed visual field loss, 
exhibited incorrect-responses to the false-negative catch trials which were outside of 
the normal range, one of whom also exhibited an abnormal fixation loss rate.
3.2,23 Imaging
Retinal nerve fibre layer thickness was undertaken using OCT with the Stratus OCT 
(Carl Zeiss, Meditec, Dublin, CA) and the 3.4 RNFL thickness protocol. This 
approach undertakes 512 sequentially obtained A-scans in 1.3 seconds along a circle 
3.4mm in diameter positioned at the centre of the optic nerve head. The contralateral 
eye was occluded and individuals viewed the internal fixation target. The z-offset and 
polarisation were obtained before each scan. Three scans were obtained and the mean 
of the three scans calculated by the instrument software. All scans exhibited a signal 
to noise ratio of greater than 25dB, and at least 90% good quality A-scans. The mean 
image was analysed by Stratus OCT software Version 3.0. Additionally a single 
representative image was analysed by Stratus OCT software Version 3.0 to produce a
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RNFL Thickness Average Analysis Report.
3.2.2.4 Analysis
The visual fields for each individual were evaluated masked to the Group status and 
to the results for the retinal nerve fibre layer thickness by one of the supervisors of the 
thesis (JMW) who has 25 years of experience of interpreting the results of automated 
perimetry and 10 years of experience in interpreting VGB-attributed visual field loss. 
VAVFL was defined before the onset of the study as a bilateral, symmetric, 
‘concentric’, steeply sided absolute defect in the peripheral field recorded by two- 
level, three-zone suprathreshold perimetry, consistent with the field loss in the central 
field recorded by threshold perimetry and with an appearance characteristic of that 
attributable to VGB. In mild to moderate cases, the field loss characteristic of VGB in 
the central field extends, to varying amounts, in an annulus above and below the 
horizontal midline at the nasal extremities of the central field and centripetally with 
varying amounts of sparing of the temporal field. In the most severe cases, the defect 
is completely concentric within the central field.
The retinal nerve fibre layer thickness for each individual was analysed in terms of 
the absolute values of thickness displayed in the RNFL Thickness Average Analysis 
Report -  Version 3.0 (i.e. the average thickness of all 4 oblique quadrants and the 
thickness for each individual oblique quadrant) and in terms of the corresponding 
percentile (< lst, <5* <100th percentile) of the result within the normal population. 
Descriptive statistics of the magnitudes of the retinal nerve fibre layer were used as
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appropriate. The StratusOCT software does not contain a database for children 
although children are considered to exhibit comparable RNFL thicknesses with 
adults; the adolescents in this study were rated against normal values for an 18-year- 
old.
The study followed the tenets of the Declaration of Helsinki. Written informed 
consent was obtained from each individual after explanation had been given of the 
nature and possible consequences of the study. In the case of the adolescents and the 
learning disabled adults, written informed consent was obtained from the parent or 
legal guardian, as appropriate. The study had approval from the local institutional 
review board.
3.2.2 Results
The summary measures (Group Mean, SD and Range) of the demographical 
characteristics for each of the three Groups are given in Table 3.2.1.
The summary measures (Group Mean, SD and Range) for each of the three Groups of 
the retinal nerve fibre layer thickness, as a function of quadrant, is given in Table
3.2.2.
The frequency, across individuals, of the magnitude of the percentile (<lst, <5th,
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<100*) of the measured value of the retinal nerve fibre layer thickness for each 
quadrant in each of the Three Groups is given in Table 3.2.3.
All 11 individuals with VAVFL visual field loss (Group I) exhibited an abnormally 
attenuated retinal nerve fibre layer (i.e. <lst or <5* percentile) when averaged across 
the four quadrants. The 11 individuals also manifested an abnormal nerve fibre layer 
thickness in the nasal quadrant; seven also exhibited an abnormal thinning in the 
superior and/or inferior quadrants. Strikingly, all 11 individuals exhibited a normal 
retinal nerve fibre layer thickness for the temporal quadrant. An example of the nasal 
attenuation and temporal sparing, together with the appearance of the field loss in the 
central field is given in Figure 3.2.1.
Twelve of the 16 individuals in Group II (i.e. those exposed to VGB but with normal 
visual fields) exhibited a normal retinal nerve fibre thickness when averaged across 
the four quadrants and also for each individual quadrant. The remaining four 
individuals all exhibited abnormally attenuated average and nasal retinal nerve fibre 
layer thicknesses in the presence of a normal temporal nerve fibre layer. Two of these 
4 individuals exhibited additional attenuation in the inferior and superior quadrants 
respectively.
Ten of the 13 individuals exposed to non-GABAergic anti-epileptic drugs exhibited a 
normal retinal nerve fibre thickness when averaged across the four quadrants and also
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for each individual quadrant. However, three of the 13 individuals each exhibited a 
normal average thickness but an abnormal thickness in one of the superior, inferior, or 
temporal quadrants, respectively. The retinal nerve fibre layer thickness in the nasal 
quadrant was normal for all 13 individuals.
The cumulative dose of VGB exhibited a moderate correlation (r = -0.65, p <0.01) 
when taken across a set of individuals with the retinal nerve fibre layer thickness in 
the nasal quadrant (Figure 3.2.2 and Table 3.2.4). The magnitude of the correlation is 
limited by the floor effect of the retinal nerve fibre thickness measurement at 
approximately 35—40um which presumably arises from glial cell hypertrophy 
(Harwerth et al., 2007) replacing the nerve fibre layer and also from the finite 
thickness of the internal limiting membrane.
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Group
(Total)
Gender Mean 
Age (yrs) 
(SD)
Mean
Duration of 
Epilepsy 
(yrs) (SD)
Mean
Duration of 
Vigabatrin
(yrs) (SD)
Cumulative 
dose of 
Vigabatrin
(kg) (SD)
Male Female
1(11) 4 7 41.5
(11.1)
25.0 (6.0) 8.8 (2.3) 9.8 (2.7)
II (16) 3 13 38.3
(16.1)
20.1 (8.4) 7.6 (2.8) 6.8 (2.6)
111(13) 4 9 47.7
(14.2)
22.7(11.4) 0 0
Table 3.2.1 The summary measures (Group Mean, standard deviation [SD]) of the 
dem ographies characteristics for each of the th ree  G roups (Group I, individuals exhibiting 
VAVFL visual field loss; Group II, individuals exposed to  VGB but with normal visual fields; 
Group III, individuals receiving non-GABA-ergic anti-epileptic drug therapy).
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Retinal Nerve Fibre Layer Thickness (microns) by Quadrant 
(Mean, SD)
Group
(Total)
Average Nasal Superior Temporal Inferior
1(11) 64.0 (7.64) 37.1 (4.81) 73.9 (15.4) 68.45(9.71) 76.2 (19.39)
II (16) 91.06 (11.92) 62.0 (14.47) 98.62 (21.63) 79.94 (16.11) 103.6 (17.00)
111(13) 93.23 (11.02) 74.8 (15.1) 107.0 (20.36) 71.38 (13.87) 117.85 (17.34)
Table 3.2.2 The summary measures of the Retinal Nerve Fibre Layer thickness (Group 
Mean, SD) for each quadrant for each of the th ree  Groups (Group I, individuals exhibiting 
VAVFL visual field loss; Group II, individuals exposed to  VGB but with normal visual fields; 
Group III, individuals receiving non-GABA-ergic anti-epileptic drug therapy).
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Average RNFL Nasal RNFL Superior RNFL Temporal RNFL Inferior RNFL
roup N <5
%
<1% N <5% <1% N <5% <1% N <5% <1% N <5% <1
%
i = ll)
0 3 8 0 3 8 4 5 2 11 0 0 3 5 3
i = 16)
12 4 0 12 4 0 15 1 0 16 0 0 15 1 0
I
i=13)
13 0 0 13 0 0 11 2 0 12 1 0 12 1 0
Table 3.2.3. The frequency, across individuals, of the  magnitude of the percentile (< I st,
^5th) of the measured value of the Retinal N erve Fibre Layer Thickness for each quadrant in 
each of the three groups. N indicates a normal value i.e. greater than the 5th percentile.
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Group
Average Nasal Superior Temporal Inferior
r P r P r P r P r P
value value value value value value value value value value
I (n= 11) -0.216 0.262 -0.495 0.061 0.064 0.426 0.186 0.292 -0.464 0.075
II (n=16) 0.029 0.458 -0.120 0.331 0.318 0.115 -0.130 0.480 0.109 0.343
Table 3.2.4 The correlative values of the Retinal Nerve Fibre Layer Thickness versus 
cumulative dose for each quadrant in both of the VGB exposed groups.
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Figure 3 .2 .1. The grey scale (top left) and the Pattern Deviation probability map (bottom  
left) recorded for the right eye with Program 30-2 and the FASTPAC algorithm of the  
Humphrey Field Analyzer exhibiting VGB-attributed visual field loss and the corresponding 
retinal nerve fibre layer attenuation illustrated in terms of the height profile (top right) and 
the quadrant and sector distributions (bottom  right) relative to  the database of normal 
values.
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Nasal RNFLT as a Function of 
Cumulative Dose of Vigabatrin
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Figure 3.2.2. Nasal retinal nerve fibre layer thickness (pm) as a function of cumulative dose 
of VGB (kg) for the  16 patients exposed to  VGB but with a normal visual field (open circles) 
and for the  11 patients manifesting VGB-attributed visual field loss.
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3.2.4 Discussion
This study confirms that attenuation of the retinal nerve fibre layer thickness, relative 
to the manufacturer’s generic database of normal values, is associated with VGB 
toxicity. Moreover, it shows that the toxicity is particularly associated with retinal 
nerve fibre layer thinning in the nasal quadrant and with preservation in the temporal 
quadrant.
The predilection for attenuation of the retinal nerve fibre layer in the nasal quadrant 
with temporal quadrant sparing is in agreement with a characteristic pattern of 
peripheral retinal nerve fibre layer atrophy, sparing of the central region, and 
corresponding secondary optic atrophy which has been found in some individuals 
with VGB toxicity and labelled, variously, as ‘C-shaped’ or ‘temporal sparing 
atrophy’ (Frisen and Malmgren, 2003) or ‘inverse atrophy’ (Buncic et al., 2004). Such 
a pattern of optic atrophy is distinct from that of acquired and congenital optic 
neuropathies. However, the inverse retinal nerve fibre atrophy of VGB toxicity is 
seemingly difficult to recognize using fundoscopy, alone (Buncic et al., 2004) and, 
when visible, probably indicates an advanced stage of atrophy. Recognition can also 
be further confounded by the presence of co-existing optic nerve hypoplasia in some 
patients treated with VGB. Temporal quadrant nerve fibre layer attenuation is likely 
to be present only when the field loss is concentric within the central field.
The attenuation of the nasal quadrant retinal nerve fibre layer and the preservation of
temporal quadrant nerve fibre layer is entirely compatible with the characteristics of 
the field loss attributable to VGB, i.e. a concentric constriction which in the mild to 
moderate stages exhibits a nasal predominance and a relative sparing of the temporal 
field. The retinotopic correspondence with the visual field is such that the retinal 
nerve fibres in the unaffected temporal optic nerve head quadrant originate from the 
papillomacular bundle and from the fovea. (Figure 3.2.3) The visual field in the 
region that corresponds to the temporal quadrant of the optic nerve head is typically 
unaffected by VGB and remains normal even in the most advanced stage of field loss. 
The fibres corresponding to those locations which exhibit nasal VGB-attributed visual 
field loss enter the optic nerve head immediately either side of the superior pole (but 
with a slightly greater preponderance superior-nasally) and nasally to the inferior pole 
(Garway-Heath et al., 2000). The attenuated nerve fibre layer in the nasal quadrant 
accounts for the temporal field loss. The mechanism of retinal toxicity is unknown, 
and the aetiological agent may be VGB itself, or the resulting elevated level of GAB A 
within the retina, or a combination thereof. The presence and pattern of nerve fibre 
layer atrophy may represent either primary or secondary soma, or primary or 
secondary fibre, damage.
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Figure 3.2.3 Association of regions of the visual field and sectors of the optic disc.
The retinotopic correspondence with the visual field derived by Program 24-2 (left- 
the visual field for a right eye, right- the optic nerve head for the right eye).
The predilection for the nasal quadrant nerve fibre layer thinning in VGB toxicity 
measured here by OCT is also compatible with that found by nerve fibre layer 
polarimetry (Dumian and Clearkin, 2007).
All 13 patients treated with non-GABA-ergic drugs manifested a nonnal nerve fibre 
layer averaged across the quadrants. Such a finding is in agreement with the presence 
of a normal retinal nerve fibre layer thickness in patients treated with the non-GABA- 
ergic anti-epileptic drug carbamazepine and with the mildly GABA-ergic dmg 
sodium valproate (Lobefalo et al., 2006) (Wild et al., 2006). However, 3 of the 13
individuals manifested an abnormally thin nerve fibre layer (below, or equal to, the 5th 
percentile) in either the superior or inferior quadrants. No clinical reason could be 
found for this mild attenuation. However, inadvertent vertical misalignment of the 
patient/scan circle can result in an apparent reduction in the nerve fibre layer 
thickness in the region of the corresponding vertical pole and it is possible that this 
might be the explanation for the findings.
Re-analysis of the cohort examined by Catherine Robson with proportional circle 
OCT scans confirmed the same pattern of inverse atrophy, with nasal quadrant RNFL 
atrophy specific to VGB toxicity. Whilst there was good quantitative agreement 
between the results for each individual sector between the 3.4RNFL scan and the 
proportional circle scan, the latter technique designated apparent temporal RNFL 
attenuation was in 50% of the non-VGB-exposed epilepsy controls, and 40% of 
individuals with VAVFL. It is likely that such results emanate from inappropriate 
confidence intervals arising from the small sample size of 20 normal individuals. It 
should be noted that the normative database for the 3.4RNFL scan comprises 
approximately 450 individuals.
Three of the 16 individuals exposed to VGB but exhibiting normal visual fields 
exhibited abnormally attenuated average and nasal quadrant retinal nerve fibre layer 
thicknesses in the presence of a normal temporal quadrant thickness. This pattern of 
nerve fibre layer thinning is identical to that encountered in the individuals with 
VAVFL visual field loss and suggests that measurement of retinal nerve fibre layer
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thickness, at least by OCT, is a more sensitive measure of VGB toxicity than 
perimetry. The finding is not surprising given that structural abnormality manifests 
before functional abnormality in, for example, open angle glaucoma (Caprioli et al., 
2006) and multiple sclerosis (Sepulcre et al., 2007). The association between 
increased nasal quadrant nerve fibre layer attenuation and increasing cumulative VGB 
dosing adds further support to this hypothesis.
Based upon the various findings, it would seem that an attenuated retinal nerve fibre 
layer, measured by OCT, in at least the nasal quadrant combined with a normal nerve 
fibre layer in the temporal quadrant is a highly sensitive and specific indicator of 
vigabatrin-attributed visual field loss. Due to the small numbers of individuals 
exposed to VGB managed at any one centre, including the cohort utilised for this 
thesis, it is difficult to estimate accurately the magnitude of the sensitivity and 
specificity. More precise estimates of the magnitudes will only become available as a 
consequence of pooling experiences between centres.
In summary, the presence of nasal quadrant retinal nerve fibre layer attenuation 
determined by OCT using the 3.4 RNFL thickness protocol possesses clinically 
excellent sensitivity and specificity as a marker of VGB toxicity. The technique 
should be used as a baseline measure to augment perimetry in all patients prior to 
commencing VGB therapy either for epilepsy or for substance abuse (Fechtner et al., 
2006). It should also be introduced into the examination routine of those patients 
already exposed to VGB and should become the technique of choice for learning
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disabled adults. It should be used wherever possible in children; however, for 
optimum interpretation of the findings, in children normal values will be required for 
the generic database. The development of nasal retinal nerve fibre layer attenuation 
should be adopted a clinical indicator for withdrawal of VGB.
3.3. RNFL Thickness as Measured by Proportional Circle Scan 
3.3.1 Aim
The RNFL data of Wild et al (Wild et al., 2006) derived by StratusOCT was 
reanalysed for the presence of an attenuated RNFL in the nasal optic nerve head 
quadrant as a specific indicator for VAVFL, and for the level of agreement of the 
RNFL thickness.
3.3.2 Methods
The raw data from the original study cohort was analysed with respect to individual 
quadrant RNFL thickness within an individual, within each of the groups. Quadrant 
attenuation was determined by 90% confidence intervals derived from the normal 
control cohort. Group I comprised 13 patients with epilepsy of varying aetiology 
previously, or at the time of the original study, exposed to VGB who manifested 
VAVFL field loss. Group II comprised 8 patients with epilepsy previously, or at the 
time of the original study, exposed to VGB who manifested normal visual fields. Two 
additional patients exposed to VGB exhibited equivocal visual fields and therefore
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could not be categorised into either Group I or II. Group III comprised 14 patients 
with epilepsy who had never been exposed to VGB and who, at the time of the 
original study, were receiving carbamazepine monotherapy. Group IV comprised 20 
clinically normal individuals who did not have epilepsy and who had not previously 
been exposed to anti-epileptic drugs. A further group of patients (Group V) patients 
had received valproate monotherapy and served as a post hoc control
All patients had been recruited from the Welsh Epilepsy Unit, University Hospital of 
Wales, Cardiff and the normal individuals from the University Hospital of Wales and 
from the Eye Clinic, Cardiff School of Optometry and Vision Sciences, Cardiff 
University. The participants had been matched as closely as possible in age within- 
and between- the respective groups. As far as possible, patients had been matched for 
age at onset, and duration, of epilepsy.
All participants had previously undergone ocular examination and conformed in each 
eye to rigid inclusion criteria including a distance refractive error less than or equal to 
5 dioptres mean sphere and less than 2.5 dioptres cylinder; open angles, clear ocular 
media; no optic nerve head or fundal abnormalities characteristic of known disease; 
no previous ocular surgery or trauma; no history of diabetes mellitus and no family 
history of glaucoma. All participants had manifested a visual acuity of 20/30 or better 
in each eye and an intraocular pressure of 21mmHg or less.
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The participants had attended for two further visits. At one visit, they had undergone 
visual field examination of the right eye; at the other visit they had undergone retinal 
imaging in the same eye. The order of the imaging and perimetry visits had been 
randomised between individuals.
Perimetry methodology was performed as detailed above.
3.3.3.1 Imaging
Each participant had firstly undergone the Fast Optic Disc scan, centred upon the 
optic disc, from which the vertical diameter of the optic nerve head had been 
obtained. The participants had undergone three separate 360° circular scans, centred 
upon the optic disc, using the Proportional Circle Scan incorporating a scan radius 
which corresponded to the vertical diameter of the optic nerve head, thereby 
accounting for between-subject differences in the size of the optic nerve head.
The contralateral eye had been occluded and participants had fixated on the internal 
fixation target. The z-offset and polarisation had been optimised before each Proportionate 
Circle and Macular Thickness scan had been acquired. All scans had exhibited the 
requirements of a signal to noise ratio greater than 25dB and at least 90% good quality A- 
scans. The right eye of each participant had been dilated with 0.5% tropicamide prior to 
imaging in order to ensure a minimum pupil diameter of 5mm.
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3.3.3 Agreement Between RNFL Thickness Derived By The Fixed Radius Scan And 
Proportional Circle Protocols.
Eight VGB-exposed individuals, and twelve individuals from Group 3 were common to 
both the current and the original study and had, therefore, undergone both modalities of 
OCT optic nerve head imaging. These 20 individuals were utilised to investigate 
agreement between the RNFL thicknesses derived by the two scan protocols.
3.3.3.2 Analysis
The RNFL quadrant thicknesses for individual participants in each group of the 
original study were compared against the lower 90 % confidence limit calculated from 
the individuals in Group IV (the normal controls) with particular emphasis on the 
normality of the nasal optic nerve head quadrant thickness. The level of agreement 
between the two scan protocols for the 20 individuals common to both studies was 
illustrated graphically (Bland and Altman, 1986) for both the average thickness (of all 
four quadrants) and for the thickness of each individual quadrant.
3.3.4 Results
The summary measures (Group Mean, SD and Range) of the demographical 
characteristics for each of the five Groups are given in Table 3.3.1.
The summary measures (Group Mean, SD and Range) for each of the five Groups of
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the retinal nerve fibre layer thickness, as a function of quadrant, are given in Table
3.3.2.
The frequency, across individuals, of the measured RNFL thickness lying beyond the 
lower 90% confidence interval for each quadrant in each of the five Groups is given 
in Table 3.3.3.
The outcome of the proportional circle scan is tabulated below for both the average of 
all four quadrants, (Table 3.4.1) and for each individual quadrant. The individual 
quadrant data is also displayed in boxplots for each of the individual quadrants, and 
compared with the lower limit for 95% confidence intervals for the individual 
quadrant.
All 13 individuals with VAVFL (Group I) demonstrated an attenuated nasal quadrant 
RNFL, and 6 of 10 VGB-exposed individuals manifesting normal fields also 
demonstrated an attenuated RNFL thickness. However, 7 of 20 individuals with 
epilepsy (Group II) also demonstrated an attenuated nasal quadrant RNFL thickness 
based on the same criterion, compared with 7 of 22 normal control individuals.
The superior and inferior quadrants were also more attenuated in the VAVFL group 
compared with the other groups. For the superior quadrant, 11 of 13 individuals with
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VAVFL demonstrated superior quadrant thickness below the lower 95% confidence 
limit. This compares with, attenuated superior quadrant rates of 6 of 11 in group II, 5 
of 20 in group III, and 5 of 22 in group IV.
Inferior quadrant attenuation occurred in 11 of 13 participants with VAVFL, 
compared with 6 of 10 individuals in Group II, although 12 of 20 individuals in 
Group III also demonstrated an attenuated RNFL value, as did 6 of 22 individuals in 
Group IV.
Strikingly, however, temporal quadrant attenuation was evident in only 6 of 13 
individuals with VAVFL, compared with 3 of 11 in group II, and a high rate of 
attenuation in the internal epilepsy group, with 10 of 20 demonstrating attenuation, 
and a background rate of 6 of 22 in group IV, the normal controls. Temporal 
quadrant attenuation therefore, was no more likely in VAVFL than in the other 
groups.
When the results from the Proportional Circle scan were re-analysed, one of the two 
individuals exposed to VGB who were unable to produce conclusive visual field 
results, demonstrated nasal RNFL attenuation, only, and one demonstrated a normal 
RNFL throughout each of the four quadrants.
105
Table 3.3.2 Summary measures for RNFLT for average and quadrant values as measured by 
proportionate circle scan for all groups.
Retinal Nerve Fibre Layer Thickness (microns) of Average and all Quadrants
Mean( SD)
Group
(Total)
Average Nasal Superior Temporal Inferior
1(13) 65.6(11.95) 41.61 (9.98) 78.46 (22.28) 61.54 (8.99) 76.15(18.23)
11(10) 94.4(16.88) 68.4 (25.80) 109.1 (22.72) 76.1 (13.95) 118.6(19.86)
III (20) 100.1 (14.50) 80.05 (14.42) 121.0 (25.60) 71.85 (17.84) 125.1 (19.73)
IV (22) 111.1 (11.10) 89.77(18.70) 128.86(16.80) 82.5 (17.25) 139.81 (20.71)
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3.3.4.1 Agreement between Proportional Circle and Fixed Radius 
Scan RNFL Data
Mean differences between the two methods were lowest for the average of all four 
quadrants, and highest for the superior and inferior quadrants (Table 3.5.1). Bland 
Altman plots, with 2 standard deviation limits inserted, demonstrate an acceptable 
agreement between the two methodologies. This held true across the groups, and was 
not affected by wide variation in measured values. Only one individual in each of the 
temporal and superior quadrants fell outside the 2SD limits -  this individual was not 
common to both.
108
Group
(Number of 
individuals)
Mean
difference
Average
RNFL
(SD)
Mean
difference
Nasal RNFL
(SD)
Mean
difference
Superior
RNFL
(SD)
Mean
difference
Temporal
RNFL
(SD)
Mean
difference
Inferior
RNFL
(SD)
VAVFL -6.25 -2.50 -5.75 -7.75 -15.25
(4) (6.18) (10.97) (7.93) (10.60) (10.53)
VGB -  Exposed 2.25 6.25 12.75 -3.75 10.75
(4) (17.3) (21.75) (42.75) (10.40) (23.78)
Epilepsy
Controls
7.9 8.67 14.50 0.08 8.17
(12)
(9.65) (18.10) (21.47) (14.46) (14.49)
Total 3.95 5.95 10.10 -2.25 4
(20) (11.83) (17.41) (25.14) (12.89) (18.10
Table 3.3.5.1 Difference between Proportional Circle and 3.4RNFL thickness values for 
average and individual quadrants.
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Bland Altman Plot of Average RNFL Thickness Difference As a function of Mean Average RNFL
Thickness
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Bland Altman Plot of Nasal Quadrant RNFL Thickness Difference As a function of Mean Nasal
Quadrant RNFL Thickness
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Bland Altman Plot of Superior Quadrant RNFL Thickness Difference As a function of Mean Superior
Quadrant RNFL Thickness
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Bland Altman Plot of Temporal Quadrant RNFL Thickness Difference As a function of Mean Temporal
Quadrant RNFL Thickness
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Bland Altman Plot of Inferior Quadrant RNFL Thickness Difference As a function of Mean Inferior
Quadrant RNFL Thickness
1 70.00-
60.00-£
s
1
50.00-
40.00
30.00-
20 .0 0 -
10.0 0 -
o °I "
l l
I"
?3
0 .0 0 -
• 10 .0 0 -
•20.00 -
•30.00 -o
!
-40.00-
C -50.00-
(Inferior Quadrant RNFL ProportionaJ Circle value ♦ Inferior Quadrant 
3.4RNFL value) /2
Figure 3.3.5.5 Bland Altman Plot of Inferior Q uadrant RNFL Thickness
status
O  vavh.
O  VGA EXPOSED 
O  EPl£PSV CONTROLS
114
3.4 Applicability of OCT Imaging to Children and Learning 
Disabled Adults
3.4.1 Introduction
New prescriptions of VGB are largely confined to the paediatric population; VGB 
controversially remains the treatment of choice for infantile spasms in West 
syndrome, (Cvitanovic-Sojat et al., 2005) particularly where the underlying cause is 
Tuberous Sclerosis. (Thiele, 2004) VGB has historically been a treatment of choice in 
learning disabled individuals. VGB, uniquely, has been shown not to adversely affect 
cognition, an important consideration in an individual’s social functional setting. 
(Gillham et al., 1993)
Perimetry requires a developmental age of approximately 9 years, thereby excluding 
many children and approximately 20% of all adults with epilepsy. We have shown 
that RNFL thickness is a reliable marker of VGB toxicity in competent adults. If 
RFNL thickness were to be adopted in these populations, it requires to be shown to 
both applicable and valid in these populations.
3.4.2 Aims
The aims of this study were two-fold; firstly to investigate whether OCT is applicable
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in children and learning disabled adults, and secondly, to investigate whether OCT 
identifies VAVFL in these populations.
3.4.3 Methods
The original study cohort described above (see 3.2.2 ) included 5 learning disabled 
adults, and 3 children, who were capable of undergoing perimetry and underwent, in a 
random order: Humphrey Field Analyzer (HFA) Three Zone 135 Point Screening 
Field; HFA Program 30-2 with the FASTPAC strategy; and standard 3.4 RNFL 
estimation at the optic nerve head using the Stratus OCT III. 3 of the children and 5 
of the adults were not able to undertake the FASTPAC strategy. A further 2 VGB- 
exposed children and a further learning disabled adult were not able to comply with 
perimetry and underwent OCT only. Four more children had been exposed to VGB in 
utero, (see chapter 4.1) and also underwent the same provided 135 screening fields 
and OCT. A further 9 healthy children (aged 3 to 16 years) underwent OCT, only, as 
normal controls. Thus, the cohort totaled 9 children and 6 learning disabled adults 
(Table 3.4.3).
3.4.4 Results
3.4.4.1 Completion Rates
OCT was successfully performed in all 18 children and 5 of 6 LDAs. The sixth 
individual exhibited congenital nystagmus and bilateral congenital Vlth nerve palsies,
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with VAVFL. Consequently, he was unable to locate the internal fixation target or to 
fixate for the required acquisition time.
3.4.4.2 Mean RNFL Thickness
Of the applicability cohort, only 8 VGB-exposed individuals had completed 
perimetry. Of these, two had VAVFL as identified by perimetry. An attenuated RNFL 
(<95% Cl, as defined by STRATUS III normative database) identified the two cases 
of VAVFL identified by perimetry. Of the 6 remaining VGB-exposed individuals 
with perimetry, all showed normal mean RNFL thickness.
3.4.4.3 Nasal RNFL Thickness
Nasal RNFL thickness was attenuated in both cases of VAVFL. A further two VGB- 
exposed individuals manifesting normal visual fields showed an attenuated nasal 
quadrant RNFL thickness.
3.4.4.4 Individuals Unable to Cooperate with Perimetry
Of the three VGB-exposed individuals unable to cooperate with perimetry, one 
demonstrated attenuated retinal nerve fibre layer thickness in both nasal quadrant and 
mean average values. The remaining two showed normal RNFL thickness.
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3.5 Retinal Nerve Fibre Layer Thickness in Healthy Children
3.5.1 Introduction
Retinal Nerve Fibre Layer Thickness (RNFLT) in children is considered to equal that 
of adults. In support of this theory, RNFLT as measured by Scanning Laser 
Polarimetry, in 143 children indeed equals that of adults, (Lundvall Nilsson, 2007). 
However, the in-built normative database for StratusOCT does not extend below the 
age of 18 years, and as OCT relies on different methodology for estimating RNFLT, 
may yield different results in children.
3.5.2 Aims
To determine whether children have comparable mean and quadrant RNFLT values, 
as estimated by OCT as adults.
3.5.3 Methods
Nine healthy children were recruited (1 male, 8 females) ranging in age from 3 years 
to 16 years. All individuals conformed to rigid inclusion criteria in each eye including 
a distance refractive error of less than or equal to 5 dioptres mean sphere and less than 
2.5 dioptres cylinder; open angles, clear ocular media; no fundal or optic nerve head 
abnormalities characteristic of known disease; no previous ocular surgery or trauma; 
no history of diabetes mellitus and no family history of glaucoma. All individuals
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exhibited a visual acuity o f 6/9 or better in each eye.
Retinal nerve fibre layer thickness was undertaken using OCT with the Stratus OCT 
(Carl Zeiss, Meditec, Dublin, CA) and the 3.4 RNFL thickness protocol. This 
approach undertakes 512 sequentially obtained A-scans in 1.3 seconds along a circle 
3.4mm in diameter positioned at the centre of the optic nerve head. The contralateral 
eye was occluded and individuals viewed the internal fixation target. The z-offset and 
polarisation were obtained before each scan. An attempt was made to measure 
RNFLT in both eyes, but only the right eye was imaged for the two youngest children 
(aged 3 years and 4 years respectively). The mean image was analysed by Stratus 
OCT software Version 3.0.
3.5.3.1 Analysis
The retinal nerve fibre layer thickness for each individual was analysed in terms of 
the average values thickness of all 4 oblique quadrants (average RNFLT) and the 
thickness for each individual oblique quadrant. In all but one case, three 
measurements were taken, and the mean of those three were used for comparative 
analysis. In the case of one individual (aged 3 years) only two records were obtained, 
and again the mean value was used for analysis. The two measures showed good 
agreement.
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3.5.4 Results
Mean and standard deviation values were derived for average and quadrant RNFLT 
value (Table 3.5.1). Whilst mean values for both average and quadrant fell within 
normal young adult values, quadrant values varied more than mean average, 
particularly temporal and inferior values.
Values plotted against age were prepared for the average RNFLT and also for the 
quadrant values. Temporal RNFLT values correlated negatively with increasing age 
(Pearson correlation = -0.792, p < 0.05), whilst inferior quadrant RNFLT values 
showed a positive correlation (Pearson correlation = 0.97, p < 0.01).
It was apparent from analysis of the raw data values that the under 6-year-old 
individuals form an outlying group in the quadrant values. The characteristics of the 
regression slopes are tabulated in Table 3.5.2 for all the control individuals both with 
and without the under 6-year-olds. The regression analyses as a function of age for the 
over 6-year-olds are displayed graphically (Figures 3.5.1-3.5.5.).
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Age
(years)
Total
number
Average 
RNFLT 
mean value 
(u) (SD) 
[Confidence 
Interval ]
Nasal 
RNFLT 
mean value 
(u) (SD) 
[Confidence 
Interval ]
Superior 
RNFLT 
mean value 
(u) (SD) 
[Confidence 
Interval ]
Temporal 
RNFLT 
mean value 
(u) (SD) 
[Confidence 
Interval ]
Inferior
RNFLT 
mean value 
(u) (SD) 
[Confidence 
Interval ]
3 1 125 145 121 157 72
4 1 109 100 170 96 64
5 1 100 78 144 111 64
6 1 112 84 148 136 76
12 2 114.5 (7.78) 67 (2.83) 152.5 (7.78) 93 (16.97) 132 (5.66)
15 2 105 (7.07) 82(1.41) 120.5
(17.67)
83.5 (9.19) 143.5
(16.26)
16 1 113 104 136 64 150
Total 9 110.9 (8.16) 
[104.62 -  
117.17]
89.89 
(24.23) 
[71.23 
108.51 ]
140.56 
(18.71) 
[126.18 -  
154.95 ]
101.89 
(29.50) 
[79.21 
154.95 ]
108.56 
(38.6) 
[78.89 
138.23 ]
Table 3.5.1 Table detailing the average and quadrant RNFLT values categorized by age.
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Cohort Inclusive Of <6 Years 
Of Age
Cohort Exclusive Of <6 Years 
Of Age
Regression
Coefficient
R Square Regression
Coefficient
R Square
Average -.64 .31 -.56 .32
Nasal Quadrant -.39 .15 -.15 .22
Superior
Quadrant
-.68 .50 -.59 .34
Temporal
Quadrant
-.50 .27 -.13 .18
Inferior
Quadrant
-.17 .03 -.64 .40
Table 3.5.2 Regression coefficient and R Square values for the  normal control cohorts 
inclusive and exclusive of the <6 year-olds respectively
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Figure 3.5.1 Average RNFL plotted against age fo r the  normal cohort over the age of 6 
years. Confidence Intervals are displayed for th e  95th and 90th percentile.
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Figure 3.5.2 Nasal quadrant RNFL plotted against age for the normal cohort over the age of 
6 years. Confidence Intervals are displayed for the  95th and 90th percentile.
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Figure 3.5.3 Superior quadrant RNFL plotted against age for the normal cohort over the  age 
of 6 years. Confidence Intervals are displayed for the  95th and 90th percentile
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Figure 3.5.4 Temporal quadrant RNFL plotted against age for the normal cohort over the  
age of 6 years. Confidence Intervals are displayed for the  95th and 90th percentile
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Figure 3.5.5 Inferior quadrant RNFL plotted against age for the  normal cohort over the age 
of 6 years. Confidence Intervals are displayed for the  95th and 90th percentile
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3.6 Discussion
3.6.2 RNFLT: Applicability to  Children and Learning Disabled Adults
OCT is a sensitive and applicable tool for identifying VAVFL in children and LDAs. 
All 18 children provided good quality images on OCT. As in adults, an attenuated 
nasal quadrant RNFL was associated with VAVFL. An attenuated nasal quadrant 
RNFL thickness was present in one of three individuals unable to cooperate with 
perimetry.
3.6.3 RNFLT: Relatedness of Adult Normative Data with reference to  
Healthy Children
The mean RNFLT values for both average and quadrant values generated by each of 
the healthy children fell within the 95% confidence interval for 18 year-olds as 
determined by the StratusOCT generic normative database. However, for optimum 
interpretation of OCT in children an age-corrected normative database will be 
required.
The generic database for the Stratus OCT is age-matched allowing for an attenuation 
in RNFL with increasing age. Unsurprisingly, regression analyses for this data also 
shows the expected decline in RNFL in both mean and quadrant values.
Adult data from a large Asian cohort also displays the same trend, though notably 
they reported a slower rate of decline, but with much wider minima and maxima
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values and hence, much larger confidence intervals. (Parikh et al., 2007) A larger 
cohort in the data presented in this thesis would, of course have likely yielded tighter 
correlations.
The likely explanation for the outlying values produced by the under 6-year-olds lies 
in pragmatic technical sizing difficulties with the OCT machine relative to both the 
head rest and the table, resulting in axis distortion. This, coupled with proportionately 
worse variation in inferior and superior quadrant values in the case of inaccurate 
fixation, (Harwerth et al., 2007) probably explain the positive correlation seen with 
inferior quadrant values, and increasing age. There is no theoretical reason to suspect 
any limitations in measuring infant data with the OCT technology.
3.7 Conclusions
In summary, the presence of nasal quadrant retinal nerve fibre layer attenuation 
determined by OCT using the 3.4 RNFL thickness protocol possesses clinically 
excellent sensitivity and specificity as a marker of VGB toxicity. The technique 
should be used as a baseline measure to augment perimetry in all patients prior to 
commencing VGB therapy either for epilepsy or for substance abuse (Fechtner et al., 
2006). It should also be introduced into the examination routine of those patients 
already exposed to VGB and should become the technique of choice for learning 
disabled adults. It should be used wherever possible in children; however, for 
optimum interpretation of the findings, in children normal values will be required for
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the generic database. The development of nasal retinal nerve fibre layer attenuation 
should be adopted a clinical indicator for withdrawal of VGB.
Longitudinal assessment of current paediatric usage of VGB, and of putative short­
term use as an anti-addiction drug, should incorporate OCT (which represents a 
breakthrough for monitoring such cases).
OCT identifies abnormality of the retinal nerve fibre layer, which is associated with 
VAVFL. This finding confirms that of Wild et al (Wild et al., 2006) using a different 
methodology and a predominantly new dataset. The mean RNFL value is attenuated 
because of nasal quadrant RNFL attenuation. The nasal quadrant is attenuated in 
100% of cases of VAVFL.
Nasal quadrant RNFL attenuation occurred in VGB-exposed individuals manifesting 
normal visual fields; this probably represents structural change prior to irreversible 
visual loss. There is a precedent for structural change in RNFL as measured by OCT 
prior to functional visual loss in glaucoma (Caprioli et al., 2006) and recently multiple 
sclerosis.(Sepulcre et al., 2007) Further supporting evidence for this includes the 
positive relationship between nasal quadrant RNFL attenuation and cumulative VGB 
dose and duration.
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Nasal quadrant RNFL attenuation was absent in all epilepsy controls, and in all 
normal individuals, confirming that nasal RNFL attenuation cannot be viewed as a 
normal finding. In contrast, temporal quadrant RNFL attenuation is seen in Optic 
Neuritis, (Sepulcre et al., 2007) and other optic neuropathies. Thus, nasal quadrant 
RFNL attenuation is a more accurate measure of VAVFL, and is a better predictor of 
VAVFL than mean RNFLT, given the variability of temporal RNFLT, and the 
contribution that makes to the mean RNFL value.
OCT is applicable to children and learning disabled adults, with high completion rates 
in this group. Development of normative databases for children would improve 
reliability of quadrant values, whilst mean RNFL values fall within that expected in 
18 year-olds. Nasal quadrant attenuation adjusted for 18 year-old values identified 
VAVFL in this group.
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Chapter 4
4.1 HRT Measures In VGB Toxicity
4.1.1 Introduction
As described in Chapter 3, previous work from our group reported the utility of both OCT and 
scanning laser ophthalmoscopy (SLO), using the Heidelberg Retinal Tomograph (HRT) II, for 
identifying VGB toxicity. (Wild et al., 2006) As also described in Chapter 3, this earlier work 
did not analyse the results in terms of the topographical (ie segmental) distribution of RNFL 
thickness. The reanalysis of the OCT segmental results (using the variable diameter scan) was 
discussed in Section 3.3.
It was also considered appropriate, in the context of the differential atrophy of the disc in 
patients exposed to VGB identified by OCT in this thesis, to reanalyse the findings obtained with 
the HRT with particular respect to the segmental distribution of neuroretinal rim thickness and to 
the other descriptive parameters of the optic nerve head.
A single case report using the HRT in a patient with VAVFL described a reduced mean RNFL 
thickness (Viestenz et al., 2003); however, no specific segmental analysis was undertaken.
HRT yields a variety of descriptive parameters of the optic nerve head; many of these are
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dependent upon the reference plane used to distinguish the neuroretinal rim from the cup. 
Measures that are independent of the reference plane include the Disc Area, Cup Shape and 
Height Variation in Contour. The standard reference plane is set as a default at 50pm below the 
contour line at the temporal disc margin, at the location of the papillomacular bundle. (Burk et 
al., 2000). At the optic nerve head, structures below this plane are ascribed to the cup whilst 
those above the reference plane are ascribed to the neuroretinal rim (NRR). The location of this 
reference plane (SRP) was deliberately selected based upon the stability of the papillomacular 
bundle in glaucoma. (Burk et al., 2000)
‘Mean retinal nerve fibre layer thickness’ measures are derived by the HRT as the difference 
between the reference plane and the retinal surface height profile along a contour line drawn by 
the user. It must be understood that, in contrast to the OCT, which defines the RNFL by 
boundaries, no such anatomical boundaries are identified by the HRT. The reference plane is an 
arbitrary fixed depth that is uniformly applied to each image and thus will be subject to inter­
individual variation in normal retinal thickness. Similarly, the retinal surface height profile is 
contour line dependent and therefore subject to further variation. Thus, the parameter of ‘mean 
RNFL thickness’, whilst a quantitative value, is merely a marker for RNFL thickness rather than 
a true estimate of RNFL. A segmental measure of RNFL thickness is not available when the 
option for such an approach is not pre-defined at the time of the examination. Therefore, sector 
NRR area values were analysed with particular reference to the presence and frequency of 
inverse optic nerve head atrophy (Frisen and Malmgren, 2003, Buncic et al., 2004). The pattern 
of atrophy in VGB toxicity as described in Chapter 3 spares the temporal oblique quadrant of the 
disc, instead affecting the nasal, superior and inferior oblique quadrants of the disc and retina.
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This “inverse optic nerve head atrophy” is in contrast to the temporal disc atrophy seen in 
primary and secondary optic nerve pathologies.
The manufacturer’s generic database o f normal values for the various HRT optic nerve head 
parameters is contained within the software package known as the Moorfield Regression 
Analysis (MRA). The database derives confidence limits (95%, 99% and 99.9%) for the 
neuroretinal rim area, taking into consideration the covariance between the NRR and optic nerve 
head. (Wollstein et al., 1998) Confidence limits are available for a global NRR measure, and also 
for each o f six sectors o f variable width/area. The sectors do not correspond to those o f the OCT 
(Figure 4.1.1.).
Figure 4.1.1 The differences in sectors betw een the Stratus O C T  (Left) and the HRT II (Right) illustrated 
from the respective printouts.
4 .1.2 Methods
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The group comprised 13 individuals with VAVFL, 8 VGB-exposed individuals manifesting 
normal visual fields, 13 patients with epilepsy exposed to alternative anti-epileptic drugs, and 21 
healthy individuals who served as normal controls.
All patients underwent the same examination routine as that described in section 3.3. Briefly, all 
patients had been recruited from the Welsh Epilepsy Unit, University Hospital of Wales, Cardiff 
and the normal individuals from the University Hospital of Wales and from the Eye Clinic, 
Cardiff School of Optometry and Vision Sciences, Cardiff University and had been matched as 
closely as possible in age within- and between- the respective groups. All patients were matched 
as far as possible, for age at onset, and duration, of epilepsy.
The inclusion criteria in each eye were a distance refractive error less than or equal to 5 dioptres 
mean sphere and less than 2.5 dioptres cylinder; a distance visual acuity of 20/30 or better in 
each eye; an intraocular pressure of 21mmHg or less, uncorrected for corneal thickness; open 
angles; clear ocular media; no optic nerve head or fundal abnormalities characteristic of known 
disease; no previous ocular surgery or trauma; no history of diabetes mellitus and no family 
history of glaucoma.
The participants had attended for two visits. At one visit, the visual field examination was 
undertaken, as detailed in Section 3.3, for the right eye only; at the other visit retinal imaging 
was undertaken in the same eye. The order of the imaging and perimetry visits was randomised
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between individuals.
4.1.2.1 Imaging
The central corneal radius had been determined, prior to imaging, using a Bausch and Lomb 
keratometer (Bausch and Lomb, Rochester, NY) in order to correct the images for ocular 
magnification. Three separate scans of the optic nerve head, and the immediate surrounding 
retina, had been automatically obtained by the HRT software which had then computed the mean 
of the three scans to form the output topography image and the SD of the mean to ascertain the 
quality of the resulting mean image. The field size was 15°xl5°. The participants had fixated on 
the internal fixation target. The SD of the mean was <10pm in 9 of the 55 participants, between 
1 lpm and 20pm in 36, and between 21 and 30pm in 9 participants and 57pm in the remaining 
participant (who was from Group III). The contour line had been drawn by IAC, a senior 
ophthalmologist trained to fellowship standard in glaucoma and highly experienced in optic 
nerve head assessment and in the drawing of the contour line with the HRT, who was masked to 
the purpose and design of the study. The images had been analysed by software version 1.6.
4.1.2.2 Analysis
The HRT standard printout including the Moorfields Regression Analysis was produced for each 
individual.
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4.1.3 Results
The box and whisker plots for the NRR sector values for each of the four groups is presented in 
Figure 4.1.1. The analysis does not identify any segmental differences in the NRR sector areas. 
Some eight data points were excluded as the data as measured by the HRT was clearly inaccurate 
and yielded illogical quantities likely representing misreading of the raw data by the MRA.
The MRA analysis by sector defined all the normal individuals as ‘normal’. (Figure 4.1.2) 
Three of the 21 patients with epilepsy with no exposure to VGB, were designated as ‘borderline’ 
in the superior nasal sector (Table 4.1.1). However, all 3 manifested normal visual fields and 
yielded normal ophthalmological findings. Six of the 13 individuals with VAVFL exhibited 
normal NRR areas in all 6 sectors. Of the remaining seven individuals, four were identified as 
‘outside normal limits’, with three identified as ‘borderline’. Of these latter four, all exhibited a 
reduced NRR area in one or more of the nasal sectors together with a normal temporal sector. Of 
the three individuals with VAVFL designated as borderline, the possible reduction in NRR areas 
was greatest in one or more of the various nasal sectors; the temporal sectors were all normal. 
One individual exposed to VGB but with normal visual fields exhibited similar reduction in the 
NRR area in the nasal sectors, combined with a normal temporal sector, to those with confirmed 
field loss.
Those individuals with VAVFL identified as abnormal by MRA also demonstrated attenuated 
mean and nasal RFNL by proportionate circle RNFL imaging with OCT and all had moderate to 
severe VAVFL.
141
Figure 4 .1. 1 Box and whisker plots for NRR area by sector. Left patients with VAVFL, middle left, 
patients exposed to VGB but with normal fields, middle right, patients with epilepsy with no exposure 
to  VGB, right, normal individuals. The solid line within the box represents the 50th percentile, the 
extrem ities of the box the 15th and 85th percentiles respectively and the whiskers the highest and low est 
values in the distribution.
VAVFL VGB exposed non VAVFL in terna l epilepsy contro ls normal contro ls
2 .5 -
2 .0 -
1.5-
0 .5 -
0 .0 -
t—i—m —i—i—r
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■  NORMAL
□  BORDERLINE 
_  OUTSIDE NORMAL
■  LIMITS
VAVFL Epilepsy Normal controls
non VAVFL controls
Figure 4.1.2 The results of the MRA analysis for the entire optic nerve head for the individuals in each of 
the four groups. The colour coding is that used on the MRA printout.
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Table 4 .1.2 Pattern of abnormality for the Neuroretinal Rim Area for those individuals deemed as 
Borderline o r Outside Normal Limits by MRA. As is conventional for this system, ticks, exclamation 
marks and crosses represent respectively, normality as defined as within the 95% confidence limits, a 
borderline result (99%) and an abnormal result (99.9% percentile).
S t a t u s M R A G l o b a l T  e m p o r a l T e m p o r a l /
S u p e r i o r
T  e m p o r a l /  
I n f e r i o r
N a s a l N a s a l /
S u p e r i o r
N a s a l /
I n f e r i o r
VAVFL O u t s i d e
Nor ma l
L i mi t s
X V j X X X X
VAVFL O u t s i d e
N o r ma l
L i mi t s
V V V V ! V X
VAVFL O u t s i d e
Normal
L i mi t s
V V V X j V X
VAVFL O u t s i d e
Nor ma l
L i mi t s
! V V V X ! j
VAVFL B o r d e r l i n e j V V V j I j
VAVFL B o r d e r l i n e V V V 1 / I
VAVFL B o r d e r l i n e V V V V V ! V
VGB
exp o s e d
N o n -
VAVFL
O u t s i d e
Nor ma l
L i mi t s
X V X I X X I
Epi lepsy
C o n t r o l
B o r d e r l i n e V V V V V j V
Epi lepsy
C o n t r o l
B o r d e r l i n e 1 V V V V i !
Epi lepsy
C o n t r o l
B o r d e r l i n e V V V V V ! V
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4.1.4 Discussion
Inverse optic nerve head atrophy defined as a reduction in the nasal NRR area beyond normal 
limits was present in 7 of 13 individuals with VAVFL, and appeared to be present in one 
individual exposed to VGB but with seemingly normal visual fields. The latter case is plausible 
in that this patient also exhibited an abnormal nasal quadrant RNFL thickness together with a 
normal RNFL thickness in the remaining three quadrants (Section 3.3). In addition, as was also 
discussed in Chapter 3, structural changes are identified in glaucoma prior to the development of 
functional loss, (Caprioli et al., 2006) and this precedent appears to hold true for VGB toxicity. 
The sensitivity of the inverse optic atrophy as an indicator of VGB toxicity is clearly not as 
good as that demonstrated by measurement of the RNFL. The specificity of the presence of 
inverse optic nerve head atrophy would seem to be worse than that obtained for the measurement 
of the RNFL (by OCT) since three individuals with epilepsy and no VGB exposure demonstrated 
both inverse optic nerve head abnormality. However, it should be noted that these three 
individuals also exhibited abnormalities in sectors other than the nasal region in RNFL thickness 
measurement by OCT.
Although the MRA was able to identify VAVFL in 7 of 13 individuals, the nasal thinning was 
clinically less obvious than that for the RNFL attenuation by OCT.
The poorer sensitivity of the HRT to detect inverse optic nerve head atrophy manifested in terms 
of reduction in the NRR area compared to the OCT manifested in terms of attenuation of retinal
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nerve fibre layer attenuation can be explained by the resolution necessary to identify abnormality 
in the structure under measurement. The NRR comprises a confined area where nerve fibres 
from all areas of the retina coalesce and merge with blood vessels prior to entering the optic 
nerve. The NRR sector measure is therefore, less likely to identify subtle attenuation in RNFL.
4.1.5 Conclusion
It would seem that the presence of inverse nasal optic atrophy as defined by a reduction in the 
NRR area is not as sensitive a marker of VGB toxicity than measurement of the RNFL by 
sectoral discrimination by OCT.
In addition, the presence of inverse nasal optic atrophy as defined by a reduction in the NRR 
area, under the resolution of the current commercially available HRT, is only associated with 
moderate to advanced cases of VAVFL.
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4.2 Placental transfer of VGB: no indication of visual field 
loss
4.2.1 Introduction
It can be surmised that, worldwide, a substantial number of women of childbearing age will 
have received VGB. However, uncertainty persists regarding the potential for visual 
dysfunction in individuals exposed in utero to VGB. To our knowledge, only one report has 
described the outcome of systematic visual field examination of prenatally exposed 
individuals; two children, unrelated to each other, each produced inconclusive visual field 
examinations (Sorri et al., 2005). Many children exposed to VGB, prenatally, are reaching the 
age where complete ophthalmological examination is possible.
4.2.2 Aim
The aim of this case series was to assess whether VGB-attributed visual field loss was present 
in children with placental transfer of VGB.
4.2.3 Methods
Three families (4 children) were identified in which each mother completed one or more 
successful pregnancies whilst receiving VGB for refractory partial epilepsy. The three
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mothers were aged 44, 39, and 39 years. The duration of the refractory partial epilepsy was 
26, 17 and 24 years and the duration of VGB exposure 8.5, 9.75 and 6.7 years, respectively. 
The cumulative VGB dose and mean daily dose were 8.75, 10.5, and 7.32 kg, and 2.82g, 
2.74g and 2.99g respectively. Two mothers (M2 and M3) had taken one other anti-epileptic 
drug (carbamazepine in both cases) within the conception period and this was continued 
throughout pregnancy in mother M3.
Three of the four children were female. The ages of the children were 6, 10, 8 and 15 years, 
respectively. All four children were bom at term and were exclusively formula fed. VGB 
placental transfer, which may reach 100% (Tran et al., 1998, Abdulrazzaq et al., 2001), 
therefore represented the only mechanism of VGB exposure. Cumulative VGB gestational 
dosage was recorded and all three mothers reported compliance with medication before and 
during pregnancy. The estimated in utero exposure to VGB using area under the curve 
estimates for fetal growth is shown in Table 4.2.1.
4.2.3.1 Perimetry
Each of the mothers underwent perimetry of the full and central field with the Humphrey 
Field Analyzer [Carl Zeiss Meditec, Dublin CA]) as recommended by the Marketing 
Authorization Holder. (Pharma, 2001) Reliable outcomes to the visual field examination, in 
terms of incorrect responses to the false negative, false positive and fixation-loss catch-trials,
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were obtained in all three mothers. Each of the children underwent two-zone suprathreshold 
perimetry of the full field in an identical manner to that of their mother. Reliable results were 
obtained in all four children.
4 . 2 . 3 . 2  I m a g i n g  w i t h  O C T
The RNFL thickness was determined for each mother and child using the RNFL Thickness
3.4 Protocol of the StratusOCT (Carl Zeiss Meditech, Dublin, CA). All scans exhibited the 
requirements of a signal to noise ratio greater than 25dB and at least 90% good quality A- 
scans. The study had approval from the South East Wales Ethics Committee.
4.2.4 Results
The three mothers and the four children were visually asymptomatic, and the visual acuity 
and fundoscopy, through dilated pupils, were normal in each individual.
Two of the three mothers each exhibited VAVFL for both types of visual field examination 
and an abnormally attenuated RNFL thickness. ( Figure 4.2.1) The third mother exhibited a 
left upper temporal partial quadrantanopia, secondary to an anterior temporal lobectomy, and 
a normal RNFL thickness. Multifocal ERGs were within normal range for all mothers for 
both eyes.
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All four children manifested normal visual fields. The mean and nasal quadrant RNFL 
thickness for each child was well within the normal range for adults (the StratusOCT software 
does not contain a database for children although children are considered to exhibit 
comparable RNFL thicknesses to adults). Results are contained in Figure 4.2.2.
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Figure 4 .2 .1 Visual fields are presented for M other I. The grayscale depictions for left and right eyes 
are situated at the top, whilst pattern and total standard deviation responses are situated middle and 
lower respectively. Bilateral VAVFL, with predom inantly nasal visual field loss is demonstrated.
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Figure 4.2.2 The RNFL thickness is dem onstrated for Mother I (top) and one of her daughters 
(bottom). The letters N, S, T, and I represent oblique quadrants nasal, superior, temporal and 
inferior respectively. The normal distribution percentiles demonstrate the normal average and sector 
responses for the daughter, and in contrast the  attenuated nasal, superior and inferior RNFL of the 
mother, with temporal sparing.
Mother 1
Normal
Distribution
Percentiles
Daughter 1.2
0 100 200 300 400 500
TEMP SUP NAS NF TEMP
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Family 1 Family 2 Family 3
Mother 1 Daughter
1.1
Daughter
1.2
Mother 2 Daughter
2.1
Mother
3
Son 3.1
ge at
ssessment
/rs)
44 6 10 42 9 43 15
GB
sstational 
□se (kg)
0.560 0.560 0.560 0.662 0.662 0.287 0.287
GB dose
ig/kg/day
quivalent
1200 1200 1410 600
isual Field 
tatus
VGB- 
attributed 
visual field 
loss
Normal Normal VGB- 
attributed 
visual field 
loss
Normal Normal Normal
lean retinal 
srve fiber 
.yer
dckness
LNFLT)
im)
55
Abnormal
109 106 70
Abnormal
110 104 115
asal RNFLT 
im)
31 102 81 34 71 74 76
Table 4.2.1 VGB in utero. The table details the  demographics and results for the three families. For 
the RNFL thickness, only abnormal results are labelled as such. All others are deemed to  be within 
normal limits. Nasal RNFLT refers to  nasal quadrant values.
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4.2.5 Discussion
This is the first report of definitively normal visual fields in children exposed prenatally to 
VGB across a range of placental doses. The four children exposed prenatally to VGB 
manifested normal visual fields and a normal RNFL thickness.
Infants treated with VGB for infantile spasms normally receive dosing regimens of 100-150 
mg/kg/day. It is noteworthy that the estimates of the maximum fetal daily dosing of the four 
children were up to ten times this amount. However, infants exposed to VGB after 6 months 
of age are approximately 2.5 times more likely to exhibit VGB toxicity compared with those 
exposed before 6 months of age (Westall, 2007) suggesting a possible physiological 
immaturity effect. A possible explanation for the lack of visual dysfunction following high in 
utero exposure may reflect the lack of placental metabolism of VGB, suggested by equal 
amounts of active and inactive enantiomers, in contrast to the maternal excess of active 
enantiomer (Challier et al., 1992). The pathogenesis of retinal toxicity in VGB is still not 
understood. It is speculative, but plausible, that the mechanism of toxicity requires VGB 
metabolites, which may be absent in utero and relatively under-produced in neonates. All 
children were exposed via placental transfer, alone. No definite assertion can be made 
regarding the safety of maternal breastfeeding whilst on VGB.
In terms of possible teratogenicity of VGB, the findings are clinically reassuring, and, if 
representative, obviate the need to identify and then examine ophthalmologically, children
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exposed to VGB in utero. Furthermore, for the few remaining women of childbearing age still 
receiving VGB, the findings can aid informed discussion about potential visual aspects of 
VGB teratogenicity. The latter should also be placed in the context of possible unplanned 
pregnancy in women treated with VGB as an anti-addiction drug. (Fechtner et al., 2006)
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4.3 VGB-Attributed Visual Field Loss In Uniquely Low Cumulative 
Dosing: Implications For Potential Use In Anti-Addiction Therapy.
4.3.1 Introduction
VGB offers potential as an anti-addiction therapy for misuse of stimulant drugs. The increase 
in brain extracellular dopamine in substance misuse is one of the markers and mediators of 
drug ‘highs’ (Gerasimov et al., 2001) and can be attenuated by elevation of GABA. The 
efficacy and visual safety of VGB as an anti-addiction therapy, has recently been investigated 
in an open-label study, (Fechtner et al., 2006) and is currently undergoing Phase II trials. In 
the trial cited above, VGB was prescribed in a short-term (9 weeks) low daily dosing and low 
cumulative dosing (0.137 kg) regime with a consequently lower risk of visual field loss.
4.3.2 Case Report
A 34-year-old man with epilepsy with no previous visual problems developed asymptomatic 
visual field loss during an estimated maximum cumulative dose of 0.15 kg of VGB i.e. 
similar to that advocated for anti-addictive therapy.
VGB had been prescribed as an adjunctive treatment to carbamazepine for intractable
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temporal lobe epilepsy. He had previously taken sodium valproate but this was discontinued 
due to a perceived lack of efficacy. Initial titration of VGB was attempted up to 500mg twice 
daily over 8 weeks. Unfortunately this regimen was not well tolerated, and he returned 
reporting non-compliance and rapid unsupervised withdrawal after some 3 weeks. A further 
attempt, involving slow titration of 250 mg increments of VGB per month, proved 
unsuccessful and his clinician finally withdrew VGB some 8 months later, citing adverse 
effects and a perceived lack of efficacy. However, the patient asserted that he had taken the 
drug irregularly, and had discontinued use several weeks earlier. He remained visually 
asymptomatic and was called for routine visual assessment, including perimetry, some 14 
months later (Figure 4.3.1). Perimetry was undertaken according to the techniques 
recommended by the marketing authorisation holder for VGB, namely two-zone (three level) 
age-corrected suprathreshold perimetry of the full field and threshold perimetry of the central 
field. The results clearly indicated a bilateral symmetrical concentric constriction with some 
sparing of the temporal field, typical of late-stage VAVFL. The individual had not been aware 
of visual field loss prior to the visual field examination and did not demonstrate any features 
consistent with functional visual loss. In addition, the field loss was remarkably consistent 
across the two types of perimetry, which necessitate two fundamentally different 
requirements in response.
4.3.3 Discussion
The use of VGB as a potential anti-addiction agent is predicated upon a short-term, low 
cumulative dose schedule and is therefore designed to minimise the risk of visual field
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loss. Unfortunately, there are large inter-individual differences at which individuals manifest 
VAVFL following VGB. The dosing regimen is based upon an exposure of <10% of that 
considered to result in VAVFL. However, the original study investigating relationships 
between VGB dosing and visual field loss reported only a modest correlation between visual 
field defects and cumulative dose ingested (spearman correlation coefficient = 0.506, p = 
0.09). (Manuchehri et al., 2000)
In the pilot addiction study, VAVFL did not occur in 18 individuals with methamphetamine 
or cocaine addiction who received a cumulative VGB dose of 0.137 kg, over 9 weeks. 
(Fechtner et al., 2006) It is notable that three weeks of the therapy schedule comprised 3.0 
g/day of VGB (compared with typical adult epilepsy doses ranging from 0.5 to 3.0 g). A high 
mean daily dosing is known to carry an increased risk of VAVFL. (Wild et al., 2007)
Pragmatically, VGB prescription in addiction is likely to require higher doses than have been 
proposed. It may be possible to overcome the attenuation of dopamine increase in ‘highs’ 
with escalated substance dosing. To date, I am not aware of any research that investigates this 
issue. In a clinical context, higher baseline substance doses might respond more effectively to 
increased doses of VGB. Relapse may further obviate repeat prescription, further increasing 
the cumulative dose.
Our case demonstrates that VGB dosing within the proposed range for anti- addiction can 
cause irreversible visual field loss in susceptible individuals. Screening individuals
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exposed to VGB with perimetry merely serves to document the onset of irreversible visual 
field loss. Currently, there are no available definitive predictors of individual risk factors for 
the development of VAVFL. An alternative biomarker for the development of VAVFL is an 
attenuated retinal nerve fibre layer thickness (Wild et al., 2006) and in particular, nasal 
quadrant attenuation (Chapter 3). Nasal quadrant attenuation may precede visual field loss, 
and in the absence of definitive trials (which would be ethically unsound), screening of the 
retinal nerve fibre layer thickness, with particular reference to the nasal quadrant might be 
adopted.
This case report supports the notion that there is no ‘safe’ dosing regimen for VGB for any 
given individual. Any anti-addiction protocol would need to be carefully discussed with the 
individual concerned, particularly as visual field loss might result in revocation of driving 
privileges. Anecdotally, I perceive that clinical use of VGB in epilepsy is once again 
increasing, possibly driven by the request by the Market Holders of VGB (Ovation) to licence 
VGB for partial-onset epilepsy in the US. The discussion here is clearly relevant in both 
settings, but individual contexts (e.g. no possibility of driving) might facilitate use of VGB 
with more ready acceptance of the visual risks.
Figure 4.3.1 This Visual Field Print-Out From The Full Field 135 Screening Test And The Three Zone 
Age-Corrected Strategy (Top) And O f Program 30-2 Using The FASTPAC Strategy, Exhibits VGB 
Attributed Visual Field Loss.
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Chapter 5: The mfERG In VGB Toxicity
5.1 The Application Of Multifocal Technology In VAVFL: 
Introduction to mfERG
5.1.1 mfERG: Justification for using Multi-focal Technology
Of the variety of electrophysiological tools used to investigate VAVFL, the standard 
ERG has been most widely used. It seems clear that the most reliable indices of the 
standard ERG as markers of VAVFL include reduced photopic b-wave amplitudes 
(Arndt et al., 1999, Coupland et al., 2001, Krauss et al., 1998, Sills et al., 2001) and a 
reduced 30Hz flicker ERG. (Harding and Wild et al. 2000) Despite this, several 
studies have reported normal ERGs in VAVFL. (Blackwell et al., 1997, Gross-Tsur et 
al., 2002, Harding, 1997, Lawden et al., 1999). Section 1.2.12 contains a fuller 
discussion of electrophysiology changes in VGB related visual field loss.
However, there are major pragmatic technical difficulties in applying standard ERG 
to children and learning disabled populations. Young children often require sedation 
to undertake ERG, and the long testing time is labour intensive requiring several visits 
for many individuals, particularly children and learning disabled adults. The use of 
contact lens electrodes used frequently in ERG testing is associated with a significant 
risk of comeal abrasion. Thus, standard ERG requires a major time commitment (with 
the inherent cost therein), plus a willingness and investment in cooperation and carries
161
clinical risk of sedation and abrasion, making it a poor tool for screening or 
monitoring paediatric populations. Certainly, in the UK, with relative paucity of 
funding and strict ethical constraints governing screening investigations and consent 
issues for children and adults deemed unsuitable to provide consent, the current 
standard ERG is not a viable option.
The mfERG provides a topographical regional response designed to identify local or 
patchy disease processes. This contrasts with standard ERG, which is a mass response 
and local variations (typical in retinopathies of all kinds) are lost.
Whilst the mfERG is technically challenging, it is faster and better tolerated than its 
standard counterpart. We use DTL fibre as the electrode rather than a glass contact 
lens and find that it is exceptionally well tolerated. Once set-up, useful information 
can be derived from just 7 minutes of recording time, split into 15 or 30 second 
intervals, and if necessary, this time can be halved.
5.1.2mfERG: Introduction In Context of Standard Electrophysiology
The standard ERG is a mass response to a single flash of light: this is recorded under 
ISCEV guidelines in photopic and scotopic conditions to generate both a rod and cone 
driven response. (Marmor et al., 2008) The ERG response largely comes from the
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outer retina (photoreceptors and bipolar cells), with little contribution from the 
ganglion cells, and optic nerve. (Tomita, 1982) The mass response is accrued from the 
entire retina, and the contribution from the central area particularly is small, as it will 
also be for small patchy eccentric areas of the retina. Small areas of abnormality (even 
in visually important areas) may be readily missed on standard ERG.
Other available electrophysiology tools include the focal ERG, and the pattern ERG 
or PERG (that provides a largely foveal response). The PERG, in contrast to the 
standard ERG, has a clear discriminant of primary ganglion cell disease in that the 
N95 component is reduced or absent in primary ganglion cell disease. (Manca et al., 
1984)
The mfERG was conceived as a topographical representation of regional responses to 
overcome the problem of missed abnormalities from massed responses. (Poloschek 
and Sutter, 2002) In combination with perimetry, localisation and monitoring of 
disease can be effected. (Hood et al., 2003b)
The mfERG also largely represents outer retina responses. The waveform bears a 
resemblance to the ERG, with a negative first wave (Nl), comparing with the a-wave 
of the ERG, and a positive second wave (PI), similar to the b-wave of the ERG, with 
a trailing ‘ledge’. (Figure 5.1) Whilst definitive certainties cannot be made regarding 
the derivation of individual mfERG waveforms (the traces are mathematically derived
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rather than generated in the truest sense of the word); plausible speculation (Hood et 
al., 2003a) accompanied by experimental design (Hood et al., 2002) and clinical 
correlation allows a reasonable attribution of retinal structure and correlation.
The mfERG (a cone response) is predominantly representative of bipolar cell activity, 
with a smaller contribution from photoreceptor cells. Damage at or before the bipolar 
cells results in reduction in amplitude of the mfERG, although bipolar cell damage 
may not result in delayed responses; delay in timing of the mfERG is likely to reflect 
photoreceptor cell or outer plexiform cell damage. Contribution from inner retinal 
cells (amacrine and ganglion cells) is relatively small; damage to the amacrine or 
ganglion cells seems to affect the waveform, in particular that of the trailing ledge of 
PI. Ganglion cell damage seems either not to affect timing of the mfERG, or may 
even shorten the PI implicit time. (Seiple et al., 2002, Fortune et al., 2004)
Figure 5.1.1 Comparison of Full-Field ERG with mfERG
A. mERG (10 Hz, 300 Hz)
Nl
N2
B. full-field ERG (1 Hz, 1000 Hz) 
Hb-wave & OPs" 
a-wave
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In summary, the multifocal electroretinogram (mfERG) comprises numerous 
simultaneously recorded local ERG responses from several regions across the retina. 
In keeping with the standard full-field ERG, the response is largely derived from the 
outer retina, and has little contribution from the ganglion cells. The mfERG may 
therefore be of most benefit in distinguishing between diseases of the outer retina and 
the ganglion cells/optic nerve. Clinically, mfERG has been mooted as a useful tool in 
monitoring retinal disease, particularly patchy retinal disease (eg retinitis pigmentosa) 
where the mass response of the standard ERG may remain normal for some time into 
the clinical syndrome. In addition, together with mfVEP, the techniques may add 
useful information in suspected non-organic visual loss.
5.1.3 mfERG: Principles
The regional traces are made possible by the stimulus presented and the software 
required to process the response. The classic stimulus is of 61 or 103, scaled 
hexagons, which subtend 50° at 32 cm viewing distance. The hexagons are scaled to 
produce approximately equivalent response sizes across the retina based on normal 
retinas; typically a central sector subtends 3° whilst a peripheral sector subtends 7°. 
The 61 sector stimulus uses slightly larger sectors but with the consequent price of 
poorer resolution.
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The hexagons or sectors all independently undergo a unique pattern of frame shifting, 
either shifting from white to black (or vice versa) or staying unchanged every 13.3 
milliseconds in a unique way, different from all other sectors (Figure 2.3.2). In fact, 
this sequence is not pseudo-random, but a set binary change sequence called a m- 
sequence, typically composed of a minimum of 64 frame shifts. Each sector begins 
this same sequence at a different point. The recorded response is a single continuous 
trace, from which the individual sector traces are extracted via a software algorithm. 
These individual traces are determined by the serial correlation between the 
stimulation sequence of a particular hexagon with the continuous single trace. 
(Jurklies et al., 2002) This system is patented by EDI, and marketed as the VERIS 
system (used in this study); other production systems use alternative similar 
techniques to extract the individual traces.
5.1.4 mfERG: Acquisition.
The multifocal response is recorded in accordance with ISCEV guidelines. (Marmor 
et al., 2003) Recordings take place in the light adapted patients. The response is 
recorded with either contact-lens electrodes (typically the glass Burian-Allen 
electrode) (Burian and Allen, 1954) or with non-contact-lens electrodes, the most 
popular of which is the Dawson- Trick-Litzkow (DTL) electrode employed in this 
thesis. (Dawson et al., 1979) Corneal electrodes provide larger better quality 
responses, but almost invariably require local anaesthetic and are less comfortable 
than non contact-lens electrodes. The stimulus is presented with a luminance of
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between 100 and 200 cd/m2 . ( M a r m o r  et al., 2003)
5.1.5 mfERG: Display and Interpretation
The responses may be displayed in a variety of ways; the individualised traces are 
seen in the trace array, and any combination of these individual traces may be 
grouped for summing or averaging (Figure 2.4.2). This trace is invaluable in 
identifying local defects, and also demonstrates the normal nasotemporal trend typical 
of the healthy retina. (Seeliger et al., 2001) The software also routinely displays 
annular rings around the fixation point. These rings are presented as response 
densities (nV/deg ) as if merely response size were displayed, then the responses 
would increase in amplitude from the centre to the periphery due to increasing area 
size. Presenting the values in a response density format enables a more useful 
comparison across the annuli. Also presented is the 3D plot. This is a three 
dimensional representation of responses across the retina. Although this plot is 
appealing and can help identify the blind spot and fovea and thus provide some 
information regarding accuracy of fixation, it must never be interpreted in isolation, 
as it can be misleading. The chief problem with the 3D plot is that noise may be 
interpreted as meaningful signal. This is because the peak response (signal per area) 
will always be at the fovea, due to the central area being smallest. Therefore, in an 
example where no recorded response is seen, and only noise is recorded, the peak 
noise will be seen at the fovea.
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5.1.6 mfERG: Limitations
Traditionally, a LCD monitor system has been used to display the stimulus, and 
allows binocular recordings, and therefore halved acquisition time. However, the 
newer VERIS model also offers the option to display the stimulus monocularly with a 
built-in fundal camera for monitoring fixation stability.
5.1.7 mfERG and VGB: Rationale
In keeping with limited VGB exposed populations and a still evolving technology, 
there is little data regarding the use of mfERG in VGB exposed populations. Lawden 
et al (Lawden et al., 1999) reported reduced peripheral amplitudes in 2 people with 
VAVFL, a finding echoed in a further 2 adults with VAVFL from an Australian 
cohort (Mackenzie and Klistomer, 1998), whilst a more specific finding of reduced b- 
wave amplitude (now called the PI in standard nomenclature) was found in 6 of 12 
adults with VAVFL. (Ponjavic and Andreasson, 2001) These groups did not report 
alteration in implicit times, although study with the wide-field mfERG, which 
assesses out to 90° of the visual field, reported a significant difference in implicit 
times, with reduced peripheral PI implicit times compared with central times. 
(McDonagh et al., 2003) This admittedly limited data in VGB in conjunction with 
current understanding regarding localisation of mfERG data encouraged me to apply 
the technology for the reasons outlined below (Section 5.2.1).
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5.2 mfERG: Study In VGB
5.2.1 Aims
The overall aim of this study was to investigate whether the mfERG technology 
identified retinal dysfunction attributable to VGB and the relationship of any 
abnormality to the visual field. More specifically, the aims were fourfold. Firstly, to 
determine whether a reduction in amplitude was present for one or more of the 
mfERG waveforms thereby implicating bipolar dysfunction in the pathophysiology of 
VGB toxicity. Secondly, to determine whether abnormalities in the implicit time of 
one or more of the mfERG waveforms were present, thereby implicating 
photoreceptor dysfunction (in the case of delayed implicit time) or retinal ganglion 
cell dysfunction (in the case of a shortened PI implicit time) in the pathophysiology 
of VGB toxicity. Thirdly, to quantify the relationship between any abnormality in 
amplitude and/or implicit time of one or more of the mfERG waveforms and the daily 
dose and duration of VGB intake. Fourthly, to quantify the relationship between any 
abnormality in amplitude and/or implicit time of one or more of the mfERG 
waveforms and the severity of the visual field loss.
5.2.2 Methods
5.2.2.1 Cohort
A normal cohort was recruited for a pilot study and is described in Table 5.2.1. A 
cohort comprising 24 normal individuals was recruited to derive the normative dataset 
and is described in Table 5.2.2. However, for reasons described below (5.2.3.1) this
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dataset had to be discarded. A further set of normal individuals containing 6 of the 
normal cohort from 6.2.2 formed part of the final study cohort used to investigate 
VAVFL and this cohort is detailed in Table 6.2.3.
Group (Total) Gender Mean Age (yrs) 
(SD)Male Female
Normal Controls (20) 9 11 28.5 (3.4)
Table 5.2.1 The summary measures (Group Mean, Standard Deviation [SD]) of the 
demographies characteristics of the pilot data cohort
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Group (Total) Gender Mean Age (yrs) 
(SD)Male Female
Normal Controls (24) 9 15 36 (9.4)
Table 5.2.2 The summary measures (Group Mean, Standard Deviation [SD]) of the
demographical characteristics of the original normative dataset
Group
(Total)
Gender Mean 
Age (yrs) 
(SD)
Mean
Duration of 
Epilepsy 
(yrs) (SD)
Mean
Duration of 
Vigabatrin
(yrs) (SD)
Cumulative 
dose of 
Vigabatrin
(kg) (SD)
Male Female
VAVFL (4) 1 4 49.0 (7.2) 25.6
(8.2)
9.49
(1.63
11.03
(2.53)
VGB-
Exposed (9)
2 7 43.0
(17.4)
24.89
(10.1)
7.64
(2.48)
6.96
(2.46)
Controls
(13)
4 9 41.69
(20.5)
0 0 0
Table 5.2.3 The summary measures (Group Mean, Standard Deviation [SD]) of the 
demographical characteristics for each of the three groups)
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5.2.2.2 Examination Protocol
Direct contact and included colleagues, fellow post-graduate students, friends and 
family recruited the normal control individuals. The VGB-exposed adults were 
recruited from the Welsh Epilepsy Unit, University Hospital of Wales, Cardiff, and 
the adolescents from the Paediatric Neurology and Adolescent services at the 
University Hospital of Wales, Cardiff. All individuals conformed to rigid inclusion 
criteria in each eye including a distance refractive error of less than or equal to 5 
dioptres mean sphere and less than 2.5 dioptres cylinder; open angles, clear ocular 
media; no fundal or optic nerve head abnormalities characteristic of known disease 
other than VGB toxicity; no previous ocular surgery or trauma; no history of diabetes 
mellitus and no family history of glaucoma. All individuals exhibited a visual acuity 
of 6/9 or better in each eye. All patients underwent standard neurological examination 
at visit 1.
5,2.23 Equipment
The mfERG was recorded using the VERIS™ Multifocal System with Integrated 
Fundus Monitoring System, (supplied by EDI) with software version VERIS 5.1.
This multifocal system utilises a built-in fundus camera designed to allow direct 
observation of fixation. However, the disadvantage of the camera is that only 
monocular mfERGs can be recorded, thereby doubling the chair time. Pragmatically, 
it was felt that, in children and learning-disabled adults, the advantage of observing
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fixation was outweighed by the increase in recording time and by the likely 
subsequent reduction in cooperation and, therefore, lower completion rates.
A pilot study in 20 normal adults was therefore undertaken to compare the results 
from the camera system to those obtained with a high-resolution CRT monitor system 
and binocular mfERG. (Appendix section A.2.2). The traces from each technique 
were treated identically in terms of smoothing and averaging. A subjective inspection 
of the data suggested similar trace quality across the two techniques. Both techniques 
yielded similar values for amplitude and implicit times although the amplitudes 
produced from the monitor system were slightly smaller. In addition, the adults were 
asked to score their experience with each technique, on a rating score from 1 to 5, 
with 5 being the most positive outcome. All consistently rated the monitor more 
highly.
5.2.2.4 Set-up
The set-up used for all participants in this study agreed with current ISCEV multifocal 
guidelines for mfERG. (Marmor et al., 2003) Pupils were dilated with 1% tropicamide 
to ensure a minimum pupil diameter of 7 mm and placed in a fully lighted room (the 
recording room) for 15 minutes prior to recording. The skin was prepared with 
standard abrasive gel used in electrophysiology (NuPrep). DTL fibre electrodes with 
disposable electrode heads were used for the reference and ground electrodes. 
(Dawson et al., 1979) The electrodes were applied at the outer canthus and forehead 
respectively with EEG paste and secured with cotton gauze and micropore.
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(Figure 5.1.1) The preparation and placement o f the electrodes were in accordance 
with ISCEV mfERG standards,(Marmor et al., 2003) Impedance was measured for 
the reference and ground electrodes, using a customised ohmmeter made by the 
Medical Physics Department at the Queens Medical Centre from a design pioneered 
by Mitchell Brigell, and was deemed acceptable if  the value was <10kQ, and if  both 
recording channels were within 2kQ o f recorded values.
Figure 5 .1. 1 Subject prepared for binocular mfERG recording
Patients were sat in front o f the screen at a recording distance o f 48-54 cm . Fixation 
was observed by direct observation o f  the patient by the researcher. Refraction was 
applied as prescription with plus 2 dioptres as a standard adjunct allowing for full 
dilation, in all individuals aged over 25 years.
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Stimulus Properties
The frame rate o f the high-resolution monitor was a CRT monitor was 75 Hz and the 
screen luminance was 150 cd/m in full light. The stimulus pattern was a standard 
hexagon sized for retinal eccentricity with 61 local stimuli. The VERIS system uses 
an m-sequence and no extra frames or specialist inserts were applied. The stimulus 
pattern subtended an angle o f 30° on either side o f  fixation. (Figure 5.2.2) The gain 
settings were 100,000 with bandpass filters o f  3 and 100 Hz. The notch filter was not 
used. No averaging with neighbouring responses was applied. A red cross, 0.5°in 
diameter, served as the fixation target.
Figure 5.2.2 An example of the stimulus scaled for retinal eccentricity and similar to  that 
applied in the current study
5.2.3.1 Artefactual Change in the First Normative Dataset for mfERG
The characteristics o f the cohort forming the first nonnative database are given in
175
Table 5.2.2.
This first dataset revealed significant differences in PI implicit times, as compared 
with all 8 VGB exposed individuals examined up to the date of the preliminary 
analysis. However, this latency delay was present for all waveform at all locations and 
affected both central and peripheral regions equally and was identical in each 
individual.
One possibility for the delay in implicit times could have resulted from the older ages 
of the 8 VGB-exposed individuals compared to the majority of the normal 
individuals.
The PI implicit times of the normal individuals were re-analysed by age and also by 
the calendar date of the examination. In addition, some individuals were repeated to 
validate the magnitude of the PI implicit times.
The PI implicit times showed a tendency to increase with increasing age. As a 
consequence, the range in the age of the normative database was expanded to include 
individuals from 18 to 77 years of age. The expanded database showed a clear 
increase in PI implicit times with increasing age.
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However, the calendar-based analysis showed a clear difference in PI implicit times 
(and on further analysis also N1 and N2 implicit times) before and after August 2006. 
Further analysis of those individuals in whom traces had been recorded before and 
after August 2006 was undertaken. In particular, one individual had had bilateral 
recordings taken 5 times over this time period and her data clearly showed an increase 
in implicit time of approximately 5 ms in all traces performed after mid-August 
(Figure 5.2.3). The remaining four other individuals also exhibited a similar increase 
in implicit times by 5ms at all three waveforms and in a uniform manner and over the 
same time period.
The only identifiable change to the VERIS system during this time period was a 
software upgrade on the VERIS system from V.l to V.3 uploaded from disc 
seemingly without incident. The software was uploaded to address a problem with 
malfunctioning software that had led to system failures on attempted execution of 
certain analysis settings. It was entirely feasible that the software upgrade could have 
been responsible for the increase in implicit timings as they are derived from the 
continuous trace by a complex application of the mathematics of the M-Sequence 
which was adjusted for the software upgrade.
As a consequence, the original normative dataset was discarded and a new normative 
dataset was collected with the new software. Fortunately, all the patients exposed to 
VGB had been examined with the revised software. No further upgrades to the 
VERIS system were permitted during the course of this study.
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Figure 5.2.3 An example of a typical mfERG trace recorded from a normal individual with 
the original software (top) and with the software revision (bottom) showing a marked 
increase in all implicit times. Note, the amplitudes remain approximately the same for the 
two software versions.
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5.23.2 Sector Analysis Of mfERG
The traces produced from each of the 61 locations for each eye of each individual 
represents a huge array of data for analysis. Grouping of data, either in annuli or in 
customised clusters, is readily achievable using the VERIS software and produces an 
improvement in trace quality with the consequent narrowing of confidence intervals 
for normative values. (Tam et al., 2006)
Given that VAVFL produces a concentric field loss, predominantly in the peripheral 
field, with a nasal dominance, the interesting regions for comparison were best 
represented by central and peripheral annuli, and by annuli further quartered into 
nasal and temporal regions. The grouping of the 61 traces into 8 sectors for analysis is 
displayed in Figure 5.2.4.
Figure 5.2.4 The custom grouping of the  61 traces into 8 Sectors, Sectors I, 3, 5 and 7 
reresent the central field out to  approximately 15°; Sectors 1,2,3,4 represent the nasal 
hemifield and sectors 5, 6, 7,8 the tem poral hemifield.
Modelling the mfERG data
One of the major technical difficulties with mfERG analysis relates to the quality of 
the raw data. The low signal to noise ratio inherent in such responses gives rise to 
difficulty in determining amplitude and implicit time for each of the three designated 
waveforms.
An example of an electrically noisy trace is provided in Figure 5.2.5a. An illustration 
of the VERIS software-assigned values from which the implicit times and amplitudes 
are calculated is shown in Figure 5.2.5b. It is standard practice to attempt to model 
raw mfERG traces in order to reduce, if not eliminate, extraneous sources of noise.
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Figure 5.2.5a (left) and 5.25.b (right) depicting the  raw data from a mfERG trace from the 
right eye of a healthy individual in 6 1 traces (5.25a) and grouped into 8 sectors with values 
determined by VERIS software (5.25b)
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5.23.3 Fourier Analysis
One standard approach used to reduce noise is to apply a Fourier transformation, with 
a sharp cut-off after the third harmonic. (Hood et al., 2003a, Seiple et al., 2004) This 
was applied to all the sector traces before the analysis both of implicit times and 
amplitudes.
5.23.5 Analysis Of The Fourier-Transformed Data
The Fourier-transformed traces for each sector, for each eye, for each individual 
exposed to VGB were compared to the maxima and minima of the range of Fourier- 
transformed values, for the right and left eyes respectively, derived from the normal 
individuals for each of the N l, PI and N2 amplitude and implicit time. All VGB 
exposed individuals exhibited normal amplitudes and implicit times for all waveforms 
in each eye for all sectors. The results are shown in Tables 5.3.1 to 5.3.12.
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Sector 1
(ms)
2
(ms)
3
(ms)
4
(ms)
5
(ms)
6
(ms)
7
(ms)
8
(ms)Status
VAVFL Mean 47.00 47.80 45.20 44.80 44.40 44.20 44.40 44.20
N 5 5 5 5 5 5 5 5
SD 1.58 1.64 1.79 2.17 2.30 2.17 2.30 2.28
Minima 45.00 46.00 43.00 42.00 42.00 41.00 42.00 42.00
Maxima 49.00 50.00 48.00 47.00 47.00 47.00 48.00 48.00
VGB- Mean 47.5 48.00 47.38 47.75 45.88 45.75 46.50 46.38
Exposed N 8 8 8 8 8 8 8 8
SD 3.07 3.82 3.46 3.85 2.80 2.92 3.46 3.66
Minima 44.00 44.00 43.00 44.00 43.00 43.00 43.00 43.00
Maxima 52.00 55.00 52.00 53.00 50.00 50.00 52.00 53.00
Normal Mean 46.33 45.93 45.40 45.73 44.40 44.20 44.60 44.73
Control N 15 15 15 15 15 15 15 15
SD 4.27 4.92 4.32 3.69 4.22 4.38 4.14 4.30
Minima 40.00 39.00 39.00 40.00 38.00 38.00 39.00 39.00
Maxima 57.00 57.00 56.00 54.00 55.00 54.00 55.00 55.00
Table 5.3.1 PI Implicit times for the  right eye only
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Sector 1
(ms)
2
(ms)
3
(ms)
4
(ms)
5
(ms)
6
(ms)
7
(ms)
8
(ms)Status
VAVFL Mean 44.60 43.40 44.20 43.80 45.80 46.40 45.68 45.00
N ' 5 5 5 5 5 5 5 5
SD 2.61 2.79 2.49 2.17 1.92 1.95 1.82 2.55
Minima 43.00 41.00 42.00 42.00 44.00 44.00 44.00 42.00
Maxima 49.00 48.00 48.00 48.00 49.00 49.00 48.40 49.00
VGB- Mean 47.22 45.67 45.98 46.00 47.00 46.56 47.33 48.22
Exposed N 9 9 9 9 9 9 9 9
SD 2.87 2.65 2.16 2.40 3.08 2.40 2.65 3.93
Minima 43.00 42.00 42.80 43.00 44.00 44.00 44.00 43.00
Maxima 51.00 49.00 49.00 50.00 52.00 51.00 52.00 55.00
Normal Mean 45.91 44.83 45.08 45.08 45.33 45.67 46.18 44.75
Control N 12 12 12 12 12 12 12 12
SD 4.66 4.59 4.18 3.96 4.60 4.29 4.60 5.33
Minima 40.00 38.00 39.00 38.00 40.00 40.00 40.00 37.00
Maxima 57.00 55.00 55.00 54.00 57.00 55.00 57.00 57.00
Table 5.3.2 PI Implicit Times for the left e /e  only
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Sector 1
(nV)
2
(nV)
3
(nV)
4
(nV)
5
(nV)
6
(nV)
7
(nV)
8
(nV)Status
VAVFL Mean 3.16 1.05 2.00 1.67 2.97 2.46 3.35 2.06
N 5 5 5 5 5 5 5 5
SD 0.65 0.42 0.80 0.27 0.40 0.42 0.71 0.51
Minima 2.30 0.53 1.14 1.21 2.48 1.95 2.51 1.43
Maxima 4.09 1.49 3.06 1.87 3.59 3.02 4.28 2.64
VGB- Mean 3.26 1.36 3.01 2.28 3.41 2.46 3.13 2.00
Exposed N 9 9 9 9 9 9 9 9
SD 2.34 0.68 1.72 0.93 1.12 1.50 1.50 1.34
Minima 1.69 0.61 1.17 1.34 1.99 1.10 1.82 1.03
Maxima 9.34 2.70 7.17 4.36 5.38 5.56 6.80 5.44
Normal Mean 3.94 1.84 3.65 2.56 4.42 2.93 4.58 2.49
Control N 16 16 16 16 16 16 16 16
SD 0.98 0.59 0.98 0.88 1.18 1.03 1.12 0.82
Minima 2.01 0.88 1.68 0.61 0.76 0.76 2.45 1.03
Maxima 5.77 2.87 5.15 4.13 4.76 4.76 6.29 5.44
Table 5.3.3 PI Amplitude Values for the  right eye only
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Sector 1
(nV)
2
(nV)
3
(nV)
4
(nV)
5
(nV)
6
(nV)
7
(nV)
8
(nV)Status
VAVFL Mean 2.91 1.44 2.55 1.99 2.60 1.57 2.71 1.43
N 5 5 5 5 5 5 5 5
SD 0.67 1.10 0.70 0.67 0.70 0.84 0.49 0.71
Minima 2.10 0.20 1.89 1.20 1.67 0.72 2.31 0.52
Maxima 3.79 3.02 3.37 2.86 3.61 2.96 3.48 2.47
VGB- Mean 3.73 2.42 3.82 2.63 3.32 2.17 2.63 1.65
Exposed N 8 8 8 8 8 8 8 8
SD 2.17 1.78 2.22 1.83 2.34 1.98 1.87 1.32
Minima 1.62 0.63 1.49 1.09 1.37 0.38 0.91 0.42
Maxima 8.50 6.22 8.47 6.63 8.70 6.48 6.52 4.48
Normal Mean 4.53 2.56 4.14 3.01 4.09 2.04 3.75 2.11
Control N 11 11 11 11 11 11 11 11
SD 1.31 0.96 1.33 1.00 1.72 1.14 1.36 0.58
Minima 1.96 1.11 2.21 1.51 2.00 1.17 2.17 1.05
Maxima 6.38 3.61 6.13 4.26 6.97 6.79 6.97 3.17
Table 5.3.4 PI Amplitude Values for the left eye only
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Sector 1
(ms)
2
(ms)
3
(ms)
4
(ms)
5
(ms)
6
(ms)
7
(ms)
8
(ms)Status
VAVFL Mean 26.40 26.40 25.40 24.80 24.40 24.00 24.40 24.50
N 5 5 5 5 5 5 5 4
SD 1.82 2.70 2.07 1.64 2.30 1.58 1.95 1.91
Minima 24.00 23.00 23.00 23.00 22.00 22.00 23.00 23.00
Maxima 29.00 30.00 28.00 26.00 27.00 26.00 27.00 27.00
VGB- Mean 26.25 26.50 26.00 26.00 25.13 26.13 25.75 25.25
Exposed N 8 8 8 8 8 8 8 8
SD 2.38 1.60 2.67 1.93 2.47 2.47 2.25 2.19
Minima 24.00 25.00 22.00 24.00 23.00 23.00 23.00 22.00
Maxima 31.00 29.00 30.00 29.00 29.00 30.00 29.00 28.00
Normal Mean 25.00 25.00 25.25 25.44 24.31 23.94 24.00 24.56
Control N 16 16 16 16 16 16 16 16
SD 3.25 3.88 3.39 2.80 2.80 3.32 3.01 2.87
Minima 20.00 20.00 20.00 20.00 20.00 20.00 19.00 20.00
Maxima 33.00 34.00 34.00 34.00 31.00 32.00 31.00 32.00
Table 5.3.5 NI Implicit Times for the right eye only
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Table 5.3.6 NI Implicit Times for the left eye only
Sector 1
(ms)
2
(ms)
3
(ms)
4
(ms)
5
(ms)
6
(ms)
7
(ms)
8
(ms)Status
VAVFL Mean 24.60 24.60 24.00 24.20 24.80 26.60 25.00 25.00
N 5 5 5 5 5 5 5 5
SD 1.95 1.82 1.87 1.30 1.30 1.82 1.87 1.41
Minima 23.00 22.00 22.00 23.00 24.00 25.00 23.00 23.00
Maxima 28.00 27.00 27.00 26.00 27.00 29.00 27.00 26.00
VGB- Mean 25.67 24.22 25.11 25.22 26.00 25.56 25.33 26.67
Exposed N 9 9 9 9 9 9 9 9
SD 1.87 3.46 1.69 1.72 2.34 1.81 2.91 3.50
Minima 23.00 19.00 23.00 23.00 24.00 23.00 20.00 23.00
Maxima 29.00 30.00 28.00 29.00 30.00 29.00 30.00 33.00
Normal Mean 24.72 23.72 25.09 24.90 25.09 25.45 25.54 24.81
Control N 11 11 11 11 11 11 11 11
SD 3.52 4.00 3.59 3.27 3.44 3.30 3.70 4.90
Minima 20.00 16.00 20.00 20.00 20.00 20.00 20.00 18.00
Maxima 33.00 31.00 33.00 32.00 32.00 31.00 34.00 35.00
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Sector 1
(nV)
2
(nV)
3
(nV)
4
(nV)
5
(nV)
6
(nV)
7
(nV)
8
(nV)Status
VAVFL Mean -1.94 -1.02 -1.62 -1.16 -1.58 -1.79 -1.46 -1.08
N 5 5 5 5 5 5 5 5
SD 0.92 0.26 0.49 0.64 0.20 0.54 0.86 0.92
Minima -3.04 -1.42 -2.28 -2.01 -1.83 -2.74 -2.38 -2.45
Maxima -1.01 -0.74 -1.10 -0.29 -1.32 -1.44 -0.16 -0.01
VGB- Mean -2.30 -0.97 -2.23 -1.76 -2.70 -2.03 -3.16 -1.62
Exposed N 9 9 9 9 9 9 9 9
SD 1.22 0.300 1.15 1.27 2.50 1.55 2.03 0.59
Minima -5.21 -1.54 -4.99 -4.88 -9.19 -5.98 -8.31 -2.82
Maxima -0.64 -0.62 -1.34 -0.87 -1.15 -1.15 -1.81 -0.72
Normal Mean -3.29 -1.49 -3.24 -2.23 -3.46 -2.33 -3.09 -1.97
Control N 15 15 15 15 15 15 15 15
SD 1.19 0.62 1.27 0.77 1.12 0.75 1.16 0.64
Minima -5.72 -2.55 -5.75 -3.29 -5.46 -3.10 -5.17 -3.05
Maxima -1.46 -0.57 -0.93 -1.12 -1.55 -0.87 -1.33 -1.10
Table 5.3.7 NI Amplitude Values for the right eye only
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Sector 1
(nV)
2
(nV)
3
(nV)
4
(nV)
5
(nV)
6
(nV)
7
(nV)
8
(nV)Status
VAVFL Mean -2.29 -1.16 -2.09 -1.47 -1.79 -1.22 -1.81 -1.14
N 5 5 5 5 5 5 5 5
SD 0.60 0.17 0.61 0.56 0.59 0.59 0.64 0.19
Minima -3.10 -1.42 -3.03 -2.13 -1.88 -1.88 -2.30 -1.42
Maxima -1.54 -0.96 -1.34 -0.60 -0.29 -0.29 -0.80 -0.97
VGB- Mean -2.58 -1.56 -2.52 -2.24 -2.92 -1.85 -3.05 -1.60
Exposed N 8 8 8 8 8 8 8 8
SD 2.17 1.37 2.33 1.47 2.63 1.00 2.18 0.98
Minima -7.46 -4.66 -7.93 -5.63 -9.29 -3.75 -7.92 -3.69
Maxima -0.55 -0.48 -1.06 -0.87 -1.23 -0.59 -0.82 -0.31
Normal Mean -3.36 -1.51 -2.87 -2.01 -2.86 -2.18 -2.84 -1.54
Control N 12 12 12 12 12 12 12 12
SD 1.12 0.77 1.28 0.74 1.15 0.86 0.73 0.75
Minima -5.44 -3.26 -5.75 -4.17 -4.17 -3.59 -4.23 -2.43
Maxima -1.92 -0.36 -0.90 -0.12 -0.12 -0.75 -1.29 -0.23
Table 5.3.8 NI Amplitude Values for the  left eye only
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Sector 1
(ms)
2
(ms)
3
(ms)
4
(ms)
5
(ms)
6
(ms)
7
(ms)
8
(ms)Status
VAVFL Mean 67.40 67.00 65.80 64.80 64.80 64.00 65.60 64.80
N 5 5 5 5 5 5 5 5
SD 2.07 4.06 2.17 2.17 2.39 2.74 3.36 3.42
Minima 65.00 63.00 64.00 63.00 62.00 60.00 61.00 61.00
Maxima 70.00 73.00 69.00 68.00 68.00 67.00 70.00 70.00
VGB- Mean 68.22 68.00 67.25 67.78 65.89 66.89 67.22 66.44
Exposed N 9 8 8 9 8 9 9 9
SD 4.05 4.87 4.78 4.63 3.30 4.31 4.21 4.88
Minima 62.00 64.00 61.00 64.00 62.00 62.00 62.00 62.00
Maxima 75.00 79.00 74.00 78.00 71.00 74.00 74.00 78.00
Normal Mean 67.27 65.14 65.53 65.07 64.13 65.00 65.00 64.67
Control N 15 14 15 15 15 15 15 15
SD 5.40 4.91 4.53 4.08 5.00 5.10 5.10 6.79
Minima 61.00 60.00 59.00 60.00 58.00 58.00 58.00 58.00
Maxima 82.00 80.00 76.00 74.00 78.00 77.00 77.00 82.00
Table 5.3.9 N2 Implicit Time for the  right eye only
191
Sector 1
(ms)
2
(ms)
3
(ms)
4
(ms)
5
(ms)
6
(ms)
7
(ms)
8
(ms)Status
VAVFL Mean 64.40 62.60 64.40 63.60 65.60 65.40 65.20 63.80
N 5 5 5 5 5 5 5 5
SD 3.21 3.65 2.88 2.30 2.30 2.30 2.77 3.03
Minima 62.00 60.00 62.00 62.00 62.00 62.00 62.00 62.00
Maxima 70.00 69.00 69.00 67.00 67.00 67.00 69.00 69.00
VGB- Mean 68.50 65.75 65.88 65.25 66.50 65.13 66.88 67.63
Exposed N 8 8 8 8 8 8 8 8
SD 4.75 3.54 3.39 2.55 3.12 3.13 3.14 4.98
Minima 62.00 62.00 62.00 63.00 64.00 61.00 63.00 63.00
Maxima 74.00 71.00 73.00 70.00 72.00 71.00 71.00 76.00
Normal Mean 66.92 64.64 64.83 64.83 65.25 65.42 66.79 64.67
Control N 12 11 12 12 12 12 12 12
SD 7.17 5.61 5.18 4.32 6.08 5.60 7.99 6.07
Minima 59.00 58.00 56.00 58.00 58.00 57.00 59.50 56.00
Maxima 85.00 80.00 77.00 75.00 81.00 79.00 90.00 79.00
Table 5.3.10 N2 Implicit Time for the left eye only
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Sector 1
(nV)
2
(nV)
3
(nV)
4
(nV)
5
(nV)
6
(nV)
7
(nV)
8
(nV)Status
VAVFL Mean -1.89 -0.68 -1.95 -1.18 -2.68 -2.09 -2.29 -1.21
N 5 5 5 5 5 5 5 5
SD 0.45 0.11 0.71 0.56 0.98 0.55 0.64 0.49
Minima -2.46 -0.81 -3.00 -1.69 -3.98 -2.67 -3.07 -1.67
Maxima -1.28 -0.51 -1.03 -0.24 -1.45 -1.52 -1.44 -0.56
VGB- Mean -1.94 -1.21 -1.43 -1.05 -2.55 -1.81 -2.64 -1.30
Exposed N 9 7 9 8 8 9 9 9
SD 1.50 0.95 1.03 0.78 1.76 1.07 1.18 0.72
Minima -5.45 -2.98 -3.26 -2.40 -6.56 -3.67 -4.83 -2.43
Maxima -0.68 -0.20 -0.42 -0.17 -1.02 -0.12 -0.96 -0.05
Normal Mean -2.76 -1.16 -2.56 -1.87 -3.34 -2.12 -2.94 -1.68
Control N 15 14 15 15 15 15 15 15
SD 1.06 -.48 1.01 0.79 1.33 0.74 1.01 0.73
Minima -5.10 -2.30 -4.51 -3.42 -5.57 -3.34 -3.93 -2.86
Maxima -0.67 -0.44 -0.47 -0.98 -1.16 -0.50 -0.71 -0.28
Table 5.3.1 I N2 Amplitude Values for the  right eye only
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Sector 1 2 3 4 5 6 7 8
Status (nV) (nV) (nV) (nV) (nV) (nV) (nV) (nV)
VAVFL Mean -1.89 -0.68 -1.95 -1.18 -2.68 -2.09 -2.29 -1.21
N 5 5 5 5 5 5 5 5
SD 0.45 0.11 0.71 0.56 0.98 0.56 0.64 0.49
Minima -2.46 -0.81 -3.00 -1.69 -3.98 -2.67 -3.07 -1.67
Maxima -1.28 -0.51 -1.03 -0.24 -1.45 -1.52 -1.44 -0.56
VGB- Mean -1.94 -1.21 -1.41 -1.05 -2.55 -1.81 -2.64 -1.30
Exposed N 9 7 9 8 8 9 9 9
SD 1.50 0.95 1.03 0.71 1.76 1.07 1.18 0.72
Minima -5.45 -2.98 -3.26 -6.56 -6.56 -3.67 -4.83 -2.43
Maxima -0.68 -0.20 -0.42 -1.02 -1.02 -0.12 -0.96 -0.05
Normal Mean -2.76 -1.16 -2.60 -1.87 -3.34 -2.12 -2.94 -1.68
Control N 15 14 15 15 15 15 15 15
SD 1.06 0.48 1.01 0.79 1.33 0.74 1.01 0.73
Minima -5.10 -2.30 -4.51 -3.42 -5.57 -3.34 -3.93 -2.86
Maxima -0.67 -0.44 -0.47 -0.98 -1.16 -0.50 -0.71 -0.28
Table 5.3.12 N2 Amplitude Values for the left e /e  only
The data (usually from N1 or N2) from some sectors of some individuals in the 
normal and VGB-exposed groups could not be modelled and therefore is 
automatically excluded.
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In keeping with amplitude data from large normative databases, the amplitude data 
from this dataset is highly variable across individuals -  yielding greater variability 
and wide confidence intervals.
The minima values for PI amplitude data were smaller in the VAVFL groups for one 
individual in sectors 2 and 3 for the right eye and several sectors including 2 and 3 for 
the left eye. VAVFL N1 amplitudes were similarly smaller but in different sector 
locations, whilst all bar one sector of the N2 VAVFL amplitudes fell within the range 
demonstrated by the controls. However, the amplitude values are very small and even 
the modelled data fails to identify particularly N1 and N2 in both the control and 
VGB-exposed groups highlighting difficulty interpreting this data.
Analysis Adjusted For Age
It has previously been suggested that the implicit time increases and the amplitude 
reduces for all mfERG waveforms with increasing age. (Seiple et al., 2003, Tam et 
al., 2006, Langrova et al., 2008). As a consequence, age-specific confidence intervals 
were calculated from the normal individuals. These are reproduced in full in the 
Appendix A.2.1.
The original values for amplitude and implicit time are presented in Tables 5.3.13 to
5.3.24 for each of the waveforms, in each eye, of each of the VGB-exposed
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individuals, subdivided into with and without field loss. Any sector values that fall 
outside the age-adjusted 95% confidence intervals are highlighted in bold. Missing 
values reflect instances where the data could not be modelled due to excessive noise.
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Case Age
(years)
R1
(ms)
R2
(ms)
R3
(ms)
R4
(ms)
R5
(ms)
R6
(ms)
R7
(ms)
R8
(ms)
VAVFL 39 29 28 25 26 27 25 26
VAVFL 44 26 26 24 26 25 24 23 25
VAVFL 52 26 25 27 23 22 23 23 23
VAVFL 54 27 30 28 26 26 26 27 27
VAVFL 56 24 23 23 23 22 22 23 23
VGB-
Exposed
16 24 25 24 24 23 23 23 22
VGB-
Exposed
18 31 26 30 29 29 27 29 28
VGB-
Exposed
31 24 25 26 27 24 24 24 23
VGB-
Exposed
43 27 28 27 26 27 25 26 26
VGB-
Exposed
48 25 28 26 26 25 26 24 25
VGB-
Exposed
55 25 25 22 24 23 23 25 24
VGB-
Exposed
55 28 29 29 28 27 30 29 28
VGB-
Exposed
59 26 26 24 24 23 23 26 26
Table 5.3.13 NI Implicit Time values for each of the  VAVFL and VGB-Exposed individuals in 
the right eye only
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Case Age
(years)
LI
(ms)
L2
(ms)
L3
(ms)
L4
(ms)
L5
(ms)
L6
(ms)
L7
(ms)
L8
(ms)
VAVFL 39
24
25 24 24 25 29 27 26
VAVFL 44 24 25 24 25 24 26 23 24
VAVFL 52 24 24 22 23 24 25 24 26
VAVFL 54 28 27 27 26 27 28 27 26
VAVFL 56 23 22 23 23 24 25 24 23
VGB-
Exposed
16 23 23 23 24 24 23 24 23
VGB-
Exposed
18 28 30 27 29 30 27 20 33
VGB-
Exposed
31 26 28 25 25 25 26 28 27
VGB-
Exposed
43 26 19 24 25 29 29 30 31
VGB-
Exposed
48 25 24 26 25 24 26 25 25
VGB-
Exposed
55 24 23 23 24 24 24 23 23
VGB-
Exposed
55 25 22 25 26 25 26 25 26
VGB-
Exposed
59 26 22 25 23 25 25 26 28
VGB-
Exposed
62 29 27 28 26 28 24 27 24
Table 5.3.14 NI Implicit Time values for each of the  VAVFL and VGB-Exposed individuals in
the left eye only
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Case Age
(years)
LI
(n V )
L2
(nV)
L3
(nV)
L4
(nV)
L5
(nV)
L6
(nV)
L7
(nV)
L8
(nV)
VAVFL 39 -1.01 -0.74 -1.96 -2.01 -1.68 -1.64 -0 .16 -0 .01
VAVFL 44 -1.66 -1.12 -1.10 -0.88 -1.83 -1.70 -1.58 -1.18
VAVFL 52 -3.04 -1.42 -2.28 -0 .2 9 -1.58 -2.74 -2.38 -2.45
VAVFL 54 -1.21 -0.9 -1.29 -1.45 -1.32 -1.45 -1.19 -0 .52
VAVFL 56 -2.77 -0.9 -1.45 -1.16 -1.47 -1.44 -2.01 -1.23
VGB-
Exposed
16 -2.08 -0.97 -1.94 -1.08 -2.26 -1.85 -2.19 -1.67
VGB-
Exposed
18 -2.57 -0.62 -2.89 -2.02 -3.06 -2.33 -3.69 -1.98
VGB-
Exposed
31 -2.38 -0-.70 -2.16 -1.57 -1.69 -1.77 -3.22 -0.72
VGB-
Exposed
43 -2.03 -1.19 -2.07 -1.17 -2.35 -1.32 -2.07 -1.65
VGB-
Exposed
48 -5.21 -1.54 -4.99 -4.88 -9.19 -5.98 -8.31 -2.82
VGB-
Exposed
55 -2.20 -1.16 -1.39 -1.14 -1.15 -1.71 -2.79 -1.80
VGB-
Exposed
55 -0.64 -0.63 -1.98 -2.21 -1.50 -1.40 -1.81 -1.55
VGB-
Exposed
59 -1.76 -0.93 -1.34 -0.88 -1.35 -0.61 -2.18 -1.19
VGB-
Exposed
62 -1.84 -1.02 -1.34 -0.87 -1.76 -1.33 -2.17 -1.17
Table 5.3.16 Nl Amplitude Values for each of the  VAVFL and VGB-Exposed individuals in
the left eye only
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Case Age
(years)
R1
(nV)
R2
(nV)
R3
(nV)
R4
(nV)
R5
(nV)
R6
(nV)
R7
(nV)
R8
(nV) _
VAVFL 39 -1.54 -1.12 -3.03 -0.60 -1.00 -0.29 -2.10 -1.42
VAVFL 44 -2.57 -1.42 -2.02 -1.73 -2.17 -1.22 -0.80 -0.97
VAVFL 52 -3.10 -1.10 -2.11 -1.47 -1.88 -1.88 -2.30 -1.25
VAVFL 54 -1.91 -1.22 -1.34 -1.42 -1.93 -1.17 -1.57 -1.06
VAVFL 56 -2.33 -0.96 -1.95 -2.13 -1.98 -1.55 -2.29 -1.00
VGB-
Exposed
16 -1.76 -0.79 -1.70 -1.52 -1.67 -0.59 -1.60 -0.90
VGB-
Exposed
18 -1.92 -1.85 -1.06 -2.38 -2.26 -1.55 -1.51 -1.95
VGB-
Exposed
31 -0.55 -0.80 -2.72 -1.94 -1.62 -2.34 -2.86 -1.28
VGB-
Exposed
43 -2.01 -0.60 -1.95 -0.87 -2.90 -1.66 -3.22 -1.66
VGB-
Exposed
48 -7.46 -4.66 -7.93 -5.63 -9.29 -3.75 -7.92 -3.69
VGB-
Exposed
55 -2.26 -1.36 -1.61 -2.34 -2.18 -2.56 -3.40 -1.54
VGB-
Exposed
55 -3.60 -1.93 -1.77 -2.07 -2.23 -1.31 -3.05 -1.49
VGB-
Exposed
59 -1.04 -0.48 -1.42 -1.16 -1.23 -1.06 -0.82 -0.31
Table 5.3.15 NI amplitude values for each of the  VAVFL and VGB-Exposed individuals in the 
right eye only
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Case Age
(years)
R1
(ms)
R2
(ms)
R3
(ms)
R4
(ms)
R5
(ms)
R6
(ms)
R7
(ms)
R8
(ms)
VAVFL 39 48 49 45 46 46 45 45 44
VAVFL 44 47 46 45 46 45 44 44 44
VAVFL 52 46 47 45 42 42 44 42 43
VAVFL 54 49 50 48 47 47 47 48 48
VAVFL 56 45 47 43 43 42 41 43 42
VGB-
Exposed
16 45 45 44 44 43 43 43 43
VGB-
Exposed
18 52 52 51 53 49 48 51 50
VGB-
Exposed
31 46 47 46 46 44 44 45 44
VGB-
Exposed
43 50 49 51 52 48 49 48 48
VGB-
Exposed
48 45 44 46 45 46 46 45 44
VGB-
Exposed
55 44 45 43 45 43 43 43 43
VGB-
Exposed
55 51 55 52 52 50 50 52 53
VGB-
Exposed
59 47 47 46 45 44 43 45 46
Table 5.3.17 PI Implicit Time values for each of the  VAVFL and VGB-Exposed individuals in
the right eye only
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Case Age
(years)
LI
(ms)
L2
(ms)
L3
_(ms)
L4
(ms)
L5
(ms)
L6
(ms)
L7
(ms)
L8
(ms)
VAVFL 39 43 42 44 42 45 47 46 45
VAVFL 44 45 44 45 45 46 47 46 45
VAVFL 52 43 42 42 43 45 45 44 44
VAVFL 54 49 48 48 47 49 49 48 49
VAVFL 56 43 41 42 42 44 44 44 42
VGB-
Exposed
16 43 42 42 43 44 44 44 43
VGB-
Exposed
18 51 49 48 50 52 49 49 55
VGB-
Exposed
31 47 47 45 45 45 45 49 49
VGB-
Exposed
43 50 48 49 47 52 51 52 54
VGB-
Exposed
48 46 46 46 47 45 46 45 46
VGB-
Exposed
55 43 42 43 43 45 45 44 46
VGB-
Exposed
55 49 47 46 47 47 48 48 48
VGB-
Exposed
59 47 43 46 44 45 44 47 47
VGB-
Exposed
62 49 47 48 48 48 47 48 46
Table 5.3.18 PI Implicit Time values for each of the  VAVFL and VGB-Exposed individuals in
the left eye only
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Case Age
(years)
LI
(nV)
L2
(nV)
L3
_CnV)
L4
(nV)
L5
(nV)
L6
(nV)
L7
(nV)
L8
(nV)
VAVFL 39 2.30 0.71 1.38 1.21 2.48 2.40 3.86 2.30
VAVFL 44 2.93 0.53 2.55 1.87 2.97 2.20 3.01 1.43
VAVFL 52 4.09 1.11 1.14 1.81 2.98 3.02 2.51 2.30
VAVFL 54 3.12 1.40 1.90 1.78 3.59 2.73 4.28 2.64
VAVFL 56 3.37 1.49 3.06 1.66 2.85 1.95 3.09 1.63
VGB-
Exposed
16 3.21 1.47 2.78 1.93 3.10 2.01 3.85 2.20
VGB-
Exposed
18 2.30 0.61 1.17 1.43 1.99 1.34 2.48 1.30
VGB-
Exposed
31 2.77 1.07 2.08 1.78 3.85 3.25 2.59 1.65
VGB-
Exposed
43 1.69 0.74 1.84 1.34 2.01 1.76 2.46 1.04
VGB-
Exposed
48 9.34 2.70 7.17 4.36 4.68 5.56 6.80 5.44
VGB-
Exposed
55 1.94 0.85 3.32 2.03 5.38 2.98 3.07 1.84
VGB-
Exposed
55 3.05 1.64 3.44 2.86 3.51 1.91 3.06 2.23
VGB-
Exposed
59 2.05 1.12 2.78 2.09 3.25 2.24 1.82 1.29
VGB-
Exposed
62 2.96 2.08 2.49 2.70 2.94 1.10 2.06 1.03
Table 5.3.20 PI Amplitude values for each of the  VAVFL and VGB-Exposed individuals in the 
left eye only
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Case Age
(years)
R1
(nV)
R2
(nV)
R3
(nV)
R4
(nV)
R5
(nV)
R6
(nV)
R7
(nV)
R8
(nV)
VAVFL 39 2.10 0.20 1.89 1.97 3.61 2.96 2.31 1.63
VAVFL 44 2.44 0.63 2.21 1.20 1.67 0.72 2.42 0.52
VAVFL 52 3.22 1.76 3.24 2.86 2.54 1.23 2.42 1.25
VAVFL 54 3.79 3.02 3.37 2.42 2.79 1.62 3.48 2.47
VAVFL 56 3.00 1.57 2.04 1.51 2.40 1.34 2.90 1.28
VGB-
Exposed
16 3.61 2.01 3.52 2.43 2.81 1.92 3.16 1.17
VGB-
Exposed
18 2.82 0.63 3.38 1.67 2.54 1.25 1.14 1.08
VGB-
Exposed
31 3.37 1.34 3.21 2.43 2.21 0.38 0.91 0.42
VGB-
Exposed
43 1.62 2.35 1.49 1.20 1.77 1.16 1.47 0.85
VGB-
Exposed
48 8.50 6.22 8.47 6.63 8.70 6.48 6.52 4.48
VGB-
Exposed
55 3.62 3.14 3.85 1.78 2.87 2.01 3.04 2.49
VGB-
Exposed
55 4.58 2.80 5.09 3.81 4.28 3.47 3.50 1.92
VGB-
Exposed
59 1.74 0.83 1.56 1.09 1.37 0.68 1.35 0.78
Table 5.3.19 PI Amplitude values for each of the  VAVFL and VGB-Exposed individuals in the 
right eye only
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Case Age
(years)
R1
(ms)
R2
(ms)
R3
(ms)
R4
(ms)
R5
(ms)
R6
(ms)
R7
(ms)
R8
(ms)
VAVFL 39 63 61 62 62 63 62 64 62
VAVFL 44 64 62 65 65 67 67 62 62
VAVFL 52 62 60 64 62 67 67 67 64
VAVFL 54 70 69 69 67 68 67 69 69
VAVFL 56 63 61 62 62 63 64 64 62
VGB-
Exposed
16 69 66 66 63 65 61 66 66
VGB-
Exposed
18 69 66 64 65 65 64 68 66
VGB-
Exposed
31 62 63 63 63 64 64 64 64
VGB-
Exposed
43 63 62 62 63 64 64 63 63
VGB-
Exposed
48 74 64 67 67 70 64 68 76
VGB-
Exposed
55 74 71 73 70 72 70 71 74
VGB-
Exposed
55 65 63 65 64 64 65 64 63
VGB-
Exposed
59 72 71 67 67 68 69 71 69
Table 5.3.21 N2 Implicit Time values for each of the  VAVFL and VGB-Exposed individuals in
the right eye only
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Case Age
(years)
LI
(ms)
L2
(ms)
L3
(ms)
L4
(ms)
L5
(ms)
L6
(ms)
L7
(ms)
L8
(ms)
VAVFL 39 65 64 64 63 62 60 64 61
VAVFL 44 67 63 65 64 65 63 66 64
VAVFL 52 69 73 67 66 66 66 67 66
VAVFL 54 70 69 69 68 68 67 70 70
VAVFL 56 66 66 64 63 63 64 61 63
VGB-
Exposed
16 68 66 67 65 64 63 65 65
VGB-
Exposed
18 67 67 65 65 64 64 66 65
VGB-
Exposed
31 62 64 61 64 62 62 62 62
VGB-
Exposed
43 64 64 64 64 63 63 63 62
VGB-
Exposed
48 72 67 66 73 72 69
VGB-
Exposed
55 71 70 74 78 70 73 69 66
VGB-
Exposed
55 66 66 64 66 64 66 64 64
VGB-
Exposed
59 75 79 74 72 71 70 74 78
VGB-
Exposed
62 69 68 69 69 69 68 70 67
Table 5.3.22 N2 Implicit Time values for each of the  VAVFL and VGB-Exposed individuals in
the left eye only
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Table 5.3.23 N2 Amplitude values for each of the VAVFL and VGB-Exposed individuals in
the right eye only
Case Age
(years)
R1
(nV)
R2
(nV)
R3
(nV)
R4
(nV)
R5
(nV)
R6
(nV)
R7
(nV)
R8
(nV)
VAVFL 39 -2.45 -1.54 -5.00 -2.13 -2.92 -0.51 -3.64 -1.42
VAVFL 44 -1.60 -1.1 -1.84 -1.42 -1.29 -1.13 -0.06 -0.32
VAVFL 52 -3.55 -2.49 -2.72 -1.25 -1.25 -1.34 -2.01 -1.27
VAVFL 54 -1.82 -1.09 -1.23 -1.47 -1.20 -0.16 0.57
VAVFL 56 -2.53 -1.52 -2.46 -2.31 -2.23 -1.27 -1.97 -0.96
VGB-
Exposed
16 -2.20 -1.16 -2.19 -1.47 -2.15 -0.98 -1.29 -0.77
VGB-
Exposed
18 -0.82 -0.99 -0.33 -0.20 -0.38 -0.68
VGB-
Exposed
31 -1.30 -0.39 -2.43 -2.23 -1.87 -2.45 -1.66 -0.38
VGB-
Exposed
43 -2.18 -0.47 -1.35 -1.63 -0.94 -0.39 -1.17
VGB-
Exposed
48 -9.32 -3.60 -5.16 -3.60 -2.95 -2.07 -6.34 -3.04
VGB-
Exposed
55 -2.44 -1.26 -1.55 -2.01 -1.38 -0.91 -2.24
VGB-
Exposed
55 -2.24 -1.19 -1.25 -1.26 -1.78 -0.17 -1.97 -0.98
VGB-
Exposed
59 -0.95 -0.54 -1.00 -0.56 -1.02 -0.45 -0.62 -0.33
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Table 5.3.24 N2 Amplitude values for each o f the VAVFL and VGB-Exposed individuals in
the left eye only
Case Age
(years)
LI
(nV)
L2
(nV)
L3
(nV)
L4
(nV)
L5
(nV)
L6
(nV)
L7
(nV)
L8
(nV)
VAVFL 39 -2.05 -0.69 -3.00 -1.20 -3.22 -2.66 -2.52 -0.56
VAVFL 44 -1.28 -0.75 -1.03 -0.24 -1.62 -1.62 -1.85 -1.59
VAVFL 52 -2.01 -0.81 -2.10 -1.69 -3.07 -2.67 -3.07 -1.39
VAVFL 54 -1.63 -0.51 -1.88 -1.43 -1.44 -1.52 -1.44 -0.84
VAVFL 56 -2.46 -0.65 -1.72 -1.35 -2.55 -2.00 -2.55 -1.67
VGB-
Exposed
16 -1.96 -0.87 -1.74 -0.90 -2.47 -2.21 -2.47 -1.21
VGB-
Exposed
18 -0.78 -0.77 -1.61 -1.20 -1.61 -0.98
VGB-
Exposed
31 -2.66 -0.52 -2.36 -1.23 -2.97 -2.54 -2.97 -1.88
VGB-
Exposed
43 -1.34 -0/82 -0.42 -0.55 -0.96 -0.12 -0.96 -0.05
VGB-
Exposed
48 -5.45 -2.98 -3.26 -2.40 -4.83 -3.67 -4.83 -1.18
VGB-
Exposed
55 -1.39 -1.18 -0.66 -1.39 -3.93 -1.61 -3.93 -2.43
VGB-
Exposed
55 -0.76 -0.72 -0.17 -2.04 -2.18 -2.04 -1.31
VGB-
Exposed
59 -0.68 -0.20 -0.48 -0.41 -2.08 -0.60 -2.08 -0.68
VGB-
Exposed
62 -2.40 -1.89 -2.31 -1.34 -2.85 02.15 -2.85 -1.98
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The age-adjusted amplitude data largely falls within the 95% confidence intervals for 
age. Although there are exceptions, these occur in varied individuals and varied 
sectors, with no clear topographical or individual patterns. These outlying values are 
very likely to reflect technical limitations of the mfERG with respect to signal-to- 
noise ratios.
5.2.4 Discussion
The results indicate that exposure to VGB, at least within the range for 12 of the 13 
individuals included in the study does not influence either the implicit time or the 
amplitude of the three mfERG waveforms when compared to the maxima and minima 
of the range of values from a control group of 13 individuals and in 12 of 13 
individuals when compared to the age-adjusted confidence intervals. However, the 
outlying individual is different in the two modes of analysis. This finding applies 
whether the stimuli were of central or peripheral origin or of nasal or temporal origin.
The outlier in the age- adjusted analysis was an 18-year-old male with normal fields 
who yielded increased implicit times at the 95% confidence intervals in certain 
sectors for both N1 and PI. The N2 response was within normal limits. However, 
even this individual had values that fell within the 90% confidence intervals for these 
same sectors. He was myopic and was corrected for the study according to his current 
refraction prescription. Uncorrected myopia increases implicit time for all three 
waveforms of mfERG (Chen et al., 2006a) and it is possible that his prescription 
represented an under-correction of the myopia.
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The negative outcome for the detection of VGB toxicity of the mfERG in the current 
study should be placed in the context of results from other mfERG studies of VGB 
toxicity. Such studies have been conducted, as in the current study, with small cohorts 
of individuals exposed to VGB and have reported low frequencies of various types of 
mfERG abnormality. The low frequency of abnormality combined with the diversity 
of the abnormality suggests that the mfERG recorded out to 30° eccentricity is of 
limited value in the detection of VGB toxicity. This is unfortunate, given the apparent 
utility of mfERG for the investigation of visual dysfunction in children and learning- 
disabled adults.
The findings are seemingly at odds with those found for the wide-field mfERG, which 
exhibited 100% sensitivity for the detection of VAVFL and 86% specificity in 19 of 
32 patients exposed to VGB for greater than 3 years. (McDonagh et al., 2003) The 
discrepancy between the wide-field mfERG literature and the standard mfERG 
literature may arise simply from the fact that VAVFL is a predominantly peripheral 
abnormality. However, all 4 individuals with VAVFL in this study manifested 
substantial field loss within the central field out to 30° eccentricity.
An alternative explanation for the negative outcome of the mfERG in the current 
study is that the underlying generators of the mfERG waveforms are not influenced 
by VGB toxicity, at least in the early stages of VGB dysfunction. It is entirely 
plausible that the standard mfERG does not identify VGB toxicity. Given the 
advances since beginning this thesis in structural quantification of VGB toxicity,
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it seems more likely that there is retinal ganglion cell loss either as a primary 
pathology, or at least as an early stage in the pathogenesis. As the mfERG is largely 
derived from bipolar cells (amplitude) and photoreceptors (implicit time) and there is 
little contribution from the ganglion cells (occasionally producing a trailing ledge on 
the PI) it is perhaps not surprising that the mfERG results should be normal. This 
latter argument is consistent with the increased implicit time in the periphery on wide 
field -mfERG examination which can be explained by an advanced cellular 
dysfunction peripherally with likely involvement of the reduced numbers of bipolar 
and photoreceptor cells with increasing eccentricity.
5.2.5 Conclusions
There is no evidence from this study that standard mfERG can identify VGB toxicity. 
The most likely reason for this finding lies in the cellular derivation of the mfERG. It 
would seem reasonable to conclude that retinal toxicity attributable to VGB is not 
primarily mediated by bipolar or photoreceptor cells. Given that retinal ganglion cell 
dysfunction does not affect the mfERG, the latter cell type still remains a candidate 
for the primary lesion in VGB toxicity.
More directed electrophysiology aimed at determining ganglion cell abnormality 
including the PERG would seem a fruitful area for further research.
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Chapter 6: The mfVEP In VGB Toxicity
6.1 Utility Of mfVEP In Assessing Vigabatrin Toxicity
6.1.1 Introduction to mfVEP
Standard VEP technology has been available for some 60 years. The VEP is the 
electroencephalographic response, recorded at the primary visual cortex (VI), to a 
visual stimulus. The response reflects the combined function of the visual pathway 
and will contain contributions from the retina, optic nerve, optic chiasm and radiation, 
and cortex. The VEP is, therefore, anatomically non-specific; however, it provides the 
only functional visual cortical measure currently available. Localisation of any 
abnormality is difficult without consideration of other findings from ophthalmological 
and neurological examinations.
Some of the general principles of standard VEP also apply to the multifocal VEP. 
Since both are recorded at the primary visual cortex (VI) an understanding of 
neuroanatomy is essential for interpretation of the VEP and mfVEP responses. The 
primary visual cortex is infolded to form the calcarine sulcus. Visual mapping of the 
visual field at the cortex is in keeping with the semi-decussation of the retinal 
ganglion fibres at the optic chiasm; consequently the right hemifield is represented in 
the left cortex and the left hemifield is represented in the right cortex. Importantly, the 
upper visual field is represented below the calcarine sulcus, and the lower visual field 
is represented above the calcarine sulcus. However, a further principle of cortical 
sense mapping also applies the primary visual cortex; the cortex devotes more
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space and neural ability to those areas considered to be of greater importance. This is 
ensured by the greater representation of the projections of the retinal ganglion cells 
from the fovea. Thus, the central 10° radius is represented by a disproportionately 
large caudal part of the cortex. Consequently, the VEP and the mfVEP are dominated 
by the central visual field. In contrast, the peripheral visual field is less well 
represented for two reasons. Firstly, there are fewer projections of the retinal ganglion 
cells from the periphery and less cortical area devoted to the peripheral field. 
Secondly, this latter area of VI lies deeper in the calarine sulcus and an 
electrophysiogical response is, as a consequence, difficult to obtain.
6.1.2 Description Of The mfVEP
Multifocal technology permits simultaneous recording of multiple local mfVEP 
responses. As with the mfERG, a single continuous trace recording is taken; from 
these 60 responses are derived from a mathematical model based in the 
pseudorandom sequence of frame shifts referable to set locations in the multifocal 
display. Thus, 60 responses are derived which represent an area within a radius of 25° 
from fixation (i.e. the central visual field).
6.1.3 Normative values and repeatability
Normative values have been published for the mfVEP but the results from any one 
centre are not generalisable to other centres. Each centre, therefore, is required to 
establish its own normative age-related dataset and corresponding local
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confidence limits. Clearly, any limitations relating to a given centre, such as the 
presence and magnitude of ambient electrical noise, will affect the magnitude of the 
confidence limits. However, there are also large between-individual differences in the 
normal mfVEP response that mitigates against the establishment of narrow 
confidence intervals. The major reason for the between-individual variation in the 
normal mfVEP response is the between-individual variation both in surface anatomy 
and also in neuroanatomy. The mfVEP recordings are taken with reference to the 
inion, a skull notch over the occipital lobe. This anatomical surface marker varies 
between individuals with respect to size, projection and location and hence with 
respect to the relative location of the visual cortex. Whilst brain MRI with marking 
could improve the accuracy of mfVEP recording, it is not a pragmatic clinical option.
The brain foldings (sulci) of each individual are unique in both depth and position and 
this holds true for the calcarine sulcus. Consequently, mfVEP recordings may 
originate from across, above or below the calcarine sulcus dependent upon its 
positioning. The depth of the sulcus will also affect the amplitude mfVEP but should 
not impact upon the latency.
Most attempts to analyse the mfVEP are based upon the identification of a change in 
amplitude. (Zhang et al., 2002, Fortune et al., 2004, Klistomer and Graham, 2005)
The analysis of amplitude is limited by between-individual variations in the normal 
response, which affect the size of any confidence interval for the mfVEP response. 
Such sources of between-individual variability include the skull thickness and the
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localisation of the visual cortical midline (with reference to the inion) that in turn 
defines the proportion of stimuli analysed by the respective cortical hemifields. The 
within-individual between-test variability is a further confounding factor in the 
interpretation of the mfVEP. A between-test variability of 20-30% has been reported 
in normal individuals based upon the sampling of 12 pre-determined locations of the 
mfVEP. (Klistomer and Graham, 2005) A slightly lower between-test variability, 
15%, is present when all locations are considered individually and in clusters. 
(Fortune et al., 2004)
A widely adopted method to improve diagnostic ability in the presence of highly 
variable responses is that of between-eye comparison. (Hood et al., 2004b) However, 
such a between-eye approach is not well suited to a bilateral and symmetrical disease 
such as that seen in VGB toxicity.
The analysis of mfVEP implicit time is, in general, also based upon a between-eye 
approach (Hood et al., 2004b) although analyses of monocular latency have been 
reported using customised software via a method of ‘template stretching’ where the 
waveforms are stretched to a ‘best fit’ within pre-ordained limits. (Hood et al., 2004a, 
Rodarte et al., 2006) However, at the time of writing no commercially available 
software exists for the analysis of implicit time in this manner. Furthermore, there is 
no accepted method for the analysis of latency and the lack of a standardised method 
makes comparison of implicit times across studies difficult.
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6.1.4 The Relationship O f The mfVEP To The Conventional VEP
The mfVEP response bears a superficial resemblance to the conventional VEP; there 
are two identifiable deflections. The first (Cl) is a positive deflection at 65ms 
analogous to N75 and the second (C2) is a negative deflection at approximately 95ms 
analogous to P100. However, these responses are not ‘little’ VEPs, (Fortune et al., 
2004) and the slight latency differences in C2, along with the smaller C2 response 
compared with PI00, bear testimony to this. It is speculated that the mfVEP response 
has a larger extrastriate contribution than the conventional VEP. (Hood et al., 2003b)
6.1.5 Relationship Of The mfVEP To Static Perimetry
The results of mfVEP have been compared to the results from static threshold 
perimetry, i.e. the differential light threshold. One comparative approach is simply to 
overlay the two sets of results at each location within the visual field. This approach 
requires the scaling of the mfVEP responses to account for the central dominance of 
mfVEP. (Hood and Greenstein, 2003) A moderate correlation between mfVEP 
amplitude and differential light sensitivity has been demonstrated for optic neuritis 
(Klistomer et al., 2008) and glaucoma using this method. (Hood and Greenstein, 
2003)
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6.1.6 The mfVEP In Vigabatrin Toxicity
The majority of studies which have used the VEP to investigate vigabatrin toxicity in 
adults have reported normal results (Liegeois-Chauvel et al., 1989, Eke et al., 1997, 
Mauguiere et al., 1997, Wilson and Brodie, 1997, Reuther, 1998) Lawden et al., 
1999). A normal VEP has also been found in children.(Uldall et al., 1995) However, 
three papers involving two adult cohorts have reported an abnormal VEP in 25% of 
four cases of VAVFL (Krauss et al., 1998), 22% in 18 cases of VAVFL (including the 
4 individuals reported by Krauss and associates) (Miller et al., 1999) and 30% of 10 
cases, respectively. (Daneshvar et al., 1999) However, the majority of patients in the 
latter cohort exhibited severe VAVFL. An abnormal VEP has also been reported in 
30% of 15 children exposed to VGB; of the 5 deemed to have abnormal VEPs, 4 had 
VAVFL. (Gross-Tsur et al., 2000) A possible explanation for abnormal VEPs in 
some cohorts might be related to the central dominance of the conventional VEP and 
the late involvement of the central visual field in severe VAVFL. At the time of 
writing, no reports are available of the utility of mfVEP in VAVFL.
The pathogenesis of VGB toxicity remains uncertain; however; the retinal ganglion 
cell layer remains a likely location. Whilst cellular correlation is less well understood 
for the mfVEP as compared with the mfERG, some functional-pathological 
correlations are accepted. Ganglion cell loss in glaucoma is inferred by the reduction 
of the mfVEP signal amplitude. (Hood and Greenstein, 2003) However, alterations in 
mfVEP latency/ implicit time do not seem to be altered in glaucoma. (Grippo et al.,
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2006, Rodarte et al., 2006) Retinal disease (autoimmune retinopathy, vascular retinal 
disease and non-specific retinopathies) has been reported to show increases in implicit 
time. (Chen et al., 2006b)
6.2 The utility of the mfVEP in VGB toxicity
6.2.1 Aims
The overall aim of the study was to investigate whether the mfVEP identified retinal 
dysfunction attributable to VGB and, if so, the topographical relationship between the 
abnormality and the visual field loss. More specifically, the aims were threefold. 
Firstly, to investigate whether a reduction in amplitude was present for the mfVEP 
waveform thereby implicating retinal ganglion cell dysfunction in the 
pathophysiology of VGB toxicity. Secondly, to quantify the relationship between any 
abnormality in amplitude of the mfVEP waveform and the severity of the visual field 
loss. Thirdly, to quantify the relationship between any abnormality in amplitude of the 
mfVEP waveform and the daily dose and duration of VGB intake.
6.2.2 Methods
6.2.2.1 Demographics o f the study cohort
The cohort comprised three groups of individuals; one group of 5 individuals with
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VAVFL, one group of 9 individuals exposed to VGB but with normal fields and a 
third group of 16 normal individuals. Normal individuals were recruited from 
colleagues, fellow post-graduate students, friends and family. The VGB exposed 
adults were recruited from the Welsh Epilepsy Unit, University Hospital of Wales, 
Cardiff, and the adolescents from the Paediatric Neurology and Adolescent services at 
the University Hospital of Wales, Cardiff.
6.2.2.2 Inclusion Criteria
All individuals conformed to rigid inclusion criteria in as described in Chapter 3.2. 
Briefly, each eye exhibited a distance refractive error of less than or equal to 5 
dioptres mean sphere and less than 2.5 dioptres cylinder; a visual acuity of 6/9 or 
better; open angles, clear ocular media; no fundal or optic nerve head abnormalities 
characteristic of known disease other than VGB toxicity; no previous ocular surgery 
or trauma; no history of diabetes mellitus and no family history of glaucoma.
The demographics of the cohort are detailed in Table 6.2.1. The cohort control group 
was younger than either of the VGB-exposed groups by approximately 7 and 12 years 
respectively. However, no effect of age has been reported in mfVEP, in contrast to 
mfERG. (Fortune et al., 2004)
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Group
(Total)
Gender Mean 
Age (yrs) 
(SD)
Mean
Duration of 
Epilepsy 
(yrs) (SD)
Mean
Duration of 
Vigabatrin
(yrs) (SD)
Cumulative 
dose of 
Vigabatrin
(kg) (SD)
Male Female
VAVFL (5) 1 4 49.00
(7.2)
25.60
(8.2)
9.49
(1.6)
11.03
(2.5)
VGB- 
Exposed (9)
4 5 42.60
(16.5)
26.30
(10.53)
7.30
(2.6)
6.79
(2.37)
Controls
(16)
7 9 37.62
(12.4)
0.0 0.0 0.0
Table 6.2.1 The summary measures (G roup Mean, Standard Deviation [SD]) of the 
demographical characteristics for each of the  th ree  groups
6.2.23 Patient Set-up
Prior to recording the mfVEP, all patients underwent standard neurological 
examination. At the time of the study, and at the time of writing, no agreed ISCEV 
mfVEP guidelines are available. Therefore, the set-up used for all patients in this 
study was in accordance with that of Hood and colleagues who use an identical 
VERIS system. (Hood et al., 2003b)
Patients were placed in a fully lighted room (the recording room) for 15 minutes prior 
to recording and, therefore, were light adapted. Disposable electrodes were used
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as described for the mfERG. Skin preparation and electrode fixation was achieved 
using the same products as that described for the mfERG in Chapter 5.2. The 
recording electrodes were secured with cotton gauze squares. The ground electrode 
was secured at the forehead with micropore. The standard two vertical and horizontal 
recording channels were used which were both referenced to the palpated inion. The 
vertical channels were applied 3 cm above and 1 cm below the inion, respectively. 
The horizontal channels were applied 1cm above the inion, and 2 cm either side of the 
midline, respectively.
Impedance was measured for all the recording electrodes, compared with the ground, 
using a commissioned ohmmeter made by the Department of Medical Physics at the 
Queens Medical Centre, University of Nottingham. Impedance was deemed 
acceptable if <5kQ, and if both recording channels were within 2kQ of each other 
(Figure 3.3.2). Patients sat in front of the screen at a recording distance of 50 cm 
wearing the refractive correction optimised for the viewing distance. Fixation was 
observed by direct observation of the patient. Responses were recorded monocularly 
for each eye.
6.2.2.4 Stimulus Properties
A high-resolution CRT monitor with a frame rate of 75 Hz was used with a screen 
luminance of 150 cd/m2 in full room lighting. The stimulus pattern was a pre-set 
standard of 60 polygons. The size of the polygons had been scaled for cortical
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magnification by the manufacturer; the central sectors subtended 1° at the eye whilst 
the peripheral sectors subtend 7° at the eye. The stimuli were presented in the default 
manner using the m-sequence, i.e., with no additional or modified stimulus frames. 
The stimulus field subtended a radius of 25°. A red cross, set at a diameter of 0.5°, 
served as the fixation target. The gain settings were 100,000 with a bandpass filter of 
3 and 100 Hz. The notch filter was not used.
6.2.3 Analysis
All responses were analysed using the VERIS 5.1 software with the standard mfVEP 
Analysis 60 Protocol. The averaging function, which permits averaging of each trace 
with 17% of its neighbours, was not activated.
6.2.3 Sector Analysis Of mfVEP
As discussed in Chapter 5 (5.2.3.2), the customised grouping of traces is desirable as 
the procedure permits specific regional comparisons and produces improvements in 
trace quality and narrower confidence intervals for normative data. The mfVEP 
traces were grouped in identical sectors as those used for the analysis of the mfERG. 
(Figure 6.2.3.1)
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Figure 6.2.3.1 The Custom Grouping O f The 61 Traces Into 8 Sectors, Sectors I, 3, 5 and 7 
represent the central field out to  approximately 15°; Sectors 1,2,3,4 represent the nasal 
hemifield and sectors 5, 6, 7,8 the tem poral hemifield.
6.2.3.3 Establishing signal-to-noise ratios and estimating amplitude
As discussed above (Section 6.1.3) there are wide between-individual variations in the 
normal mfVEP trace and also the inherent difficulty of recording a small signal in the 
presence of electrical and muscular noise of any magnitude.
The analytical approach utilised signal-to-noise ratios as a measure of amplitude. This 
technique calculates the root-mean-square analyses of the signal window divided by 
the averaged signal of the noise sector. (Zhang et al., 2002) Thus, two time periods of 
the complete mfVEP trace are analysed; firstly, the signal window (45- 150ms); and 
secondly, a noise window (325 -  430ms). The traces at each location were custom
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grouped as illustrated in Figure 6.2 above and SNR measures were used as a marker 
of amplitude.
6.2.4 Results
The group mean mfVEP amplitude and the group maximum and the group minimum 
values for the group with VAVFL and for the group exposed to VGB but with normal 
fields are compared to the corresponding values for the normal individuals in Table 
6.2.2. The vast majority of individuals exposed to VGB exhibited an amplitude in 
each eye which was greater than the lowest value exhibited by any individual in the 
normal group for any sector. As is evident from Table 6.2.1 VGB- exposed 
individuals manifesting normal fields fell outside the normal range for the right eye in 
sectors 4 and 5. These represent two solitary individuals with one low amplitude 
value in sector 4 and 5 respectively. The remainder of the individuals in the VGB- 
exposed group exhibited values greater than the second lowest value demonstrated in 
the normal group. Table 6.2.2 demonstrates greater abnormality for both VAVFL and 
VGB-exposed groups. Again, all the abnormalities represent solitary individuals 
falling outside the range and only one individual in the VAVFL group exhibited low 
values in two sectors; the remainder only exhibited one abnormal sector. As with the 
right eye values, all those individuals falling within the normal range, had minimum 
values greater than the second lowest values in the normal group, or in the case of 
sectors 2 and 4 for the VAVFL group, greater than the third lowest value. Thus, there 
was no similarity in the pattern of apparent abnormality between eyes of an individual 
or between individuals.
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Table 6 .2 .1 RMS SNR as markers for amplitude values for the right eye only
Sector 1 2 3 4 5 6 7 8
Status
VAVFL Mean 2.73 3.91 6.38 7.48 2.04 2.14 3.13 2.95
N 5 5 5 5 5 5 5 5
SD 0.89 7.81 7.81 6.43 0.75 1.04 1.51 1.82
Minima 1.81 1.49 1.49 1.71 1.41 1.35 1.41 1.08
Maxima 3.57 15.39 15.39 14.41 2.86 3.32 4.23 4.71
VGB- Mean 2.56 1.82 2.60 2.83 2.11 2.79 4.81 1.54
Exposed N 9 9 9 9 9 9 9 9
SD 2.35 0.45 1.13 2.49 1.62 2.60 5.07 0.44
Minima 0.92 1.15 1.25 0.56 0.50 0.94 1.04 0.94
Maxima 5.95 2.12 3.74 6.14 4.26 6.64 12.28 1.90
Normal Mean 5.18 4.09 2.98 4.21 5.76 5.51 3.58 3.21
Control N 16 16 16 16 16 16 16 16
SD 2.91 2.55 1.70 2.51 5.94 4.94 1.89 2.09
Minima 0.80 0.73 0.99 1.09 1.72 0.82 0.61 0.78
Maxima 11.31 10.21 6.60 10.82 26.30 21.02 8.09 9.43
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Table 6.2.2 RMS SNR as markers for amplitude values for the left eye only
Sector 1 2 3 4 5 6 7 8
Status
VAVFL Mean 2.42 2.06 4.01 5.13 2.93 3.16 2.25 2.11
N 5 5 5 5 5 5 5 5
SD 1.46 1.44 3.46 3.43 0.80 0.44 0.63 1.09
Minima 0.78 0.68 1.18 2.27 2.01 3.11 1.81 1.13
Maxima 3.58 3.55 7.87 8.93 3.41 3.19 2.97 3.28
VGB- Mean 2.66 3.95 3.61 3.80 2.80 3.53 2.08 2.27
Exposed N 9 9 9 9 9 9 9 9
SD 1.12 3.23 3.15 2.82 2.11 1.94 1.16 1.65
Minima 1.25 0.58 1.23 1.62 0.86 0.82 0.58 0.76
Maxima 4.04 8.84 8.31 8.50 5.39 5.60 3.65 5.08
Normal Mean 5.36 4.48 3.07 3.39 5.29 4.74 3.19 5.12
Control N 15 15 15 15 15 15 15 15
SD 3.50 3.01 1.48 1.74 2.63 3.14 1.56 4.77
Minima 1.34 1.28 1.25 1.54 0.98 1.05 0.45 1.14
Maxima 12.90 13.25 5.62 6.96 10.08 13.17 5.92 18.05
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6.2.5 Discussion
The mfVEP amplitude failed to identify the effects of VGB toxicity. There are two 
major explanations for this finding.
The first possibility is that retinal ganglion cells do not demonstrate dysfunction in 
VGB toxicity. This theory cannot be discounted. However, retinal ganglion cell 
disruption has been observed in the description of the one post mortem eye with 
VAVFL (Ravindran et al., 2001) and given the structural changes to the RNFL in 
VGB toxicity, the retinal ganglion cell layer seems a highly plausible pathological 
target. (Wild et al., 2006, Dumian and Clearkin, 2007)
The second, more plausible, theory relates to the discriminatory ability of the mfVEP 
to identify regional retinal ganglion cell layer dysfunction. Retinal ganglion cell layer 
dysfunction in glaucoma is represented by a reduction in mfVEP amplitude. (Hood 
and Greenstein, 2003) An interocular approach has been recommended for clinical 
monitoring with the mfVEP in glaucoma due to the accepted difficulties with 
establishing satisfactory confidence intervals for normative databases, (Hood and 
Greenstein, 2003) and to the additional difficulties of high within-individual between- 
test variability. However, scrutiny of the illustrated cases within the literature suggests 
that the predominant field loss detected by mfVEP lies close to fixation, i.e. within a 
15° radius. This is consistent with the finding that the mfVEP is useful in the
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confirmation of those cases of optic neuritis manifesting abnormality in the extreme 
central location. (Klistomer et al., 2008) It is likely, therefore, that although the 
mfVEP stimuli are located out to 30° eccentricity, and that such stimuli are scaled for 
eccentricity, there remains a strong central dominance in each response due to the 
cortical representation of the visual field within the visual cortex. Consequently, the 
mfVEP may not identify dysfunction beyond approximately 15°. In the most severe 
form of VAVFL, the field loss never encroaches within 15° eccentricity.
A further factor inhibiting the identification by mfVEP of ganglion cell layer 
dysfunction attributable to VGB is the technical limitations of the monocular analysis 
with respect to wide normative confidence intervals and high variability encountered 
in the normal individual. (Fortune et al., 2004, Klistomer and Graham, 2005). Given 
the bilateral and symmetrical nature of VGB dysfunction, any interocular analysis of 
the mfVEP amplitude, is not feasible. It is possible that the prospective repetitive 
monitoring of a given individual treated with VGB may identify an amplitude 
reduction of the mfVEP within that expected from standard confidence intervals, thus 
obviating the need for comparison with a normative database.
Implicit time was not assessed in this study. Given that no abnormality was identified 
in amplitude arising from either VAVFL or VGB dysfunction, and given the 
topography of VAVFL relative to the stimulus location and central dominance of the 
response, it seemed unlikely that any abnormality would have arisen in the implicit 
time. Nevertheless, attempts were undertaken to design a custom template stretching
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program using MATLAB, but the software had not been completed at the time of 
writing.
6.2.5 Conclusion
The mfVEP as recorded in this study identified neither VGB toxicity nor exposure to 
VGB. The lack of evidence is in direct conflict with the unequivocal evidence for 
RNFL thinning by OCT. Failure to identify any abnormality in amplitude is likely to 
arise from the disparity between the cortical functional topography of the mfVEP and 
the location of VAVFL and also from the technical limitations associated with the 
monocular analyses of the mfVEP necessary in individuals manifesting a bilateral, 
symmetrical dysfunction, such as that arising from VGB toxicity.
On the basis of the evidence from this study, the mfVEP as recorded in this study 
cannot be recommended as a screening tool for identifying VGB toxicity.
229
Chapter 7: General Summary Of Results And 
Proposals For Future Work
7.1 Summary Of Results And Conclusions
7 .1. 1 Utility of Retinal Nerve Fibre Layer Thickness as Measured by OCT in 
VGB-Attributed Visual Dysfunction
VGB is currently under application with the FDA for licensing in the United States 
for use in Infantile Spasms and adjunctive use in partial-onset epilepsy. (Ovation, 
2008) This renewed interest, and the likely increase in VGB prescribing worldwide, 
should lead to greater emphasis on the visual monitoring of VGB-exposed patients. 
This thesis has shown that an attenuated nasal quadrant retinal nerve fibre layer 
thickness with a normal temporal quadrant thickness, as measured by optical 
coherence tomography (OCT) is a characteristic indicator of VGB toxicity. The ease 
and accessibility of OCT lends credence to the argument that OCT should now 
become the principal means for monitoring VGB toxicity and, indeed, should be 
mandatory for all individuals receiving VGB. Given the limitations of perimetry with 
respect to patient understanding and cooperation, particularly prevalent in those with 
refractory epilepsy, and the unacceptably long chair time, perimetry should no longer 
be relied upon in isolation for the detection of VGB toxicity.
The chair time for OCT is much shorter than for perimetry, the results are objectively 
acquired and the technique is applicable to children as young as 3 years old. The size
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of the current equipment necessary for OCT is a practical limitation for the 
examination of neonates and young infants. Modification of OCT technology 
(including the possibility of a hand-held imaging component) would enable the 
imaging of neonates, which is of importance in other ocular conditions as well as in 
West Syndrome. The creation of OCT normative databases for infants would enable 
greater clinical confidence in paediatric decision-making.
The finding of nasal quadrant RNFL attenuation together with a normal temporal 
quadrant is unique to VGB toxicity (Chapter 3) and will prove invaluable in 
unequivocally identifying VGB toxicity. The pattern of attenuation is consistent with 
the presence of inverse optic atrophy assocated with VGB toxicity. (Frisen and 
Malmgren, 2003, Buncic et al., 2004) Furthermore, the identification of nasal 
quadrant attenuation in VGB-exposed individuals not yet manifesting visual field loss 
suggests that OCT might be used as an indicator for the withdrawal of VGB on the 
grounds of the risk of imminent visual loss. The latter represents a potential 
breakthrough in that the prediction of imminent visual loss has hitherto not been 
possible.
The prediction of imminent VAVFL might be further improved by assessing, at 
regular intervals, the given individual’s proportionate change in nasal RNFL. The 
development of nasal atrophy inside the confidence intervals for normality but outside 
range of the between-visit nonnal variability could then be used as a clinical indicator 
to withdraw VGB. This might reasonably provide an earlier pointer to the presence of
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VGB toxicity compared with that dependent upon nasal attenuation identified cross- 
sectionally by comparison with the generic normative database.
Clinical issues are inevitably affected by resource implications. Generic issues 
important in all health care costing relate to the cost/benefit as determined by primary 
drug outcomes. When considering the cost/benefit analysis of AEDs, the socio­
economic differences between seizure reduction and seizure freedom are important. In 
paediatric practice, the cost/benefit analysis is weighted by the greatly improved 
chances of developmental gain in children free from infantile spasms compared with 
those who continue to experience spasms. However, a further consideration in those 
patients treated with VGB is the additional costs, arising from the requirement for 
regular visual monitoring. The difference in costing between OCT and perimetry is 
difficult to quantify. There is also a potential significant cost saving arising from the 
prevention of VAVFL, in the event that nasal RNFL attenuation permits withdrawal 
of VGB prior to the development of VAVFL. In our current UK system, new 
prescriptions of VGB are very uncommon in adult practice (I have never initiated any 
new prescriptions of VGB whilst working in tertiary epilepsy clinics over the last 8 
years) and this situation is likely to remain unchanged in the UK given other 
developments in AEDs. Worldwide prescription of VGB may increase, however, with 
the advent of a successful application for VGB licensing in the USA.
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7.1.2 HRT Measures In Vigabatrin Toxicity
Scanning laser ophthalmoscopy, as evidenced by the HRT II, also identifies the 
pattern of inverse nasal atrophy seen in OCT (Section 7.1.1). However, the measure 
of reduction in NRR area is not as sensitive a marker of VGB toxicity as is RNFL 
measurement by OCT and identifyies only moderate to advanced cases of VAVFL. 
The reasons for this lack of sensitivity include the lack of a normative database for 
measurement of regional RNFL thickness, which in fact, is a height difference as 
opposed to a RNFL defined by anatomical boundaries, The measure of NRR area 
employed in this thesis, for which a robust formative database exists, is a surrogate 
marker of RNFL thickness only. Thus, HRT, in current commercially available 
format, cannot be recommended for the identification of VGB toxicity.
7.1.3 Placental transfer of vigabatrin: no indication of visual field loss
The licence request for VGB usage as an AED in refractory partial-onset seizures 
will, if granted, allow prescription in the US to women of child-bearing age. There is 
no indication of visual dysfunction in 4 individuals exposed to VGB in utero, as 
assessed by both static perimetry and RNFL measurement by OCT (Section 4.2). 
This result will be of interest to epileptologists, and potentially psychiatrists with an 
interest in addiction (Section 7.1.4) as, if generalisable, this finding provides useful 
information for women planning pregnancies on VGB and could obviate the need for 
visual screening in individuals exposed to VGB in utero.
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7 .1.4 Vigabatrin-Attributed Visual Field Loss In Uniquely Low Cumulative 
Dosing: Implications For Potential Use In Anti-Addiction Therapy.
VGB is currently undergoing Phase II trials as an anti-addiction agent. (Ovation, 
2008) The recommended dosing regimen is based upon a two-week titration dose and 
treatment on a 9-week basis with high peak dosing of 3g/day. Although ocular safety 
data has been published (Fechtner et al., 2006), OCT was not used for monitoring 
safety. Wide between-individual variations occur in the duration and/or in the 
cumulative and/or mean daily dose of VGB necessary to produce VAVFL. The 
development of VAVFL in an individual (described in Chapter 4.3) treated for 
epilepsy with VGB in the range proposed for addiction must represent cause for 
concern with respect to the potential widespread use of a ‘safe’ dose of VGB as an 
anti-addiction agent..
7.1.5 Utility of mfERG in VGB-Attributed Visual Dysfunction
The mfERG does not seemingly identify VGB toxicity. This is consistent with what 
we now believe regarding the location of pathogenesis in VGB toxicity. The mfERG 
largely reflects photoreceptor cells, with additional subtle changes reflecting 
involvement of bipolar cells. Whilst previous electrical studies have suggested that 
VGB toxicity might involve photoreceptors and/or bipolar cells, the structural 
changes seen on OCT implicates RNFL loss as an early marker of VGB toxicity and 
therefore implicates ganglion cells as being primarily affected.
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The limitations of multi-focal technology are numerous and include technical 
difficulties inherent in recording small, derived responses; difficulties in dealing with 
electrically noisy data and the additional technology required to further analyse the 
modelled data. Despite the large number of multifocal electrophysiology centres, 
worldwide, at the time of writing no commercial package exists to deal with analysis 
in a uniform manner.
7.1.6 Utility of mfVEP in VGB-Attributed Visual Dysfunction
The mfVEP did not identify VGB toxicity in the cohort used in this thesis. Given that 
the ganglion cell is a plausible location for the retinal toxicity seen in VAVFL and 
this is reflected in mfVEP amplitude, this requires explanation. The large inter­
individual differences recorded in mfVEP amplitudes render normative databases 
very difficult to interpret. Skull thickness affects the recorded signal of the mfVEP, 
whilst electrode placement affects the relative positive and negative waveforms 
according to the position of the sulcal folding in the brain, in turn affecting inter­
reliability results for mfVEP. (Klistomer and Graham, 2005) Many authors prefer to 
use interocular analyses for this reason (Hood and Greenstein, 2003) -  not a helpful 
strategy in an essentially symmetrical bilateral disease such as VGB toxicity. Others 
have devised complex analyses to address the issue of normative databases 
(Klistomer and Graham, 2005) though as with mfERG no commercially available 
approach exists, as yet. Thus, ganglion cell involvement remains a distinct possibility 
in VGB toxicity but the limitations inherent in mfVEP recording and analysis might
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fail to reveal important differences in bilateral disease.
7.2 Proposals For Future Work
7.2.1 The Potential O f O C T In VGB Toxicity
The examination of the retinal nerve fibre layer by OCT should be mandatory for all 
VGB-exposed individuals including individuals participating in clinical studies of 
VGB as an addiction therapy.
OCT technology continues to improve and the resolution of individual retinal layers is 
now possible. (Drexler and Fujimoto, 2008) Imaging using High Resosolution (HR) 
OCT and adaptive optics enables resolution of 5-6 p,m, The use of such technology 
might delineate the retinal site(s) of VGB toxicity, as well as providing clues as to the 
pathogenesis.
7.2.2 The Potential Further Investigation O f The Retinal Ganglion Cell In VGB 
Toxicity
If ganglion cells are of prime importance in the pathogenesis of VGB toxicity, then an 
appropriate direct discriminator of ganglion cell dysfunction is the PERG. (Manca et 
al., 1984) Electrophysiology studies utilising the pattern ERG (PERG) in VGB- 
exposed individuals might provide information on the pathogenesis of VAVFL. 
Alternatively, prospective studies utilising mfVEP amplitude in individuals currently 
receiving VGB might allow identification of retinal ganglion cell dysfunction with 
amplitude reduction outside that allowed for by inter-test variability, alone.
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Electrophysiology has, thus far, proved a less sensitive indicator of VGB toxicity, and 
remains less clinically accessible, compared to measurement of the RNFL with OCT.
7.2.3 Pharmacogenomics In VGB
Cumulative dose of VGB and daily dose of VGB have emerged as significant factors 
in the development of VAVFL. Still, there remain some individuals on long-term 
VGB who do not develop VAVFL. Conversely, some individuals develop VAVFL on 
low dose VGB after short-term exposure. The reason for this is not established, 
though between-individual differences related to genetic susceptibilities seem a 
plausible reason.
There has been one published attempt to relate the development of VAVFL to allelic 
heterogeneity in the ornithine delta aminotransferase gene. (Hisama et al., 2001) This 
group did not identify any mutations but identified a common intronic polymorphism. 
It is possible that differences in single nucleotide polymorphisms in candidate genes 
relate to the pathogenesis of VGB toxicity. A multi-centre trial investigating the 
pharmacogenomics of VGB has recently been established in the UK. (Ovation, 2008)
Identification and stratification of epileptic patients in this way would be informative 
to clinicians and might enable many more individuals to be treated with VGB. In 
particular, this would enable children and adults to be treated according to clinical 
need and efficacy rather than at the behest of currently unquantifiable risks of adverse
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VGB effects.
Clinical-genetic stratification and estimation of individualised visual field risk in 
VGB will inform clinical outcomes and thereby improve service organisation and 
delivery, since prescribing will be based on clearer risk/benefit analyses.
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Appendix
A.1 Key To Abbreviations In The Text
ACTH Adrenocorticotrophic Hormone
AED Anti-epileptic Drug
AI Arden Index
CBZ Carbamazepine
Cl Confidence Intervals
DANA Dopamine levels in the nucleus accumbens
DTL Dawson-T rick-Lithgo
ERG Electro-Oculogram
ERG Electro-Retinogrram
HFA Humphrey Visual Field Analyzer
HRT Heidelberg Retinal Tomograph
IS Infantile Spasms
ISCEV International Society for Clinical Electrophysiology of Vision
mfERG Multifocal Electroretinography
mfVEP Multifocal Visual Evoked Potential
MRA Moorfields Regression Analysis
NRR Neuroretinal Rim
OCT Optical Coherence Tomography
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PERG Pattern Electroretinography
QoL Quality of Life
RCT Randomised Control Trial
RGC Retinal Ganglion Cell
RNFL Retinal Nerve Fibre Layer
RPE Retinal Pigment Epithelium
SLD Super Luminescent Diode
SLO Scanning Laser Opthalmoscopy
TS Tuberous Sclerosis
UKISS United Kingdom Infantile Spasm Study 
VAVFL Vigabatrin-Attributed Visual Field Loss 
VEP Visual Evoked Potential 
VERIS Trademark software of EDI 
VGB Vigabatrin
A.2.1 Age-Adjusted Confidence Intervals For The mfERG
The confidence intervals for the mfERG data based on the controls from the cohort 
are detailed below.
95% Confidence Limits 18:35 W ednesday, N ovem ber 19, 2008 I
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-3.85 - -0.66 -3.87 - -0.67 -3.89 - -0.69 -3.90--0.71 -3.92 - -0.72
-5 .7 4 - - I . I  1 -5 .7 2 --1 .0 8 -5 .7 0 --1 .0 6 -5 .67--1 .04 -5.65 --1 .01
-3.84 - -0.75 -3.81 - -0.73 -3.79 - -0.70 -3.76 - -0.68 -3.74 - -0.66
-4.89 - -0.86 -4.73 - -0.70 -4.57 - -0.55 -4.42 - -0.39 -4.26 - -0.23
-3.02 - -0.72 -2.95 - -0.64 -2.87 - -0.56 -2.79 - -0.49 -2.72 - -0.41
data var cl25 cl30 cl35 cl40 cl45
263
n I imptim 11 17.25 - 28.40 17.75 - 28.90 18.25 - 29.40 18.75 - 29.90
19.25 - 30.40
12 14.84 - 29.14 15.30 - 29.59 15.76 - 30.05 16.21 - 30.51
16.67- 30.97
data cl50 cl55 d 6 0  cl65 cl70
n I imptim 19.75 - 30.90 20.25 - 3 1.40 20.75 - 3 1.90 2 1.25 - 32.40 2 1.76
- 32.90
17.13 - 31.42 17.59 - 31.88 18.04 - 32.34 18.50 - 32.79 18.96 -
33.25
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data var cl25 cl30 cl35 cl40 cl45
n I imptim 13 17.99 - 27.70 18.58 - 28.29 19 .17 - 28.88 19.76 - 29.47
20.36 - 30.06
14 18.25 - 27.66 18.77 - 28.18 19.28 - 28.69 19.79 - 29.20
20.31 - 29.72
15 17.88 - 28.43 18.39 - 28.94 18.90 - 29.45 19.41 - 29.96
19.92 - 30.47
16 18.34 - 29.23 18.78 - 29.67 19.22 - 30.11 19.66 - 30.55
20.10- 30.99
17 17.73 - 29.31 18.27 - 29.85 18.80 - 30.38 19.33 - 30.91
1 9 .8 6 -3 1 .4 4
264
16.67
20.23
18.00
21.21
19.98
20.61
18.95
19.42
20.73
33.02
32.28
33.02
■ 33.22
■ 30.45
■ 32.54
■30.14
31.56
28.67
29.61
29.18
29.06
18 14.16 - 30.70 14.78 - 31.33 15.41 - 31.96 16.04 - 32.59
rl 18.17 - 28.39 18.69 - 28.91 19.20 - 29.42 19.72 - 29.94
r2 16.38 - 30.92 16.79 - 31.32 17.19 - 31.73 17.59 - 32.13
r3 18.65 - 27.58 19.29 - 28.22 19.93 - 28.86 20.57 - 29.50
r4 17.98 - 29.56 18.48 - 30.06 18.98 - 30.56 19.48 - 31.06
r5 18.65 - 26.70 19 .14 - 2 7 .19 19.63 - 27.68 20 .12 - 28 .17
r6 16.90 - 27.56 17.41 - 28.07 17.92 - 28.58 18.44 - 29.10
r7 17.59 - 27.35 18.05 - 27.81 18.51 - 28.27 18.96 - 28.73
r8 18.73 - 27.05 19.23 - 27.55 19.73 - 28.05 20.23 - 28.56
data cl50 cl55 cl60 cl65 cl70
20.95 - 30.66 2 1.54 - 3 1.25 2 2 .13 - 3 1.84 22.72 - 32.43 23.32 -
20.82 - 30.23 2 1.33 - 30.74 2 1.85 - 3 1.26 22.36 - 3 1.77 22.87 -
20.43 - 30.98 20.94 - 3 1.49 2 1.45 - 32.00 2 1.96 - 32.51 22.47 -
265
33.19
34.10
36.36
33.02
34.56
33.34
34.05
31.12
32.16
31.47
31.57
20.54 - 3 1.43 20.98 - 3 1.87 2 1.42 - 3 2 .3 1 2 1.86 - 32.75 22.30 -
20.39 - 3 1.97 20.93 - 3 2 .51 2 1.46 - 33.04 2 1.99 - 33.57 22.52 -
17.30 - 33.85 17.93 - 34.47 18.56 - 35.10 19 .19 - 35.73 19.82
20.75 - 30.97 2 1.26 - 3 1.48 21.77 - 32.00 22.29 - 32 .51 22.80 -
18.40 - 32.94 18.81 - 33.35 19.21 - 33.75 19.61 - 34.15 20.02
2 1.85 - 30.78 22.49 - 3 1.42 23.13 - 32.06 23.77 - 32.70 24.41 -
20.48 - 32.06 20.98 - 32.56 2 1.47 - 33.06 2 1.97 - 33.55 22.47 -
2 1. 10 - 29 .16 2 1.59 - 29.65 22.08 - 30 .14 22.58 - 30.63 23.07 -
19.46 - 30.12 19.97 - 30.63 20.48 - 31.14 20.99 - 31.65 21.50 -
19.88 - 29.64 20.34 - 3 0 .10 20.79 - 30.56 2 1.25 - 3 1.0 1 21.71 -
2 1.23 - 29.56 2 1.74 - 30.06 22.24 - 30.56 22.74 - 3 1.06 23.24 -
data var cl25 cl30 cl35 cl40 cl45
n2amp 11 -5.90 - -0.45 -5 .81 - -0.35 -5 .71 - -0.26 -5.62 - -0 .17 -5.53
- -0.08
266
12 -3.35 - 0.38 -3.36 - 0.38 -3.36 - 0.37 -3.36 - 0.37 -3.37 -
0.37
13 -5.23 - 0.10 -5 .2 7 - 0.05 -5 .32 - 0.01 -5.37 --0 .04  -5.41 - -
0.09
data cl50 cl55 d 6 0  cl65 cl70
n2amp -5.44 - 0.02 -5.34 - 0.11 -5.25 - 0.20 -5.16 - 0.29 -5 .07-
0.39
-3.37 - 0.36 -3.38 - 0.36 -3.38 - 0.35 -3.38 - 0.35 -3.39 - 0.35
-5.46 - -0 .14 -5 .5 1 - -0 .18 -5.55 - -0.23 -5.60 - -0.28 -5.65 - -0.32
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data var cl25 cl30 cl35 cl40 cl45
n2amp 14 -3.74 - -0.35 -3 .7 1 - -0.33 -3.69 - -0 .31 -3.67 - -0.28 -3.65
- -0.26
15 -6.09 - 0.04 -6.09 - 0.04 -6.09 - 0.05 -6.08 - 0.05 -6.08 -
0.05
16 -3.42 - -0.37 -3.37 - -0 .3 1 -3.32 - -0.26 -3.27 - -0.21 -3.21 - -
0.15
17 -5.26 - 0.19 -5.13 - 0.32 -5.00 - 0.45 -4 .87- 0.58 -4.74 -
0.71
18 -2 .71 - -0.72 -2.63 - -0.63 -2.54 - -0.54 -2.46 - -0.46 -2.37 - -
0.37
r I -5 .15 - - 1.20 -5.04 - - 1.08 -4.93 - -0.97 -4 .81 - -0.86 -4.70 - -
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0.74
0.17
0.53
0.22
0.69
0.59
1.37
0.35
r2 -2 .1 2 - -0 .1 2  -2 .1 3 --0 .1 3  -2 .1 5 --0 .1 4  -2 .1 6 --0 .1 6  -2.18
r3 -4.83 - -0.74 -4.78 - -0.69 -4.73 - -0.64 -4.67 - -0.58 -4.62 - -
r4 -3 .51 - -0.22 -3 .5 1 - -0.22 -3 .51 - -0.22 -3 .51 - -0.22 -3 .51
r5 -6.33 - - 1. 10 -6.23 - - 1.00 -6 .12 - -0.89 -6.02 - -0.79 -5 .91 - -
r6 -3.75 - -0.73 -3.72 - -0.70 -3.68 - -0.66 -3.65 - -0.63 -3 .61 -
r7 -5 .0 7 --2 .0 5  -4 .9 0 --1 .8 8  -4 .72--1 .71  -4 .55 --1 .54  -4 .3 8 --
r8 -3 .31 - -0.73 -3.22 - -0.64 -3 .12 - -0.54 -3.03 - -0.45 -2.93 - -
data cl50 c!55 cl60 cl65 cl70
-3.62 - -0.24 -3.60 - -0.22 -3.58 - -0 .19 -3.56 - -0 .17 -3.53 - -0 .15
-6 .08 - 0.05 -6 .0 8 - 0.06 -6 .0 7 - 0.06 -6 .07- 0.06 -6.07- 0.07
-3 .16 - -0.10 -3 .1 1 - -0.05 -3.06 - 0.00 -3.00 - 0.06 -2.95 - 0 .11
-4 .61 - 0.84 -4 .4 8 - 0.97 -4.35 - 1.10 -4 .22- 1.23 -4.09- 1.36
-2.28 - -0.29 -2.20 - -0.20 -2 .1 I - -0 .11 -2.02 - -0.03 - 1.94 - 0.06
-4.59 - -0.63 -4.47 - -0 .5 1 -4.36 - -0.40 -4.24 - -0.29 -4 .13 - -0 .17
-2 .19 - -0 .19 -2.20 - -0.20 -2.22 - -0 .21 -2.23 - -0.23 -2.25 - -0.24
-4.57 - -0.48 -4 .5 1 - -0.42 -4.46 - -0.37 -4.41 - -0.32 -4.36 - -0.26
-3 .5 1 - -0.22 -3 .51 - -0.22 -3 .51 - -0.22 -3.51 - -0.22 -3 .51 - -0.22
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58.35 -
56.13-
57.68 -
58.25 -
- 82.99
78.43
76.91
75.13
-5 .8 1 - -0.58 -5 .7 1 - -0.48 -5.60 - -0.37 -5.50 - -0.27 -5.40 - -0 .17
-3.58 - -0.56 -3.55 - -0.53 -3 .51 - -0.49 -3.48 - -0.46 -3.45 - -0.42
-4 .21 - - 1.20 -4.04 - - 1.03 -3.87 - -0.86 -3.70 - -0.68 -3.53 - -0.51
-2.84 - -0.26 -2.74 - -0 .16 -2.65 - -0.07 -2.55 - 0.03 -2.46 - 0 .12
data var cl25 d 3 0  cl35 cl40 cl45
n2imptim II 53.48 - 72.04 54.69 - 73.26 55 .91 - 74.47 57.13 - 75.69
76.91
12 53 .11 - 71.64 53.86 - 72.39 54.62 - 73.15 55.37 - 73.90
74.66
13 54.48 - 69.73 55.28 - 70.52 56.08 - 71.32 56.88 - 72.12
72.92
14 55.84 - 69.71 56.45 - 70.31 57.05 - 70.91 57.65 - 71.52
72.12
data cl50 cl55 cl60 cl65 cl70
n2imptim 59.56 - 7 8 .12 60.78 - 79.34 62.00 - 80.56 63.22 - 8 1.78 64.43
56.88 - 75 .41 57.63 - 7 6 .17 58.39 - 76.92 59 .14 - 77.68 59.90 -
58.48 - 73.72 59.28 - 74.52 60.07 - 75.32 60.87 - 76 .11 6 1.67 -
58.85 - 72.72 59.46 - 73.32 60.06 - 73.92 60.66 - 74.53 61.26 -
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data var cl25 cl30 cl35 cl40 cl45
n2imptim 15 52.98 - 7 1.27 53.90 - 7 2 .18 54 .81 - 73 .10 55.73 - 74.01
56.64 - 74.93
16 53.78 - 71.72 54.56 - 72.50 55.34 - 73.28 56.12 - 74.06
56.90 - 74.84
55.34 - 79.63
55.90 - 74.47
60.78 - 74.56
58.01 - 73.73
59.69 - 72.03
58.65 -71.96
56.77-72.13
57.05 - 71.33
58.16- 72.55
17 50.58 - 74.88 51.77 - 76.07 52.96 - 77.25 54.15 - 78.44
18 52.32 - 70.89 53.22 - 71.79 54.1 I - 72.68 55.01 - 73.58
rl 56.60 - 70.38 57.65 - 71.42 58.69 - 72.47 59.74 - 73.51
r2 54.67 - 70.39 55.50 - 71.23 56.34 - 72.06 57.17 - 72.90
r3 56.33 - 68.68 57.17 - 69.51 58.01 - 70.35 58.85 - 71.19
r4 56.18 - 69.48 56.80 - 70.10 57.42 - 70.72 58.04 - 71.34
r5 53.48 - 68.84 54.30 - 69.66 55.13 - 70.48 55.95 - 71.31
r6 53.76 - 68.05 54.58 - 68.87 55.40 - 69.69 56.23 - 70.51
r7 54.49 - 68.89 55.41 - 69.80 56.33 - 70.72 57.24 - 71.63
r8 50.09 - 71.36 51.18 - 72.45 52.27 - 73.54 53.36 - 74.63
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54.45 - 75.72
data
79.50
78.75
85.58
78.95
79.78
77.91
76.22
75.05
76.25
75.44
77.13
cl50 cl55
57.55 - 75.84 58.47
57.68 - 75.62 58.46
56.53 - 80.82 57.72
56.80 - 75.37 57.70
61.83 - 75.60 62.88
58.84 - 74.57 59.68
60.52 - 72.87 61.36
59.27 - 72.58 59.89
57.60 - 72.95 58.42
57.87 - 72.16 58.69
59.07 - 73.47 59.99
55.54 - 76.82 56.64
cl60 cl65
76.75 59.38 - 77.67
76.40 59.24 - 77.18
82.01 5 8 .9 1 - 83.20
76.26 58.59 - 77.16
76.65 63.92 - 77.69
75.40 6 0 .5 1 - 76.24
73.71 62.20 - 74.55
73.19 6 0 .5 1 - 73.81
73.78 59.24 - 74.60
72.98 5 9 .51 - 73.80
74.38 60 .91 - 75.30
77.91 57.73 - 79.00
cl70
60.30 - 78.58 61.21 -
60.02 - 77.97 60.80 -
60.09 - 84.39 61.28 -
59.49 - 78.05 60.38 -
64 .97- 78.74 66 .01-
61.35 - 77.07 62.19 -
63.04 - 75.38 63.88 -
61.13 - 74.43 61.75 -
60.07 - 75.42 60.89 -
60.33 - 74.62 61.15 -
61.82 - 76.22 62.74 -
58.82 - 80.09 59.91 -
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81.18
data var cl25 cl30 cl35 cl40 cl45
pi amp II 2.25 - 7.49 2.16 - 7.40 2 .07 - 7.31 1.98- 7.22 1.89
- 7.13
12 0.40 - 4.09 0.48 - 4.17 0.57 - 4.26 0.65 - 4.34 0 .74 -
4.43
6.95
4.95
7.72
6.68
13 1.32 - 6.94 1.32 - 6.94 1.33 - 6.95 1.33 - 6.95 1.33-
14 0.75 - 4.59 0.84 - 4.68 0.93 - 4.77 1.02- 4.86 1.1
15 0.46 - 7.71 0 .4 6 -  7.71 0 .4 6 -  7.71 0.46 - 7.71 0 .46 -
data cl50 cl55 cl60 cl65 cl70
pi amp 1.80 - 7.04 1.71 - 6.95 1.62 - 6.86 1.53 - 6.77 1.44
0 .82 - 4.51 0 .9 1 - 4.59 0 .9 9 -  4.68 1.07- 4.76 1.16- 4.85
1.33 - 6.95 1.34 - 6.95 1.34 - 6.96 1.34- 6.96 1.34- 6.96
1.20 - 5.04 1.29 - 5.13 1.39 - 5.22 1.48 - 5.31 1.57- 5.40
0.46 - 7.72 0.47 - 7.72 0.47 - 7.72 0.47 - 7.72 0.47 - 7.72
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data var cl25 cl30 cl35 cl40 cl45
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4.34
6.61
3.33
5.95
3.06
5.62
4.34
6.70
5.08
6.74
4.19
pi amp 16 -0 .5 2 -  4 .04 -0.45 - 4.11 -0 .3 7 - 4.19 -0 .3 0 - 4.26 -0.22
17 0.99 - 6.72 0.96 - 6.69 0.94 - 6.67 0 .9 1 - 6.64 0 .8 8 -
18 0.92 - 3.36 0.91 - 3.35 0.91 - 3.34 0.90 - 3.34 0.89 -
rl 1.93 - 5.97 1.93 - 5.97 1.92 - 5.96 1.92- 5.96 1.91-
r2 0.54 - 2.94 0 .5 7 -  2.97 0.60 - 3.00 0.63 - 3.03 0.66 -
r3 1.78 - 5.77 1.74 - 5.73 1.70 - 5.70 1.66- 5.66 1.63
r4 0.85 - 4.45 0.82 - 4.42 0.80 - 4.40 0.77 - 4.37 0.74 -
rS 2 .3 7 - 7.05 2.28 - 6.96 2.19 - 6.87 2 .10 - 6.79 2.02
r6 0 .7 4 - 5.00 0 .7 6 -  5.02 0 .7 8 -  5.04 0 .80 - 5.06 0 .82 -
r7 2.63 - 7.06 2.55 - 6.98 2.47 - 6.90 2.39 - 6.82 2 .31 -
r8 0 .7 7 - 4.17 0 .7 8 -  4.18 0.78 - 4.18 0 .78 - 4.18 0.79
data cl50 cl55 cl60 cl65 cl70
-0 .1 5 -  4.41 -0 .0 7 -  4.49 0 .0 0 -  4.56 0 .0 8 -  4.64 0 .1 5 -  4.71
273
40.23
37.42
39.03
39.14
38.76
3 9 .1 1
0 .8 6 - 6.59 0.83 - 6.56 0.80 - 6.53 0 .78 - 6.51 0 .75 - 6.48
0 .8 8 - 3.32 0 .8 8 -  3.32 0.87 - 3.31 0 .86 - 3.30 0 .86 - 3.29
1.91 - 5.95 1.90- 5.94 1.90 - 5.94 1.89- 5.93 1.89- 5.93
0 .6 9 - 3.09 0 .7 3 -  3.13 0.76 - 3.16 0 .79 - 3.19 0 .82 - 3.22
1.59- 5.58 1.55- 5.54 1.51 - 5.51 1.47- 5.47 1.44- 5.43
0.71 - 4.31 0.68 - 4.29 0.66 - 4.26 0.63 - 4.23 0.60 - 4.20
1.93 - 6.61 1.84- 6.52 1.75 - 6.43 1.66- 6.34 1.57- 6.26
0 .84 - 5.10 0 .8 6 -  5.12 0.88 - 5.14 0 .90 - 5.16 0 .92 - 5.18
2.23 - 6.66 2 .1 5 - 6.59 2.08 - 6.51 2 .00 - 6.43 1.92- 6.35
0 .79 - 4.19 0 .8 0 - 4.20 0.80 - 4.20 0.81 - 4.21 0.81 - 4.21
var cl25 cl30 cl35 cl40 cl45
p I imptim 
52.52
12
52.93
13
51.86
14
51.69
15
52.71
16
52.91
37 .10 - 49.39 37.88 - 5 0 .17 38.66 - 50.96 39.44 - 5 1.74
35.07 - 50.58 35.66 - 51.16 36.25 - 51.75 36.84 - 52.34
36.56 - 49.39 37.18 - 50.00 37.79 - 50.62 38.41 - 51.24
36.89 - 49.44 37.45 - 50.00 38.01 - 50.56 38.57 - 51.12
36.02 - 49.96 36.70 - 50.65 37.39 - 51.33 38.08 - 52.02
36.73 - 50.53 37.33 - 51.13 37.92 - 51.72 38.52 - 52.32
data cl50 cl55 cl60 cl65 cl70
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p I imptim 4 1.0 1 - 53.30 4 1.79 - 54.09 42.57 - 54.87 43.36 - 55.65 4 4 .14
- 56.43
38.01 - 53.52 38.60 - 5 4 .10 39.19 - 54.69 39.77 - 55.28 40.36 -
55.87
54.95
54.49
56.14
55.89
39.65 - 52.48 40.27 - 53.09 40.88 - 53 .71 4 1.50 - 54.33 4 2 .12
39.70 - 52.25 40.26 - 5 2 .8 1 40.82 - 53.37 4 1.38 - 53.93 4 1.95
39.45 - 53.39 4 0 .13 - 54.08 40.82 - 54.76 41 .51 - 55.45 4 2 .19 -
39.71 - 53.51 40.30 - 5 4 .1 I 40.90 - 54.70 4 1.49 - 55.30 42.09 -
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data var cl25 cl30 cl35 cl40 cl45
p I imptim 17 36.97 - 50.58 37.67 - 5 1.28 38.38 - 5 1.99 39.09 - 52.69
39.79 - 53.40
18 33.76 - 50.56 34.52 - 51.32 35.28 - 52.07 36.03 - 52.83
36.79 - 53.59
rl 37.72 - 49.17 38.52 - 49.97 39.32 - 50.77 40.12 - 51.57
40.92 - 52.36
r2 35.35 - 50.83 36.14 - 51.62 36.93 - 52.40 37.71 - 53.19
38.50 - 53.98
r3 36.47 - 48.75 37.24 - 49.52 38.02 - 50.29 38.79 - 51.06
275
39.56
40.49
38.78
37.77
38.80
39.18
56.93
57.39
56.36
57.91
55.70
54.62
■51.84
•51.47
■50.61
■ 51.19
■ 50.96
■ 50.90
r4 37.96 - 48.94 38.59 - 49.57 39.23 - 50.20 39.86 - 50.84
r5 35.72 - 47.56 36.49 - 48.32 37.25 - 49.09 38.01 - 49.85
r6 34.88 - 48.29 35.60 - 49.02 36.32 - 49.74 37.05 - 50.46
r7 35.93 - 48.09 36.65 - 48.81 37.36 - 49.53 38.08 - 50.24
r8 36.00 - 47.73 36.79 - 48.52 37.59 - 49.32 38.38 - 50.11
data c!50 cl55 cl60 cl65 c!70
40.50 - 54 .10 4 1.20 - 5 4 .8 1 4 1.9 1 - 55.52 42 .61 - 56.22 43.32 -
37.55 - 54.35 38.31 - 55.1 I 39.07 - 55.87 39.83 - 56.63 40.59
4 1.72 - 53 .16 42.52 - 53.96 43.32 - 54.76 4 4 .12 - 55.56 44.92
39.29 - 54.76 40.07 - 55.55 40.86 - 56.34 4 1.65 - 5 7 .12 42.43 -
40.33 - 52 .61 4 1. 1 I - 53.38 4 1.88 - 54 .15 42.65 - 54.93 43.42 -
41.12 - 52.10 41.75 - 52.73 42.38 - 53.36 43 .01 - 53.99 43.65 -
39.54 - 51.38 40.30 - 5 2 .14 4 1.07 - 52.90 4 1.83 - 53.67 42.59 -
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54.43
38.50 - 5 1.9 1 39.22 - 52.64 39.94 - 53.36 40.67 - 54.08 4 1.39 -
54.81
39 .51 - 5 1.67 40.23 - 52.39 40.94 - 53.10 4 1.66 - 53.82 42.38 -
54.54
39.97 - 5 1.70 40.77 - 52.49 4 1.56 - 53.29 42.36 - 54.08 43.15 -
54.88
90% Confidence Limits 18:35 W ednesday,
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data var cl25 cl30 cl35 cI40 cl45
nlam p II -5.55 --1 .60  -5.49 --1 .5 4  -5 .4 2 --1 .4 7  -5.36--1.41 -5.29
- -1.34
12 -3 .01 - -0.25 -2.97 - -0 .2 1 -2.94 - -0 .18 -2.90 - -0 .14 -2.87 - -
0.11
0.61
0.65
0.75
0.61
.53
13 -5.39 --0 .99  -5.30 --0 .8 9  -5.20 --0 .80  -5.1 I - -0.70 -5.02-
14 -3.36 - -0.65 -3.36 - -0.65 -3.36 - -0.65 -3.36 - -0.65 -3.36 - -
15 -4.92 - -0.69 -4.94 - -0 .7 1 -4.95 - -0.72 -4.97 - -0.74 -4.98 - -
16 -3.87 - -0.78 -3.83 - -0.74 -3.78 - -0.69 -3.74 - -0.65 -3.70 -
17 -4 .3 0 --1 .7 2  -4.25 --1 .6 7  -4 .20 --1 .62  -4 .16--1 .58  -4.
18 -3 .01 - -0.43 -2.96 - -0.38 -2 .91 - -0.32 -2.85 - -0.27 -2.80 - -
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0.22
1.23
0.36
0.94
0.84
1.42
0.97
1.27
0.94
r I -5 .7 1 - - 1.66 -5.60 - - 1.55 -5.49 - - 1.44 -5.39 - - 1.33 -5.28
r2 -2 .6 9 --0 .4 5  -2.66 --0 .4 3  -2 .6 4 --0 .4 1 -2.62 --0 .38  -2 .5 9 --
r3 -5.66 - - 1.09 -5.63 - - 1.06 -5.59 - - 1.02 -5.55 - -0.98 -5 .51 - -
r4 -3.57 - -0.78 -3.59 - -0.79 -3 .6 1 - -0 .81 -3.62 - -0.83 -3.64 - -
r5 -5 .57--1 .51  -5.55 --1 .4 9  -5.53 --1 .47  -5 .50 --1 .44  -5 .4 8 --
r6 -3 .7 7 --1 .0 7  -3 .7 4 --1 .0 4  -3 .7 2 --1 .0 2  -3 .69 --1 .00  -3 .6 7 --
r7 -5 .4 2 --1 .8 9  -5 .2 6 --1 .7 3  -5 .1 0 --1 .5 8  -4.95 --1 .42  -4 .79-
r8 -3 .2 6 --1 .2 4  -3.19 - -1 .1 7  -3 .1 1 --1 .0 9  -3.03 - - I .0 I  -2.96
data c!50 cl55 cl60 c!65 cl70
.02
nlam p -5.23 - - 1 . 2 8  -5.17 - -1.21 -5.10 - -1 .15 -5.04 - -1 .09 -4.97 - -
-2.83 - -0.07 -2.80 - -0.04 -2.76 - -0.00 -2.73 - 0.03 -2.69 - 0.07
-4.92 - -0 .5 1 -4.83 - -0.42 -4.73 - -0.32 -4.64 - -0.23 -4.54 - -0 .13
-3.36 - -0.65 -3.36 - -0.65 -3.36 - -0.65 -3.36 - -0.65 -3.36 - -0.65
-5.00 - -0.77 -5.02 - -0.78 -5.03 - -0.80 -5.05 - -0.82 -5.06 - -0.83
-3.66 - -0.57 -3.62 - -0.53 -3.57 - -0.49 -3.53 - -0.44 -3.49 - -0.40
278
-4 .06 --1 .49 -4 .0 2 --1 .4 4 -3 .9 7 --1 .3 9 -3 .92--1 .35 -3 .88--1 .30
-2 .74 --0 .16 -2 .6 9 - -0 .l l -2.64 - -0.06 -2.58 - -0.00 -2.53 - 0.05
-5.17 - -1.12 -5.06 - -1 .01 -4.95 - -0.90 -4.85 - -0.79 -4.74 - -0.69
-2.57 - -0.34 -2.55--0.31 -2.52 - -0.29 -2.50 - -0.27 -2.48 - -0.24
-5.47 - -0.90 -5.44 - -0.87 -5.40 - -0.83 -5.36 - -0.79 -5.32 - -0.75
-3.65 - -0.86 -3.67 - -0.87 -3.69 - -0.89 -3 .70--0 .91 -3.72 - -0.92
-5 .45 --1 .40 -5 .43--1 .37 -5.41 - -1.35 -5 .3 8 --1 .3 3 -5 .36 --1 .30
-3.65 - -0.95 -3.62 - -0.92 -3.60 - -0.90 -3.57 - -0.87 -3.55 - -0.85
-4 .6 4 - - I . 1 1 -4.48 - -0.95 -4.32 - -0.80 -4 .1 7 --0 .6 4 -4.01 - -0.48
-2.88 - -0.86 -2.80 - -0.78 -2.73 - -0.71 -2.65 - -0.63 -2.57 - -0.55
var c!25 cl30 cl35 cl40 cl45
n I imptim 11 17.95 - 27.70 18.45 - 28.20 18.95 - 28.70 19.45 - 29.20
19.95 -29.71
12 15.74 - 28.24 16.19 - 28.70 16.65 - 29.16 17.1 I - 29.62
17.57- 30.07
data cl50 cl55 cl60 cl65 cl70
n I imptim 20.45 - 30.21 20.95 - 30 .71 2 1.45 - 3 1.2 1 2 1.95 - 3 1.7 1 22.45
-32.21
18.02 - 30.53 18.48 - 30.99 18.94 - 3 1.44 19.39 - 3 1.90 19.85 -
32.36
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20.96
20.89
20.58
20.78
20.59
17.71
20.87
18.91
21.77
20.70
21.11
19.61
data var cl25 d 3 0  cl35 cl40 cl45
n I imptim 13 18.59 - 27.09 19.19 - 27.68 19.78 - 28.27 20.37 - 28.86
29.46
14 18.84 - 27.07 19.35 - 27.59 19.87 - 28.10 20.38 - 28.62
29.13
29.81
30.31
■ 30.72
■32.18
■29.81
■31.63
• 29.58
30.83
28.16
28.94
15 18.54 - 27.77 19.05 - 28.28 19.56 - 28.79 20.07 - 29.30
16 19.02 - 28.54 19.46 - 28.99 19.90 - 29.43 20.34 - 29.87
17 18.46 - 28.59 18.99 - 29.12 19.52 - 29.65 20.05 - 30.19
18 15.19 - 29.67 15.82 - 30.30 16.45 - 30.92 17.08 - 31.55
rl 18.81 - 27.75 19.33 - 28.27 19.84 - 28.78 20.35 - 29.30
r2 17.29 - 30.01 17.69 - 30.42 18.10 - 30.82 18.50 - 31.22
r3 19.20 - 27.02 19.84 - 27.66 20.48 - 28.30 21.13 - 28.94
r4 18.71 - 28.84 19.20 - 29.34 19.70 - 29.84 20.20 - 30.34
r5 19.15 - 26.20 19.64 - 26.69 20.13 - 27.18 20.62 - 27.67
r6 17.57 - 26.90 18.08 - 27.41 18.59 - 27.92 19.10 - 28.43
r7 18.20 - 26.74 18.66 - 27.20 19.12 - 27.66 19.57 - 28.12
280
20.03 - 28.57
r8 19.25 - 26.53 19.75 - 27.03 20.25 - 27.53 20.75 - 28.03
21.25 -28.54
data cl50 cl55 cl60 d65 d70
2 1.55 - 30.05 2 2 .15 - 30.64 22.74 - 3 1.23 23.33 - 3 1.82 23.92 -
32.42
31.70
32.36
32.51
33.38
35.33
32.39
33.65
32.79
33.33
2 1.4 1 - 29.64 2 1.92 - 3 0 .16 22.44 - 30.67 22.95 - 31.18 23.46 -
2 1.09 - 30.32 2 1.60 - 30.83 2 2 .11 - 3 1.34 22.62 - 3 1.85 23 .13 -
21.22 - 30.75 21.66 - 31.19 22.10 - 31.63 22.54 - 32.07 22.98 -
21.12 - 31.25 21.65 - 31.78 22.18 - 32.31 22 .71- 32.85 23.24 -
18.33 - 32 .81 18.96 - 33.44 19.59 - 34.07 20.22 - 34.70 20.85 -
2 1.38 - 30.33 2 1.90 - 30.84 22 .41 - 3 1.36 22.93 - 3 1.87 23.44 -
19 .3 1 - 32.03 19.72 - 32.44 2 0 .12 - 32.84 20.52 - 33.24 20.93 -
22 .41 - 30.22 23.05 - 30.86 23.69 - 3 1.50 24.33 - 32 .15 24.97 -
2 1.20 - 3 1.33 2 1.70 - 3 1.83 22.20 - 32.33 22.70 - 32.83 23.20
2 1.6 1 - 28.65 2 2 .10 - 2 9 .14 22.59 - 29.64 23.08 - 3 0 .13 23.57 -
281
30.62
31.49
30.86
31.05
- -0.42
0.13
0.42
0.04
2 0 .12 - 29.45 20.63 - 29.96 21.14 - 30.47 2 1.65 - 30.98 2 2 .16 -
20.49 - 29.03 20.95 - 29.49 2 1.40 - 29.95 2 1.86 - 30.40 22.32
2 1.75 - 29.04 22.26 - 29.54 22.76 - 30.04 23.26 - 30.54 23.76
data var cl25 cl30 cl35 cl40 cl45
n2amp II -5.56 --0 .79  -5.47 - -0.70 -5.37 - -0.60 -5 .2 8 --0 .5 1 -5.19
12 - 3 .1 2 -0 .1 5  - 3 .1 2 - 0 .1 4  - 3 .1 3 -0 .1 4  -3 .1 3 -0 .1 4  -3.13
13 -4.89 - -0.23 -4.94 - -0.28 -4.99 - -0.33 -5.03 - -0.37 -5.08 - -
data cl50 cl55 cl60 cl65 c!70
n2amp -5 .10 - -0.33 -5.00 - -0.23 -4 .91 - -0.14 -4.82 - -0.05 -4.73
-3 .1 4 -0 .1 3  - 3 .1 4 -0 .1 2  -3 .1 5 -0 .1 2  -3 .1 5 -0 .1 2  -3 .I5 -O .I I  
-5 .13 - -0.47 -5 .17 - -0.52 -5.22 - -0.56 -5.27 - -0 .61 -5.31 - -0.66
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data var cl25 cl30 cl35 cl40 cl45
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- -0.47
0.33
0.35
0.37
0.50
0.99
0.30
0.78
0.42
1.01
0.78
.56
0.51
n2amp 14 -3.52 - -0.56 -3.50 - -0.54 -3.48 - -0.52 -3.46 - -0.49 -3.43
15 -5 .71 - -0.34 -5 .7 1 - -0.34 -5.70 - -0.34 -5.70 - -0.34 -5.70 - -
16 -3.23 - -0.56 -3 .1 8 - -0.50 -3.13 - -0.45 -3.08 - -0.40 -3.02 -
17 -4 .9 2 --0 .1 5  -4 .7 9 --0 .0 2  -4.66 - 0.11 -4.53 - 0.24 -4.40
18 -2.59 - -0.84 -2.50 - -0.76 -2.42 - -0.67 -2.33 - -0.58 -2.24 -
rl -4 .9 1 - - 1.44 -4.79 - -1.33 -4 .6 8 -- l.2 2  -4 .5 6 - - I .I0  -4 .4 5 --
r2 - 1.99 - -0.24 -2 .0 1 - -0.26 -2.02 - -0.27 -2.04 - -0.28 -2.05 -
r3 -4 .5 8 --1 .0 0  -4.52 --0 .9 4  -4.47 --0 .89 -4.42 --0 .84  -4 .3 6 --
r4 -3.30 - -0.42 -3.30 - -0.42 -3.30 - -0.42 -3.30 - -0.42 -3 .31 - -
r5 -6.00 --1 .43  -5 .9 0 --1 .3 2  -5 .80 --1 .22  -5.69 --1 .12 -5 .5 9 --
r6 -3.56 --0 .9 2  -3.53 --0 .8 8  -3.49 --0.85 -3.46 - -0.82 -3.43 - -
r7 -4.88 - -2.24 -4 .71 - -2.07 -4.54 - - 1.90 -4.36 - - 1.73 -4 .19 - -
r8 -3.15 --0 .8 9  -3.06 --0 .80  -2.96 - -0.70 -2.87--0.61 -2 .7 7 --
283
cl50 cl55 c!60 cl65 cl70
-3.41 - -0.45 -3.39 - -0.43 -3.37 - -0.40 -3.34 - -0.38 -3.32 - -0.36
-5.69 - -0.33 -5.69 - -0.33 -5.69 - -0.32 -5.69 - -0.32 -5.68 - -0.32
-2.97 - -0.29 -2.92 - -0.24 -2 .86 --0 .19 -2.81 - -0.14 -2.76 - -0.08
-4 .2 7 - 0.50 -4 .1 4 - 0.63 -4.01 - 0.76 -3 .88- 0.89 -3.74- 1.02
-2 .16--0 .41 -2.07 - -0.32 -1 .98 --0 .24 -1 .90--0 .15 -1.81 - -0.06
-4.34 - -0.88 -4.22 - -0.76 -4.1 1 - -0.65 -4.00 - -0.53 -3.88 - -0.42
-2 .06--0 .31 -2.08 - -0.33 -2.09 - -0.34 -2.11 - -0.35 -2 .12--0 .37
-4.31 - -0.73 -4.26 - -0.68 -4.21 - -0.63 -4 .15--0 .57 -4 .10--0 .52
-3.31 - -0.43 -3.31 - -0.43 -3.31 - -0.43 -3.31 - -0.43 -3.31 - -0.43
-5 .48--0 .91 -5.38 - -0.80 -5.28 - -0.70 -5 .17--0 .60 -5.07 - -0.49
-3.39 - -0.75 -3 .36 --0 .71 -3.32 - -0.68 -3.29 - -0.65 -3.26 - -0.61
-4 .0 2 --1 .3 9 -3 .85 --1 .21 -3 .68 --1 .04 -3.51 - -0.87 -3.34 - -0.70
-2.68 - -0.42 -2.58 - -0.32 -2.49 - -0.23 -2 .39--0 .14 -2.30 - -0.04
var cl25 cl30 cl35 cl40 cl45
n2imptim 11 54.64 - 70.88 55.85 - 7 2 .10 57.07 - 73.31 58.29 - 74.53
59.51 -75.75
12 54.26 - 70.48 55.02 - 71.23 55.77 - 71.99 56.53 - 72.74
57.28 - 73.50
13 55.44 - 68.77 56.24 - 69.57 57.03 - 70.37 57.83 - 71.17
58.63 -71.97
14 56.71 - 68.84 57.31 - 69.45 57.91 - 70.05 58.52 - 70.65
5 9 .1 2 -7 1 .2 5
284
data cl50 cl55 cl60 cl65 d70
n2imptim 60.72 - 76.96 6 1.94 - 78.18 63 .16 - 79.40 64.38 - 80.62 65.59
-81.83
58.04 - 74.25 58.79 - 7 5 .0 1 59.55 - 75.76 60.30 - 76.52 6 1.06 -
77.27
59.43 - 72.77 60.23 - 73.56 6 1.03 - 74.36 6 1.83 - 75 .16 62.62 -
75.96
59.72 - 7 1.85 60.32 - 72.45 60.92 - 73.06 6 1.53 - 73.66 62.13 -
74.26
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data var cl25 cl30 cl35 cl40 cl45
n2imptim 15 5 4 .13 - 7 0 .13 55.04 - 7 1.04 55.95 - 7 1.95 56.87 - 72.87
57.78 - 73.78
16 54.90 - 70.60 55.68 - 71.38 56.46 - 72.16 57.24 - 72.94
58.02 - 73.72
17 52.10 - 73.36 53.29 - 74.55 54.48 - 75.74 55.67 - 76.93
56.86 - 78.12
18 53.48 - 69.73 54.38 - 70.63 55.27 - 71.52 56.17 - 72.42
57.06-73.31
rl 57.46 - 69.51 58.51 - 70.56 59.55 - 71.61 60.60 - 72.65
61.65 -73.70
r2 55.65 - 69.41 56.49 - 70.24 57.32 - 71.08 58.16 - 71.92
285
58.99
60.46
59.49
57.73
57.94
59.06
55.78
78.36
77.62
84.06
77.79
78.92
• 72.75
■71.26
71.13
■71.17
■70.44
■71.65
74.39
r3 57.10 - 67.90 57.94 - 68.74 58.78 - 69.58 59.62 - 70.42
r4 57.01 - 68.65 57.63 - 69.27 58.25 - 69.89 58.87 - 70.51
r5 54.44 - 67.88 55.26 - 68.70 56.09 - 69.52 56.91 - 70.35
r6 54.66 - 67.16 55.48 - 67.98 56.30 - 68.80 57.12 - 69.62
r7 55.39 - 67.99 56.31 - 68.90 57.23 - 69.82 58.14 - 70.74
r8 51.42 - 70.03 52.51 - 71.12 53.60 - 72.21 54.69 - 73.30
data c!50 cl55 cl60 cl65 c!70
58.70 - 74.70 5 9 .6 1 - 7 5 .6 1 60.53 - 76.53 6 1.44 - 77.44 62.36
58.80 - 74.50 59.58 - 75.28 60.36 - 76.06 61.14 - 76.84 6 1.92 -
58.05 - 79.30 59.23 - 80.49 60.42 - 8 1.68 6 1.6 1 - 82.87 62.80
57.96 - 7 4 .2 1 58.86 - 7 5 .10 59.75 - 76.00 60.65 - 76.89 6 1.54 -
62.69 - 74.74 63.74 - 75.79 64.78 - 76.83 65.83 - 77.88 66.87 -
59.83 - 73.59 60.66 - 74.42 6 1.50 - 75.26 62.33 - 76.09 63.17 -
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76.93
75.45
74.22
75.29
74.55
76.23
79.85
- 6.81
4.20
6.60
4.71
7.26
61.30 - 72.10 6 2 .13 - 72.94 62.97 - 73.77 6 3 .8 1 - 7 4 .6 1 64.65 -
6 0 .10 - 7 1.74 60.72 - 72.36 6 1.34 - 72.98 6 1.96 - 73.60 62.58
58.56 - 7 1.99 59.38 - 72.82 60.20 - 73.64 6 1.03 - 74.46 6 1.85 -
58.76 - 7 1.26 59.58 - 72.08 60.40 - 72.90 6 1.22 - 73.73 62.04
59.97 - 72.57 60.89 - 73.48 6 1.8 1 - 74.40 62.72 - 75.32 63.64
56.87 - 75.49 57.97 - 76.58 59.06 - 77.67 60 .15 - 78.76 6 1.24
data var cl25 cl30 cl35 cl40 c!45
pi amp II 2.57 - 7.16 2.48 - 7.07 2 .39 - 6.98 2 .30 - 6.90 2.22
12 0.63 - 3.86 0.71 - 3.94 0.80 - 4.03 0.88 - 4.11 0.97
13 1.67 - 6.59 1 .67- 6.59 1.68 - 6.59 1.68 - 6.60 1.68 -
14 0.99 - 4.35 1.08 - 4.44 1.17 - 4.53 1.26 - 4.62 1.35 -
15 0.91 - 7.26 0.91 - 7.26 0.91 - 7.26 0.92 - 7.26 0.92 -
287
data cl50 cl55 cl60 cl65 cl70
pi amp 2.13 - 6.72 2.04 - 6.63 1.95 - 6.54 1.86 - 6.45 1.77 -
6.36
1.05- 4.28 1.14- 4.36 1.22- 4.45 1.30- 4.53 1.39- 4.62
1.68- 6.60 1.69- 6.60 1.69- 6.61 1.69- 6.61 1.69- 6.61
1.44- 4.80 1.53 - 4.89 1.62- 4.98 1.72- 5.07 1.81 - 5.17
0 .9 2 - 7.26 0 .9 2 - 7.26 0 .9 2 - 7.27 0 .92 - 7.27 0 .92- 7.27
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data var cl25 cl30 cl35 cl40 cl45
pi amp 16 -0 .24 - 3.75 -0.16 - 3.83 -0.09- 3.90 -0.01- 3.98 0.06
- 4.05
17 1.35 - 6.36 1.32 - 6.33 1.29 - 6.31 1.27 - 6.28 1.24 -
6.26
3.18
5.70
2.91
5.37
4.12
18 1.07 - 3.21 1.07 - 3.20 1.06 - 3.19 1.05 - 3.18 1.04-
rl 2.19 - 5.72 2.18 - 5.71 2.18 - 5.71 2 .17 - 5.70 2 .17 -
r2 0.69 - 2.79 0.72 - 2.82 0.75 - 2.85 0 .78 - 2.88 0 .81-
r3 2.03 - 5.52 1.99 - 5.48 1.95 - 5.45 1.91 - 5.41 1.87 -
r4 1.08 - 4.23 1.05 - 4.20 1.02 - 4.17 0 .9 9 -  4.14 0 .9 7 -
288
6.41
4.81
6.47
3.98
rS 2.66 - 6.76 2 .5 7 -  6.67 2.48 - 6.58 2 .4 0 -  6.49 2.31
r6 1.00 - 4.73 1.02- 4.75 1.04- 4.77 1.06- 4.79 1.08
r7 2.90 - 6.78 2.82 - 6.70 2.75 - 6.62 2 .67 - 6.54 2.59 -
r8 0.98 - 3.96 0.99 - 3.96 0.99 - 3.97 1.00- 3.97 1.00 -
data cl50 c!55 cl60 c!65 c!70
0 .1 4 - 4.13 0.21 - 4.20 0.29 - 4.28 0.36 - 4.35 0 .44 - 4.43
1.21 - 6.23 1.19- 6.20 1.16- 6.18 1.14- 6.15 l.l 1 - 6.12
1.04- 3.17 1.03 - 3.16 1.02- 3.16 1.02- 3.15 1.01 - 3.14
2 .16 - 5.69 2 .1 6 - 5.69 2.15 - 5.68 2 .15 - 5.68 2 .14 - 5.67
0 .8 4 - 2.94 0 .8 8 - 2.98 0.91 - 3.01 0 .94 - 3.04 0 .97 - 3.07
1.84- 5.33 1.80- 5.29 1.76- 5.26 1.72- 5.22 1.69- 5.18
0 .9 4 - 4.09 0.91 - 4.06 0.88 - 4.03 0.85 - 4.01 0 .83 - 3.98
2 .22 - 6.32 2.13 - 6.23 2 .04 - 6.14 1.95- 6.05 1.87- 5.96
1. 10 - 4.83 1.12- 4.85 1.14- 4.87 1.16- 4.89 1.18- 4.91
2.51 - 6.39 2.43 - 6.31 2.35 - 6.23 2 .27 - 6.15 2 .20- 6.07
1.01 - 3.98 1.01 - 3.98 1.01 - 3.99 1.02- 3.99 1.02- 4.00
var c!25 c!30 c!35 c!40 c!45
p I imptim 11 37.86 - 48.62 38.65 - 49.40 39.43 - 5 0 .19 4 0 .2 1 - 50.97
4 0 .9 9 -5 1 .7 5
289
12 36.04 - 49.61 36.63 - 50.20 37.22 - 50.78 37.81 - 51.37
38.39 - 51.96
13 37.36 - 48.58 37.98 - 49.20 38.60 - 49.82 39.21 - 50.44
39.83 - 51.06
14 37.67 - 48.65 38.24 - 49.22 38.80 - 49.78 39.36 - 50.34
39.92 - 50.90
15 36.89 - 49.09 37.57 - 49.78 38.26 - 50.46 38.95 - 51.15
39.63 - 51.83
16 37.59 - 49.67 38.19 - 50.27 38.79 - 50.86 39.38 - 51.46
39.98 - 52.05
data cl50 cl55 cl60 cl65 cl70
p I imptim 4 1.78 - 52.53 42.56 - 53.32 43.34 - 54 .10 4 4 .12 - 54.88 44 .91
- 55.66
38.98 - 52.55 39.57 - 5 3 .13 4 0 .16 - 53.72 40.74 - 54.31 41.33 -
54.90
54.15
53.71
55.27
55.03
40.45 - 5 1.67 4 1.07 - 52.29 4 1.69 - 52 .91 42.30 - 53.53 42.92 -
40.48 - 5 1.46 4 1.04 - 52.02 4 1.6 1 - 52.59 4 2 .17 - 53 .15 42.73 -
40.32 - 52.52 4 1.0 1 - 53 .21 4 1.69 - 53.89 42.38 - 54.58 43.06 -
40.57 - 52.65 41.17 - 53.24 4 1.76 - 53.84 42.36 - 54.43 42.95 -
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40.64
37.84
41.64
39.47
40.33
41.17
39.52
38.61
39.56
39.91
data var d 2 5  cl30 d 35  d 40  cl45
p I imptim 17 37.82 - 49.73 38.52 - 50.43 39.23 - 51.14 39.94 - 5 1.84
52.55
18 3 4 .8 1 -  49.51 35.57 - 50.27 36.33 - 51.02 37.08 - 51.78
■ 52.54
■51.65
■53.01
■51.07
■ 50.78
■ 49.87
50.35
■ 50.20
■50.17
rl 38.44 - 48.45 39.24 - 49.25 40.04 - 50.05 40.84 - 50.85
r2 36.32 - 49.86 37.1 I - 50.65 37.89 - 51.44 38.68 - 52.22
r3 37.24 - 47.98 38.01 - 48.75 38.78 - 49.52 39.56 - 50.30
r4 38.65 - 48.25 39.28 - 48.89 39.91 - 49.52 40.54 - 50.15
r5 36.46 - 46.82 37.23 - 47.58 37.99 - 48.35 38.75 - 49 .11
r6 3 5 .7 1 -  47.45 36.44 - 48.18 37.16 - 48.90 37.89 - 49.63
r7 36.69 - 47.33 37.41 - 48.05 38.12 - 48.77 38.84 - 49.48
r8 36.73 - 46.99 37.53 - 47.79 38.32 - 48.58 39.12 - 49.38
data c!50 c!55 c!60 c!65 c!70
4 1.35 - 53.25 42.05 - 53.96 42.76 - 54.67 43.47 - 55.37 4 4 .17 -
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56.08
56.34
55.65
56.94
54.93
53.94
53.69
53.97
53.78
54.14
38.60 - 53.30 39.36 - 54.06 4 0 .12 - 54.82 40.88 - 55.58 4 1.64
42.43 - 52.45 43.23 - 53.25 44.03 - 54.05 44.83 - 54.85 45.63
40.25 - 53.80 4 1.04 - 54.58 4 1.83 - 55.37 42 .61 - 56 .16 43.40
41.10 - 51.84 41.87 - 52.61 42.65 - 53.39 43.42 - 54.16 44.19 -
4 1.8 1 - 5 1.4 1 42.44 - 52.04 43.07 - 52.68 43.70 - 53.31 44.33 -
40.28 - 50.64 4 1.04 - 5 1.40 4 1.8 1 - 52 .16 42.57 - 52.93 43.33 -
39.33 - 5 1.07 40.06 - 5 1.80 40.78 - 52.52 4 1.5 1 - 53.24 42.23 -
40.27 - 5 0 .9 1 40.99 - 51.63 4 1.70 - 52.34 42.42 - 53.06 43.14
40.70 - 50.97 4 1.50 - 5 1.76 42.29 - 52.55 43.09 - 53.35 43.88 -
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data var cl25 cl30 cl35 cl40 cl45
nlam p II -5.29 --1 .86  -5.23 --1 .80  -5.16 --1.73 -5 .10--1 .67  -5.03
- - 1.60
12 -2.83 - -0.43 -2.79 - -0.39 -2.76 - -0.36 -2.72 - -0.32 -2.69 - -
292
0.29
0.90
0.83
1.03
0.81
1.70
0.39
1.49
0.51
1.24
1.03
.69
.15
1.50
13 - 5 .10 - - 1.28 -5 .0 1 - - 1. 18 -4.92 - - 1.09 -4.82 - -0.99 -4.73
14 -3.19 --0 .83  -3.19 --0 .83  -3.19 --0.83 -3 .19--0 .83  -3.19 - -
15 -4.64 - -0.97 -4.66 - -0.98 -4.67 - - 1.00 -4.69 - - 1.02 -4.71 - -
16 -3.66 - -0.98 -3.62 - -0.94 -3.58 - -0.90 -3.54 - -0.86 -3.50 - -
17 -4.13 --1 .8 9  -4 .0 8 --1 .8 4  -4.03 --1 .79  -3 .99--1 .75  -3.94
18 -2.84 - -0.60 -2.79 - -0.55 -2.74 - -0.49 -2.68 - -0.44 -2.63
rl -5 .4 4 --1 .9 2  -5.33 --1 .8 2  -5.23 --1.71 -5 .12 --1 .60  -5.01 - -
r2 -2.54 - -0.60 -2.52 - -0.58 -2.49 - -0.55 -2.47 - -0.53 -2.45 - -
r3 -5 .3 6 --1 .3 9  -5 .3 2 --1 .3 6  -5.29 --1 .32  -5.25 --1 .28 -5.21 - -
r4 -3.39 - -0.96 -3 .4 1 - -0.98 -3.42 - -0.99 -3.44 - - 1.0 1 -3.45 -
r5 -5 .3 1 - -1.78 -5.28 --1 .76  -5 .26--1 .73  -5.24--1.71 -5.21 - -
r6 -3.59 --1 .25  -3 .5 7 --1 .2 2  -3 .54 --1 .20  -3 .52--1 .17  -3.49
r7 -5 .1 8 - -2 .1 2  -5.03 - -1 .9 7  -4 .8 7 --1 .8 1  -4 .7 2 --1 .6 5  -4.56
293
1.07
r8 -3.13 - -1 .3 8  -3.05 - -1 .3 0  -2 .9 8 --1 .2 2  -2 .9 0 --1 .1 5  -2 .8 2 -
0.74
20.59
data c!50 cl55
n I amp -4.97 - - 1.54 -4 .9 1 - - 1
-2.65 - -0.25 -2.62 - -0.22
-4.63 - -0.80 -4.54 - -0.71
-3 .19- -0.83 -3 .19 - -0.83
-4.72 - -1.05 -4.74 - -1.06
-3.46 - -0.77 -3.41 - -0.73
-3.89 - -1.65 -3.85 - -1.61
-2.57 - -0.33 -2.52 - -0.28
-4.90 - -1.38 -4.79 - -1.28
-2.42 - -0.48 -2.40 - -0.46
-5 .17- -1.21 -5 .1 4 - -1.17
-3.47 - -1.04 -3.49 - -1.06
-5 .19- -1.66 -5 .1 6 - -1.64
-3.47 - -1.12 -3 .4 4 - - 1.10
-4.40 - -1.34 -4.25 - -1.18
-2.75 - -0.99 -2.67 - -0.92
var c!25 c!30
n I imptim 11 18.59 - 27.06
29.06
c!60 c!65 c!70
.47 -4.84 - - 1.41 -4 .78 - -0.80 -4.71 -
-2 .5 8 --0 .1 8 -2 .55- 0.23 -2.51 - 0.27
-4.44 - -0.61 -4.35 - 0.09 -4 .25- 0.18
-3 .1 9 --0 .8 3 -3 .19 --0 .46 -3 .19--0 .46
-4 .7 5 --1 .0 8 -4.77--0.51 -4.79 - -0.53
-3.37 - -0.69 -3.33 - -0.22 -3 .29--0 .18
-3 .8 0 --1 .5 6 -3 .75 --1 .16 -3.71 --1.11
-2.47 - -0.22 -2.41 - 0.18 -2 .36- 0.24
-4 .6 9 --1 .1 7 -4.58 - -0.50 -4.47 - -0.40
-2.38 - -0.44 -2 .3 5 --0 .ll -2.33 - -0.08
-5.10 - -1.13 -5.06 - -0.47 -5.02 - -0.43
-3 .5 0 --1 .0 7 -3.52--0.71 -3.53 - -0.72
-5 .1 4 --1 .6 2 -5 .12 --1 .04 -5 .09 --1 .01
-3 .4 2 --1 .0 7 -3.39 - -0.68 -3.37 - -0.66
-4 .09 --1 .03 -3.94 - -0.39 -3.78 - -0.23
-2.59 - -0.84 -2.52 - -0.49 -2.44 - -0.41
c!35 cl40 c!45
- 27.56 19.59 - 28.06 20.09 - 28.56
294
12 16.56 - 27.42 17.02 - 27.88 17.47 - 28.34 17.93 - 28.79
18.39-29.25
data cl50 cl55 cl60 cl65 cl70
n I imptim 2 1.09 - 29.56 2 1.59 - 30.07 22.09 - 30.57 22.59 - 32.40 23.09
- 32.90
18.84 - 2 9 .7 1 19.30 - 3 0 .16 19.76 - 30.62 20.22 - 32.79 20.67 -
33.25
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data var cl25 cl30 cl35 cl40 cl45
n I imptim 13 19.15 - 26.53 19.74 - 2 7 .12 20.34 - 27 .71 20.93 - 28 .31
21.52-28 .90
14 19.38 - 26.53 19.90 - 27.05 20.41 - 27.56 20.92 - 28.07
21.44-28 .59
15 19 .14 - 2 7 .16 19.65 - 27.67 2 0 .16 - 28 .18 20.67 - 28.69
21 .18-29 .20
16 19.64 - 27.92 20.08 - 28.36 20.52 - 28.80 20.96 - 29.24
21.40-29 .68
17 19.12 - 27.92 19.66 - 28.46 20.19 - 28.99 20.72 - 29.52
21.25 - 30.05
18 16.14 - 28.72 16.77 - 29.34 17.40 - 29.97 18.03 - 30.60
18 .66 -31 .23
rl 19.40 - 27.17 19.91 - 27.68 20.43 - 28.20 20.94 - 28.71
295
21.46
19.74
22.28
21.37
21.58
20.22
20.59
21.73
33.02
32.28
33.02
33.19
29.22
30.79
■ 29.07
•30.17
■ 27.70
28.33
■28.01
28.06
r l  18.13 - 29.18 18.53 - 29.58 18.93 - 29.98 19.34 - 30.39
r3 19.72 - 2 6 .51 20.36 - 2 7 .15 2 1.00 - 27.79 2 1.64 - 28.43
r4 19.37 - 28.17 19.87 - 28.67 20.37 - 29.17 20.87 - 29.67
r5 1 9 .61 - 25.73 20.10 - 26.22 20.59 - 26.72 21.09 - 27.21
r6 18.18 - 26.28 18.69 - 26.80 19.20 - 27.31 19.71 - 27.82
r7 18.76 - 26.18 19.22 - 26.64 19.68 - 27.10 20.14 - 27.56
r8 19.72 - 26.05 20.23 - 26.55 20.73 - 27.05 21.23 - 27.56
data cl50 cl55 cl60 cl65 cl70
22.1 I - 29.49 22.70 - 30.08 23.30 - 30.67 23.89 - 32.43 24.48 -
2 1.95 - 2 9 .10 22.46 - 29 .6 1 22.98 - 30 .13 23.49 - 3 1.77 24.00 -
2 1.69 - 2 9 .7 1 22.20 - 30.22 22 .71 - 30.73 23.22 - 32.51 23.73 -
2 1.85 - 3 0 .12 22.29 - 30.56 22.73 - 3 1.00 23.17 - 32.75 23.61 -
2 1.78 - 30.58 2 2 .3 1 - 3 1. 12 22.85 - 3 1.65 23.38 - 33.57 2 3 .9 1 -
296
34.10
36.36
33.02
34.56
33.34
34.05
31.12
32.16
31.47
31.57
-0.73
0.08
19.29 - 31.86 1 9 .9 1 - 32.49 20.54 - 33.12 21.17 - 35.73 21.80 -
2 1.97 - 29.74 22.49 - 30.25 23.00 - 30.77 23.52 - 32.51 24.03 -
2 0 .15 - 3 1.20 20.55 - 3 1.60 20.96 - 32.00 2 1.36 - 34 .15 21.76 -
22.92 - 29.71 23.56 - 30.35 24.20 - 30.99 24.84 - 32.70 25.48 -
2 1.87 - 30.67 22.37 - 31.17 22.86 - 3 1.67 23.36 - 33.55 23.86 -
22.07 - 2 8 .19 22.56 - 28.68 23.05 - 29 .17 23.54 - 30.63 24.03
20.74 - 28.84 2 1.25 - 29.35 2 1.76 - 29.86 22.27 - 3 1.65 22.78 -
2 1.05 - 28.47 21.51 - 28.93 2 1.97 - 29.39 22.42 - 3 1.0 1 22.88 -
22.23 - 28.56 22.74 - 29.06 23.24 - 29.56 23.74 - 3 1.06 24.24 -
data var cl25 cl30 cl35 cl40 cl45
n2amp II -5.25 - -1 .10 -5.15 - -1.01 -5.06 - -0.92 -4.97 --0 .82 -4.88
12 -2 .9 0 --0 .0 7  -2 .9 1 --0 .0 7  -2 .91 --0 .07  -2.92 --0 .08 -2.92
13 -4.59 - -0.54 -4.63 - -0.59 -4.68 - -0.63 -4.73 - -0.68 -4.77 - -
297
0.73
data cl50 cl55 d 6 0  cl65 cl70
n2amp -4.78 - -0.64 -4.69 --0 .5 5  -4.60 --0 .45  -4 .51- 0.29 -4 .41-
0.39
-2.92 - -0.09 -2.93 - -0.09 -2.93 - -0.09 -2.94 - 0.35 -2.94 - 0.35
-4.82 - -0.77 -4.87 - -0.82 -4 .9 1 - -0.87 -4.96 - -0.28 -5.01 - -0.32
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data var cl25 cl30 cl35 cl40 cl45
n2amp 14 -3.33 - -0.76 -3 .3 1 - -0.73 -3.29 - -0.71 -3.26 - -0.69 -3.24
- -0.67
15 -5.36 - -0.70 -5.35 - -0.69 -5.35 - -0.69 -5.35 - -0.69 -5.35 - -
0.68
16 -3.06 - -0.73 -3.00 - -0.68 -2.95 - -0.63 -2.90 - -0.57 -2.85 - -
0.52
17 -4.61 - -0.47 -4.48 - -0.34 -4.35 - -0.20 -4.21 - -0.07 -4.08 -
0.06
18 -2.48 --0 .9 6  -2.39 --0 .8 7  -2.30 --0 .78  -2.22 --0 .70 -2.13 - -
0.61
rl -4 .6 8 --1 .6 7  -4 .5 6 --1 .5 6  -4.45 --1 .44  -4 .34--1 .33  -4 .2 2 --
1.22
r2 - 1.88 - -0.36 - 1.89 - -0.37 - 1.9 1 - -0.38 - 1.92 - -0.40 - 1.93 - -
0.41
298
r3 -4 .3 4 - -1 .2 3  -4 .2 9 - -1 .1 8  -4 .2 4 --1 .1 3  -4 .1 8 --1 .0 7  - 4 .1 3 - -
1.02
r4 -3 .11 --0 .61  -3 .11 --0 .61  -3 .11--0 .61 -3.12--0.61 -3.12 - -
0.61
r5 -5 .7 0 --1 .7 3  -5.60 --1 .6 2  -5 .49 --1 .52  -5 .39 --1 .42  -5 .2 9 --
1.31
r6 -3 .3 9 --1 .0 9  -3.35 --1 .0 6  -3 .32 --1 .02  -3.29 --0 .99  -3.25 - -
0.96
r7 -4.70 - -2 .4 1 -4.53 - -2.24 -4.36 - -2.07 -4 .19 - - 1.90 -4.02 - -
1.73
r8 -3.00 - - 1.04 -2 .9 1 - -0.95 -2 .81 - -0.85 -2.72 - -0.76 -2.62 - -
0.66
data cl50 cl55 cl60 cl65 cl70
-3.22 - -0.64 -3.20 - -0.62 -3 .1 7 --0 .6 0 -3 .15 --0 .17 -3.13 --0.15
-5.34 - -0.68 -5.34 - -0.68 -5.34 - -0.68 -5.33 - 0.06 -5.33 - 0.07
-2.79 - -0.47 -2.74 - -0.42 -2.69 - -0.36 -2 .64- 0.06 -2 .58- 0.11
-3.95 - 0.19 -3 .8 2 - 0.32 -3 .69 - 0.45 -3 .56- 1.23 -3 .43- 1.36
-2.04 - -0.53 -1.96 - -0.44 -1 .87 --0 .35 -1 .78--0 .03 -1 .70- 0.06
-4.1 1 - -1.10 -4.00 - -0.99 -3.88 - -0.88 -3.77 - -0.29 -3 .66--0 .17
-1.95 - -0.43 -1 .9 6 --0 .4 4 -1 .98 --0 .45 -1 .99--0 .23 -2.00 - -0.24
-4.08 - -0.97 -4 .02--0 .91 -3.97 - -0.86 -3.92 - -0.32 -3.86 - -0.26
-3 .12 - -0.61 -3 .12--0 .61 -3 .12 --0 .62 -3 .12 --0 .22 -3 .12--0 .22
-5 .18 - -1.21 - 5 .0 8 - - l . l l -4 .98 --1 .00 -4.87 - -0.27 -4 .77--0 .17
-3.22 - -0.92 -3 .1 8 --0 .8 9 -3 .15 --0 .85 -3 .12--0 .46 -3.08 - -0.42
-3.85 - -1.56 -3 .6 8 --1 .3 9 -3.51 - -1.22 -3.34 - -0.68 -3.16--0.51
299
-2.53 - -0.57 -2.43 - -0.47 -2.34 - -0.38 -2.24 - 0.03 -2 .15 - 0 .12
data var cl25 cl30 d35 cl40 cl45
n2imptim 11 55.70 - 6 9 .81 56.92 - 7 1.03 58 .14 - 72.25 59.36 - 73.46
60.57 - 74.68
12 55.33 - 69.41 56.08 - 70.17 56.84 - 70.92 57.59 - 71.68
58.35 - 72.43
13 56.31 - 67.90 57.1 I - 68.70 57.91 - 69.49 58.71 - 70.29
59.51 -71.09
14 57.51 - 68.05 58.1 I - 68.65 58.71 - 69.25 59.31 - 69.85
59.92 - 70.45
data cl50 cl55 cl60 cl65 cl70
n2imptim 6 1.79 - 75.90 6 3 .01 - 7 7 .1 I 64.23 - 78.33 65.44 - 8 1.78 66.66
- 82.99
59 .10 - 7 3 .19 59.86 - 73.94 60 .61 - 74.70 6 1.37 - 77.68 62 .12 -
78.43
60 .31 - 7 1.89 61.10 - 72.69 6 1.90 - 73.49 62.70 - 7 6 .11 63.50 -
76.91
60.52 - 7 1.06 6 1. 12 - 7 1.66 6 1.72 - 72.26 62.32 - 74.53 62.93 -
75.13
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data var cl25 cl30 cl35 cl40 cl45
30 0
58.83
59.05
58.25
58.13
62.44
59.90
61.17
60.25
58.62
58.76
59.88
57.01
n2imptim 15 55.18 - 69.07 56.09 - 69.99 5 7 .0 1 - 70.90 57.92 - 7 1.82
72.73
16 55.93 - 69.57 56.71 - 70.35 57.49 - 71.13 58.27 - 71.91
■ 72.69
• 76.72
■ 72.25
■ 72.90
71.85
■ 70.55
■ 70.36
■ 70.29
69.62
■ 70.82
73.17
17 53.50 - 71.96 54.68 - 73.15 55.87 - 74.34 57.06 - 75.53
18 54.55 - 68.66 55.45 - 69.56 56.34 - 70.45 57.24 - 71.35
rl 58.26 - 68.72 59.30 - 69.77 60.35 - 70.81 61.39 - 71.86
r2 56.55 - 68.50 57.39 - 69.34 58.22 - 70.18 59.06 - 71.01
r3 57.81 - 67.19 58.65 - 68.03 59.49 - 68.87 60.33 - 69.71
r4 57.78 - 67.89 58.40 - 68.51 59.01 - 69.12 59.63 - 69.74
r5 55.32 - 66.99 56.15 - 67.82 56.97 - 68.64 57.79 - 69.46
r6 55.48 - 66.34 56.30 - 67.16 57.12 - 67.98 57.94 - 68.80
r7 56.22 - 67.16 57.14 - 68.08 58.05 - 68.99 58.97 - 69.91
r8 52.64 - 68.81 53.73 - 69.90 54.82 - 70.99 55.91 - 72.08
data cl50 cl55 cl60 cl65 cl70
301
79.50
78.75
85.58
78.95
79.78
77.91
76.22
75.05
76.25
75.44
77.13
81.18
59.75 - 73.65 60.66 - 74.56 6 1.58 - 75.47 62.49 - 78.58 6 3 .4 1 -
59.83 - 73.47 6 0 .6 1 - 74.25 6 1.39 - 75.03 6 2 .17 - 77.97 62.95 -
59.44 - 7 7 .91 60.63 - 7 9 .10 6 1.82 - 80.29 63 .01 - 84.39 64.20 -
59.03 - 7 3 .14 59.92 - 74.04 60.82 - 74.93 6 1.7 1 - 78.05 62 .61
63.48 - 73.95 64.53 - 75.00 65.57 - 76.04 66.62 - 78.74 67.66 -
60.73 - 72.68 6 1.57 - 73.52 62.40 - 74.35 63.24 - 77.07 64.07 -
62.00 - 71.39 62.84 - 72.23 63.68 - 73.06 64.52 - 75.38 65.36 -
60.87 - 70.98 6 1.49 - 7 1.60 6 2 .11 - 72.22 62.72 - 74.43 63.34
59.44 - 71.11 60.26 - 7 1.93 6 1.09 - 72.76 6 1.9 1 - 75.42 62.73 -
59.58 - 70.44 60.40 - 71.26 61.22 - 72.08 62.04 - 74.62 62.87
60.80 - 7 1.74 6 1.72 - 72.66 62.63 - 73.57 63.55 - 76.22 64.47 -
5 8 .10 - 74.26 5 9 .19 - 75.35 60.28 - 76.45 6 1.37 - 80.09 62.46
data var cl25 cl30 cl35 cl40 cl45
302
pi amp II 2 .8 8 -  6.86 2.79 - 6.77 2 .7 0 -  6.68 2.61 - 6.59 2.52
- 6.50
12 0.84 - 3.65 0.93 - 3.73 1.01 - 3.81 1.10 - 3.90 1.18 -
3.98
13 2.00 - 6.27 2 .0 0 -  6.27 2 .00 - 6.27 2 .00- 6.27 2.01 -
6.28
14 1.21 - 4.13 1.30 - 4.22 1.39 - 4.31 1.48 - 4.40 1.57 -
4.49
15 1.33 - 6.84 1.33 - 6.84 1.33 - 6.84 1.33 - 6.84 1.33 -
6.85
data cl50 cl55 cl60 cl65 cl70
pi amp 2.43 - 6.41 2.34 - 6.32 2.25 - 6.23 2.16 - 6.77 2 .07 -
6.68
1.26- 4.07 1.35 - 4.15 1.43 - 4.24 1.52- 4.76 1.60- 4.85
2.01 - 6.28 2.01 - 6.28 2.01 - 6.28 2.01 - 6.96 2.02- 6.96
1.66- 4.58 1.75 - 4.67 1.85- 4.76 1.94- 5.31 2.03 - 5.40
1.33 - 6.85 1.34- 6.85 1.34- 6.85 1.34- 7.72 1.34- 7.72
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data var cl25 cl30 cl35 cl40 cl45
pi amp 16 0.02 - 3.49 0.10 - 3.57 0 .1 7 -  3.64 0.25 - 3.72 0.33
- 3.79
303
5.93
3.04
5.47
2.78
5.14
3.91
6.14
4.57
6.21
3.78
17 1.68 - 6.03 1.65 - 6.01 1.62 - 5.98 1.60 - 5.95 1 .57 -
18 1.21 - 3.07 1.21 - 3.06 1.20- 3.05 1.19 - 3.04 1.18 -
rl 2.42 - 5.49 2.41 - 5.48 2.41 - 5.48 2 .40- 5.47 2 .40 -
r2 0.83 - 2.65 0 .8 6 -  2.68 0.89 - 2.71 0 .92 - 2.74 0.95 -
r3 2.26 - 5.29 2.22 - 5.25 2.18 - 5.22 2 .14 - 5.18 2.10 -
r4 1.28- 4.02 1 .26- 3.99 1.23 - 3.97 1.20- 3.94 1.17-
r5 2.93 - 6.49 2 .8 4 -  6.40 2.75 - 6.31 2 .67 - 6.22 2.58
r6 1.25 - 4.49 1 .27- 4.51 1.29 - 4.53 1.31- 4.55 1.33 -
r7 3.16 - 6.52 3 .0 8 -  6.45 3.00 - 6.37 2 .92 - 6.29 2.84 -
r8 1.18 - 3.76 1.18 - 3.77 1.19 - 3.77 1.19- 3.78 1.20 -
data cl50 cl55 cl60 cl65 cl70
0 .4 0 - 3.87 0 .4 8 - 3.94 0.55 - 4.02 0.63 - 4.64 0 .70 - 4.71
1.54- 5.90 1.52- 5.87 1.49- 5.85 1.47- 6.51 1.44- 6.48
1.18- 3.03 1.17- 3.02 1.16- 3.02 1.16- 3.30 1.15- 3.29
2 .3 9 - 5.46 2 .3 9 - 5.46 2 .38 - 5.45 2 .38 - 5.93 2 .37- 5.93
304
41.70-
39.28 -
40.57 -
40.64-
40.43 -
40.77 -
- 56.43
0 .98- 2.81 1.01 - 2.84 1.04 - 2.87 1.08- 3.19 l.l 1 - 3.22
2 .07 - 5.10 2.03 - 5.06 1.99 - 5.03 1.95- 5.47 1.92- 5.43
1.14- 3.88 1.12- 3.85 1.09 - 3.83 1.06- 4.23 1.03- 4.20
2 .49 - 6.05 2 .4 0 - 5.96 2.31 - 5.87 2 .22 - 6.34 2 .13 - 6.26
1.35- 4.59 1.37- 4.61 1.39 - 4.62 1.41 - 5.16 1.43- 5.18
2 .76 - 6.13 2.69 - 6.05 2.61 - 5.97 2.53 - 6.43 2 .45- 6.35
1.20- 3.78 1.21 - 3.79 1.21 - 3.79 1.21 - 4.21 1.22- 4.21
var cl25 cl30 c!35 cl40 cl45
p I imptim 11 38.57 - 47.92 39.35 - 48.70 4 0 .14 - 49.48 40.92 - 50.26
51.04
12 36.93 - 48.72 37.52 - 49.30 38.11 - 49.89 38.70 - 50.48
51.07
13 38.10 - 47.85 38.72 - 48.46 39.33 - 49.08 39.95 - 49.70
50.32
14 38.40 - 47.93 38.96 - 48.49 39.52 - 49.06 40.08 - 49.62
50.18
15 37.69 - 48.29 38.38 - 48.97 39.06 - 49.66 39.75 - 50.35
51.03
16 38.39 - 48.88 38.98 - 49.47 39.58 - 50.07 40.17 - 50.66
51.26
data cl50 cl55 cl60 cl65 cl70
pi imptim 42.48 - 51.83 4 3 .2 7 -  52.61 44.05 - 53.39 44.83 - 55.65 45.61
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55.87
54.95
54.49
56.14
55.89
39.87 - 5 1.65 40.46 - 52.24 4 1.05 - 52.83 4 1.64 - 55.28 42.22
41.19 - 50.94 4 1.80 - 5 1.55 42.42 - 52 .17 43.04 - 54.33 43.66 -
4 1.20 - 50.74 4 1.77 - 5 1.30 42.33 - 5 1.87 42.89 - 53.93 43.45 -
4 1. 12 - 5 1.72 4 1.8 1 - 5 2 .4 1 42.49 - 53.09 4 3 .18 - 55.45 43.87 -
4 1.36 - 5 1.85 41.96 - 52.45 42.56 - 53.04 4 3 .15 - 55.30 43.75 -
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data var cl25 cl30 cl35 cl40 cl45
p I imptim 17 38.60 - 48.94 39 .31 - 49.65 40 .01 - 50.35 40.72 - 5 1.06
41 .42-51 .77
18 35.77 - 48.54 36.53 - 49.30 37.29 - 50.06 38.05 - 50.82
38.81 -51.58
rl 39.10 - 47.79 39.90 - 48.59 40.70 - 49.39 41.49 - 50.19
42.29 - 50.99
r2 3 7 .2 1 -  48.97 38.00 - 49.76 38.78 - 50.55 39.57 - 51.33
40.36 - 52.12
r3 37.94 - 47.27 38.72 - 48.05 39.49 - 48.82 40.26 - 49.59
41.03 - 50.36
r4 39.28 - 47.62 39.91 - 48.25 40.54 - 48.89 41.17 - 49.52
41.81 -50.15
306
40.20
39.38
40.26
40.58
56.93
57.39
56.36
57.91
55.70
54.62
54.43
54.81
r5 37.14 - 46.14 37.91 - 46.90 38.67 - 47.67 39.43 - 48.43
49.19
r6 36.49 - 46.68 37.21 - 47.41 37.93 - 48.13 38.66 - 48.85
49.58
rl 37.39 - 46.63 38.1 I - 47.35 38.82 - 48.07 39.54 - 48.78
■ 49.50
49.50
r8 37.41 - 46.32 38.20 - 4 7 .1 1 39.00 - 47.91 39.79 - 48.70
data c!50 cl55 cl60 cl65 cl70
4 2 .13 - 52.47 42.84 - 53.18 43.54 - 53.88 44.25 - 56.22 44.95 -
39.57 - 52.34 40.33 - 53.09 4 1.09 - 53.85 4 1.84 - 56.63 42.60 -
43.09 - 5 1.79 43.89 - 52.59 44.69 - 53.39 45.49 - 55.56 46.29
41.14 - 52 .91 4 1.93 - 53.69 42.72 - 54.48 43.50 - 5 7 .12 44.29 -
4 1.8 1 - 51.14 42.58 - 5 1.9 1 43.35 - 52.68 4 4 .12 - 54.93 44.90 -
42.44 - 50.78 43.07 - 5 1.4 1 43.70 - 52.04 44.33 - 53.99 44.96
40.96 - 49.96 4 1.72 - 50.72 42.49 - 5 1.48 43.25 - 53.67 44 .01 -
4 0 .1 I - 50.30 40.83 - 5 1.03 4 1.55 - 5 1.75 42.28 - 54.08 43.00 -
307
40.97 - 5 0 .2 1 4 1.69 - 50.93 42.40 - 5 1.65 43.12 - 53.82 43.83 -
54.54
4 1.38 - 50.29 4 2 .17 - 5 1.09 42.97 - 5 1.88 43.76 - 54.08 44.56 -
54.88
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data var cl25 cl30 cl35 cl40 cl45
nlam p II -5.09 - -2.06 -5.02 --2 .00  -4 .96 --1 .94  -4 .90--1 .87  -4.83
-  - 1.81
0.43
1.12
0.97
1.25
0.97
.83
0.52
.70
12 -2 .6 8 --0 .5 7  -2.65 --0 .53  -2 .61 --0 .50  -2.58 --0.46 -2.54-
13 -4 .8 8 --1 .5 0  -4 .78 --1 .41  -4.69--1.31 -4 .59--1 .22  -4.50
14 -3.05 - -0.97 -3.05 - -0.97 -3.05 - -0.97 -3.05 - -0.97 -3.05 - -
15 -4 .4 2 --1 .1 9  -4 .4 4 --1 .2 0  -4 .46--1 .22  -4 .47--1 .23  -4.49
16 -3.51 - - 1 .14 -3.46 - - 1.10 -3 .4 2 -- l.0 6  -3 .3 8 --I.0 I -3 .3 4 --
17 -3.99 --2 .0 2  -3.95 --1 .97  -3.90 --1.93 -3 .86--1 .88  -3.81
18 -2 .71 - -0.74 -2.66 - -0.68 -2.60 - -0.63 -2.55 - -0.57 -2.50 -
r I -5.23 - - 2 .13 -5.13 - -2.02 -5.02 - - 1.92 -4 .9 1 - - 1.8 1 -4.80 - -
308
r2 -2.43 --0 .71  -2.40 - -0 .6 9  -2.38 --0 .6 7  -2.36 --0 .6 4  -2.33 - -
0.62
r3 -5 .13 - - 1.63 -5.09 - - 1.59 -5.05 - - 1.55 -5.01 - - 1.52 -4.98 - -
1.48
r4 -3.25 - -1 .10 -3.26 --1 .1 2  -3 .28 --1 .14  -3.29 --1.15 -3 .31 - -
1.17
rS -5 .1 0 --1 .9 9  -5 .0 7 --1 .9 7  -5 .05 --1 .94  -5.03 --1 .92 -5.00 - -
1.90
r6 -3.45 --1 .39  -3.43 --1 .3 6  -3.40 --1 .34  -3.38 --1.31 -3.35 - -
1.29
r7 -5 .0 0 --2 .3 0  -4.85 - - 2 . 15 -4 .69 --1 .99  -4.53 --1.83 -4 .3 8 --
1.68
r8 -3.03 --1 .4 8  -2.95 --1 .4 0  -2 .87--1 .33  -2 .80--1 .25  -2 .7 2 --
1.17
data cl50 cl55 cl60 cl65 d70
n I amp -4.77 - - 1.74 -4.70 - - 1.68 -4.64 - - 1.6 1 -4.57 - - 1.55 -4 .51 - -
1.48
-2.51 - -0.39 -2.47 - -0.36 -2.44 - -0.32 -2.40 ■ -0.29 -2.37 -■ -0.25
-4.40 - -1.03 -4.31 - -0.93 -4.21 - -0.84 -4.12- -0.74 -4.02 - -0.65
-3.05 - -0.97 -3.05 - -0.97 -3.05 - -0.97 -3.05 - -0.97 -3.05 - -0.97
-4.50 - -1.26 -4.52 - -1.28 -4.54 - -1.30 -4.55 - -1.31 -4.57 - -1.33
-3.30 - -0.93 -3.25 - -0.89 -3.21 - -0.85 -3.17- -0.81 -3.13 - -0.76
-3.76 - -1.79 -3.72 - -1.74 -3.67 - -1.69 -3.62 - -1.65 -3.58 - -1.60
-2.44 - -0.47 -2.39 - -0.41 -2.33 - -0.36 -2.28 - -0.30 -2.23 - -0.25
-4.69 - -1.59 -4.59 - -1.48 -4.48 - -1.38 -4.37 - -1.27 -4.26 - -1.16
309
-2.31 - -0.60 -2.29 - -0.58 -2.26 - -0.55 -2.24 - -0.53 -2.22--0.51
-4 .9 4 --1 .4 4 -4.90 - -1.40 -4 .86 --1 .36 -4 .83--1 .33 -4 .79--1 .29
-3 .3 3 --1 .1 9 -3.34 - -1.20 -3 .36 --1 .22 -3 .37--1 .23 -3 .39--1 .25
-4 .9 8 --1 .8 7 -4.96 - -1.85 -4.93 --1.83 -4.91 - -1.80 -4 .89--1 .78
-3 .33 --1 .26 -3.30 - -1.24 -3 .28--1 .21 -3 .26--1 .19 -3 .23--1 .16
-4 .22 --1 .52 -4.07 - -1.37 -3.91 - - I .2 I -3 .75--1 .05 -3.60 - -0.90
-2 .6 4 - - 1 .10 -2.57 - -1.02 -2.49 - -0.94 -2.41 - -0.87 -2.34 - -0.79
var c!25 c!30 c!35 c!40 c!45
n I imptim 11 19.09 - 26.56 19.59 - 27.06 20.09 - 27.56 20.59 - 28.06
21.09-28.56
12 17.20 - 26.78 17.66 - 27.24 18.12 - 27.69 18.57 - 28.15
19.03 -28.61
data cl50 cl55 cl60 cl65 cl70
n I imptim 2 1.59 - 29.06 22.09 - 29.56 22.59 - 30.06 23.09 - 30.56 23.60
-31.07
19.49 - 29.06 19.94 - 29.52 20.40 - 29.98 20.86 - 30.44 21.32 -
30.89
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data var cl25 cl30 cl35 cl40 cl45
n I imptim 13 19.59 - 26.09 2 0 .18 - 26.69 20.77 - 27.28 21.37 - 27.87
310
21.96
21.86
21.66
21.89
21.77
19.40
21.92
20.40
22.68
21.89
21.94
20.70
21.03
2 2 .1 1
■ 28.46
14 19.81 - 26 .11 20.32 - 26.62 20.83 - 27.14 21.35 - 27.65
■28.16
15 19.62 - 26.69 20.13 - 27.20 20.64 - 27.71 21.15 - 28.22
- 28.73
■ 29.19
■ 29.53
30.49
28.76
■30.14
■ 28.67
■ 29.65
■ 27.34
27.85
27.57
27.68
16 20.13 - 27.43 20.57 - 27.87 21.01 - 28.31 21.45 - 28.75
17 19.64 - 27.40 20.18 - 27.94 20.71 - 28.47 21.24 - 29.00
18 16.89 - 27.97 17.51 - 28.60 18.14 - 29.23 18.77 - 29.86
rl 19.86 - 26.71 20.37 - 27.22 20.89 - 27.74 21.40 - 28.25
r2 18.78 - 28.52 19.19 - 28.93 19.59 - 29.33 19.99 - 29.73
r3 20.12 - 26.10 20.76 - 26.75 21.40 - 27.39 22.04 - 28.03
r4 19.89 - 27.65 20.39 - 28.15 20.89 - 28.65 21.39 - 29.15
r5 19.97 - 25.37 20.47 - 25.86 20.96 - 26.35 21.45 - 26.84
r6 18.66 - 25.80 19.17 - 26.32 19.68 - 26.83 20.19 - 27.34
r7 19.20 - 25.74 19.66 - 26.20 20.12 - 26.66 20.58 - 27.12
r8 20.10 - 25.68 20.60 - 26.18 21.10 - 26.68 21.60 - 27.18
311
31.42
30.73
31.28
31.39
32.19
33.63
31.34
32.16
31.87
32.14
29.79
30.40
data cl50 cl55 cl60 cl65 cl70
22.55 - 29.05 23.14 - 29.65 23.73 - 30.24 24.32 - 30.83 24.92 -
22.37 - 28.68 22.89 - 29.19 23.40 - 29.70 23.91 - 30.22 24.43 -
22.17 - 29.24 22.68 - 29.75 23.19 - 30.26 23.70 - 30.77 24.21 -
22.34 - 29.63 22.78 - 30.07 23.22 - 30 .51 23.66 - 30.95 2 4 .10 -
22.30 - 30.06 22.84 - 30.60 23.37 - 31.13 23.90 - 3 1.66 24.43 -
20.03 - 31.12 20.66 - 3 1.74 2 1.29 - 32.37 2 1.92 - 33.00 22.55 -
22.43 - 29.28 22.95 - 29.79 23.46 - 30 .31 23.98 - 30.82 24.49 -
20.80 - 30.54 2 1.2 1 - 30.95 2 1.6 1 - 3 1.35 22.01 - 3 1.75 22.42 -
23.32 - 29 .31 23.96 - 29.95 24.60 - 30.59 25.24 - 3 1.23 25.88 -
22.39 - 30 .15 22.89 - 30.65 23.39 - 31.14 23.88 - 3 1.64 24.38 -
22.43 - 27.83 22.92 - 28.32 23 .41 - 28.81 23.90 - 29.30 24.40 -
2 1.22 - 28.36 2 1.73 - 28.87 22.24 - 29.38 22.75 - 29.89 23.26 -
312
21.49 - 28.03 2 1.95 - 28.49 22.40 - 28.95 22.86 - 29.40 23.32 -
29.86
22.61 - 28.19 2 3 .1 1 - 28.69 23.61 - 29.19 24.11 - 29.69 24.62 -
30.19
data var cl25 cl30 cl35 cl40 d45
n2amp 11 -5.00 - - 1.35 -4 .91 - - 1.25 -4.82 - - 1. 16 -4.72 - - 1.07 -4.63
- -0.98
12 -2.74 - -0.23 -2.74 - -0.24 -2.74 - -0.24 -2.75 - -0.25 -2.75 - -
0.25
13 -4.35 - -0.78 -4.39 - -0.83 -4.44 - -0.87 -4.49 - -0.92 -4.53 - -
0.97
data cl50 cl55 cl60 cl65 cl70
n2amp -4.54 - -0.88 -4.45 - -0.79 -4.35 - -0.70 -4.26 - -0.61 -4 .17 - -
0.51
-2.76 - -0.25 -2.76 - -0.26 -2.76 - -0.26 -2.77 - -0.27 -2.77 - -0.27 
-4.58 - - 1.0 1 -4.63 --1 .0 6  - 4 .6 8 - - l . l l  -4 .72--1 .15  -4 .77--1 .20
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data var cl25 cl30 cl35 cl40 cl45
n2amp 14 -3.18 - -0 .9 1 -3 .16 - -0.89 -3 .13 - -0.86 -3 .11 - -0.84 -3.09
- -0.82
313
0.96
0.66
0.19
0.70
.39
0.50
.20
0.76
1.55
.09
1.87
0.78
15 -5.08 - -0.97 -5.08 - -0.97 -5.07 - -0.97 -5.07 - -0.96 -5.07 - -
16 -2.92 - -0.87 -2.87 - -0.82 -2.81 - -0.76 -2.76 - -0.71 -2.71 - -
17 -4.36 - -0 .71 -4.23 - -0.58 -4 .10 - -0.45 -3.97 - -0.32 -3.84 - -
18 -2.39 - - 1.05 -2.30 - -0.96 -2 .21 - -0.87 -2 .13 - -0.79 -2.04 - -
rl -4 .5 0 --1 .8 5  -4 .3 9 --1 .7 4  -4 .27 --1 .62  -4.16--1.51 -4.05
r2 -1 .7 9 --0 .4 5  -1 .8 0 --0 .4 6  -1 .8 2 --0 .4 7  -1.83 --0 .49 -1.84
r3 -4 .1 6 --1 .4 2  -4 .1 0 --1 .3 6  -4.05--1.31 -4 .00 --1 .26  -3.95
r4 -2.97 - -0.76 -2.97 - -0.76 -2.97 - -0.76 -2.97 - -0.76 -2.97 -
r5 -5 .4 7 --1 .9 6  -5.36 --1 .8 6  -5 .26 --1 .76  -5 .16--1 .65  -5.05
r6 -3.25 - - 1.23 -3.22 --1 .19  - 3 .I 8 - - I . I 6  -3.15 --1.13 -3.12
r7 -4 .5 7 --2 .5 5  -4.40 --2 .3 8  -4.23 --2.21 -4.06 --2 .04  -3 .8 8 --
r8 -2.89 - - 1. 16 -2.79 - - 1.06 -2.70 - -0.97 -2.60 - -0.87 -2 .51 - -
data cl50 cl55 cl60 cl65 cl70
314
61.41
59.18
60.19
60.54
-3.07 - -0.80 -3 .04- -0.77 -3.02 - -0.75 -3.00 - -0.73 -2.98 - -0.71
-5.07 - -0.96 -5.06 - -0.95 -5.06 - -0.95 -5.06 - -0.95 -5.05 - -0.95
-2.66 - -0.61 -2.60 - -0.55 -2.55 - -0.50 -2.50 - -0.45 -2.45 - -0.40
-3.71 - -0.06 -3.58 - 0.07 -3.45 - 0.20 -3.32 - 0.33 -3.19- 0.46
-1 .95- -0.61 -1 .87 - -0.53 -1 .78 - -0.44 -1.69- -0.36 -1.61 - -0.27
-3.93 - -1.28 -3.82 - -1.17 -3.71 - -1.05 -3.59 - -0.94 -3.48 - -0.83
-1 .86- -0.52 -1 .87 - -0.53 -1 .89 - -0.54 -1.90- -0.56 -1.91 - -0.57
-3.89 - -1.15 -3 .84 - - 1.10 -3.79 - -1.05 -3.73 - -0.99 -3.68 - -0.94
-2.97 - -0.76 -2.97 - -0.76 -2.97 - -0.76 -2.97 - -0.76 -2.97 - -0.77
-4.95 - -1.44 -4 .8 4 - -1.34 -4.74 - -1.24 -4.64- -1.13 -4.53 - -1.03
-3.08 - -1.06 -3.05 - -1.02 -3.01 - -0.99 -2.98 - -0.96 -2.95 - -0.92
-3.71 - -1.69 -3.54 - -1.52 -3.37 - -1.35 -3.20 - -1.18 -3.03 - -1.01
-2.41 - -0.68 -2.32 - -0.59 -2.22 - -0.49 -2 .13- -0.40 -2.03 - -0.30
data var cl25 cl30 d35  cl40 d45
n2imptim 11 56.54 - 68.98 57.76 - 7 0 .19 58.97 - 7 1.4 1 60 .19 - 72.63
73.84
12 56.16 - 68.58 56.92 - 69.33 57.67 - 70.09 58.43 - 70.84
71.60
13 57.00 - 67.21 57.80 - 68.01 58.60 - 68.81 59.39 - 69.61
70.41
14 5 8 .13 - 67.42 58.73 - 68.02 59.34 - 68.63 59.94 - 69.23
69.83
data cl50 cl55 cl60 cl65 cl70
315
n2imptim 62.63 - 75.06 63.84 - 76.28 65.06 - 77.50 66.28 - 78.71 67.50
- 79.93
59.94 - 72.35 60.69 - 7 3 .1 I 6 1.45 - 73.86 62.20 - 74.62 62.96 -
75.37
60.99 - 7 1.20 6 1.79 - 72.00 62.59 - 72.80 63.39 - 73.60 64 .19 -
74.40
61.14 - 70.43 6 1.74 - 7 1.03 62.35 - 7 1.64 62.95 - 72.24 63.55 -
72.84
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data var cl25 cl30 cl35 cl40 cl45
n2imptim 15 56.00 - 68.25 5 6 .9 1 - 69.17 57.83 - 70.08 58.74 - 70.99
59.66-71.91
16 56.74 - 68.76 57.52 - 69.54 58.30 - 70.32 59.08 - 71.10
59.86-71 .88
17 54.59 - 70.87 55.78 - 72.06 56.97 - 73.25 58.16 - 74.44
59.35 - 75.62
18 55.39 - 67.83 56.28 - 68.72 57.18 - 69.62 58.07 - 70.51
58.97-71.41
rl 58.88 - 68.10 59.92 - 69.15 60.97 - 70.19 62.01 - 71.24
63.06 - 72.28
r2 57.26 - 67.80 58.10 - 68.63 58.93 - 69.47 59.77 - 70.30
60.60-71 .14
r3 58.37 - 66.64 59.21 - 67.48 60.05 - 68.32 60.88 - 69.15
6 1 .7 2 -6 9 .9 9
316
60.85
59.31
59.40
60.53
57.96
76.48
75.78
81.57
75.89
77.51
75.32
74.19
■ 69.76
■ 69.60
68.98
70.18
72.21
r4 58.38 - 67.29 58.99 - 67.91 59.61 - 68.53 60.23 - 69.14
r5 56.01 - 66.30 56.84 - 67.13 57.66 - 67.95 58.48 - 68.77
r6 56.12 - 65.69 56.94 - 66.51 57.76 - 67.34 58.58 - 68.16
rl 56.87 - 66.51 57.78 - 67.43 58.70 - 68.34 59.62 - 69.26
r8 53.60 - 67.85 54.69 - 68.94 55.78 - 70.03 56.87 - 71.12
data c!50 cl55 cl60 c!65 cl70
60.57 - 72.82 6 1.49 - 73.74 62.40 - 74.65 63.32 - 75.57 64.23 -
60.64 - 72.66 6 1.42 - 73.44 62.20 - 74.22 62.98 - 75.00 63.76 -
60.54 - 76 .81 6 1.73 - 78.00 62 .9 1 - 79 .19 6 4 .10 - 80.38 65.29
59.86 - 72.30 60.76 - 73.20 61.65 - 74.10 62.55 - 74.99 63.45
64 .10 - 73.33 6 5 .15 - 74.38 6 6 .19 - 75.42 67.24 - 76.47 68.28 -
6 1.44 - 7 1.97 62.27 - 7 2 .81 6 3 .11 - 73.64 63.94 - 74.48 64.78 -
62.56 - 70.83 63.40 - 7 1.67 64.24 - 7 2 .5 1 65.08 - 73.35 6 5 .9 1 -
317
72.85
73.71
73.08
74.76
77.67
6.27
3.82
6.02
4.32
6.52
6 1.47 - 70.38 62.09 - 7 1.00 62.70 - 7 1.62 63.32 - 72.24 63.94 -
6 0 .13 - 70.42 60.95 - 7 1.24 6 1.78 - 72.07 62.60 - 72.89 63.42 -
60.23 - 69.80 6 1.05 - 70.62 6 1.87 - 7 1.44 62.69 - 72.26 63 .51 -
6 1.45 - 7 1.09 62.36 - 7 2 .0 1 63.28 - 72.92 64.20 - 73.84 6 5 .1
59.05 - 7 3 .3 1 6 0 .15 - 74.40 6 1.24 - 75.49 62.33 - 76.58 63.42 -
data var cl25 cl30 cl35 cl40 cl45
pi amp II 3.11 - 6.63 3.02 - 6.54 2.93 - 6.45 2 .84 - 6.36 2.75
12 1.01 - 3.48 1.09 - 3.56 1.18 - 3.65 1.26 - 3.73 1.35
13 2.25 - 6 .0 1 2.25 - 6.02 2.25 - 6.02 2.26 - 6.02 2.26 -
14 1.38 - 3.95 1 .47- 4.05 1.56 - 4.14 1.66 - 4.23 1.75-
15 1.66 - 6.51 1.66 - 6.52 1.66 - 6.52 1.66 - 6.52 1.66
data cl50 cl55 cl60 cl65 cl70
p I amp 2.66 - 6.18 2.57 - 6.09 2.48 - 6.00 2.39 - 5.91 2.30 -
318
5.82
1 .43 - 3.90 1.51 - 3.99 1 .60 - 4.07 1 .68- 4.15 1 .77- 4.24
2 .2 6 -  6.03 2 .2 6 - 6.03 2.27 - 6.03 2 .2 7 -  6.03 2 .2 7 -  6.03
1 .84- 4.41 1.93 - 4.50 2.02 - 4.59 2.11 - 4.68 2.20 - 4.77
1 .66 - 6.52 1 .6 6 - 6.52 1 .6 6 - 6.52 1 .66- 6.52 1.67- 6.52
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data var cl25 cl30 cl35 cl40 cl45
pi amp 16 0.23 - 3.28 0.31 - 3.36 0 .3 8 - 3.44 0 .46 - 3.51 0.53
- 3.59
17 1.93 - 5.77 1 .91- 5.75 1.88 - 5.72 1.85 - 5.69 1.83 -
5.67
18 1.32 - 2.96 1.31 - 2.95 1.31 - 2.94 1.30 - 2.93 1.29 -
2.93
rl 2.60 - 5.30 2.59 - 5.30 2.59 - 5.29 2 .58 - 5.29 2.58 -
5.28
r2 0.94 - 2.54 0 .9 7 -  2.57 1.00- 2.61 1.03 - 2.64 1.06-
2.67
r3 2.44 - 5.11 2.40 - 5.07 2.36 - 5.04 2.32 - 5.00 2.28 -
4.96
r4 1.44 - 3.86 1.42 - 3.83 1.39 - 3.80 1.36 - 3.78 1.33 -
3.75
r5 3.14 - 6.28 3.05 - 6.19 2.96 - 6.10 2 .8 8 -  6.01 2.79 -
5.93
r6 1.44 - 4.30 1 .46 - 4.31 1.48 - 4.33 1 .50- 4.35 1.52 -
319
4.37
6.01
3.63
42.25
39.98
r7 3.36 - 6.32 3 .2 8 - 6.25 3 .20 - 6.17 3.12- 6.09 3.04
r8 1.33 - 3.61 1.34- 3.61 1.34- 3.62 1.35 - 3.62 1.35
data cl50 cl55 cl60 cl65 cl70
0.61 - 3.66 0 .6 8 - 3.74 0.76 - 3.81 0.83 - 3.89 0.91 - 3.96
1.80- 5.64 1.78- 5.62 1.75 - 5.59 1.72- 5.56 1.70- 5.54
1.29- 2.92 1 .28- 2.91 1.27 - 2.91 1.27- 2.90 1.26- 2.89
2 .57 - 5.28 2 .5 7 - 5.27 2.56 - 5.27 2 .56 - 5.26 2 .55- 5.26
1.09- 2.70 1.12- 2.73 1.15 - 2.76 1.18- 2.79 1.21 - 2.82
2 .25 - 4.92 2.21 - 4.88 2.17 - 4.85 2.13 - 4.81 2 .09- 4.77
1.31 - 3.72 1.28- 3.69 1.25 - 3.66 1.22- 3.64 1.20- 3.61
2 .70 - 5.84 2.61 - 5.75 2.52 - 5.66 2.43 - 5.57 2 .35- 5.48
1.54- 4.39 1.56- 4.41 1.58 - 4.43 1.60- 4.45 1.62- 4.47
2 .96 - 5.93 2.89 - 5.85 2.81 - 5.78 2.73 - 5.70 2 .65- 5.62
1.35 - 3.63 1.36- 3.64 1.36 - 3.64 1.37- 3.65 1.37- 3.65
data var cl25 cl30 cl35 cl40 cl45
pi imptim II 39.12 - 47.36 3 9 .9 1 - 48.14 40.69 - 48.93 41.47 -49.71
50.49
12 37.63 - 48.02 38.22 - 48.61 38.81 - 49.19 39.40 - 49.78
50.37
13 38.68 - 47.27 39.29 - 47.89 39.91 - 48.51 40.53 - 49.12
320
4 1 .1 5 -4 9 .7 4
14 38.96 - 47.37 39.52 - 47.93 40.08 - 48.49 40.65 - 49.05
41.21 -49.61
15 38.32 - 47.66 39.00 - 48.35 39.69 - 49.03 40.38 - 49.72
41.06-50.41
16 39.01 - 48.26 39.60 - 48.85 40.20 - 49.45 40.80 - 50.04
41 .39-50 .64
data cl50 cl55 cl60 cl65 cl70
p I imptim 43.04 - 5 1.27 43.82 - 52.06 44.60 - 52.84 45.38 - 53.62 4 6 .17
-54.40
40.57 - 50.96 4 1. 16 - 5 1.54 4 1.75 - 52 .13 42.33 - 52.72 42.92 -
53.31
52.83
52.42
53.84
53.61
4 1.76 - 50.36 42 .38  - 50.98 43.00 - 5 1.59 43.62 - 5 2 .2 1 44.24 -
4 1.77 - 5 0 .18 42.33 - 50.74 42.89 - 5 1.30 43.45 - 5 1.86 44.02 -
4 1.75 - 5 1.09 42.43 - 5 1.78 4 3 .12 - 52.46 4 3 .8 1 - 53.15 44.49 -
4 1.99 - 5 1.23 42.58 - 5 1.83 4 3 .18 - 52.42 43.77 - 53.02 44.37 -
80% Confidence Limits 18:35 Wednesday,
November 19, 2008 6
data var c!25 c!30 c!35 c!40 c!45
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42.04
39.56
42.81
41.05
41.59
42.30
40.73
39.99
40.80
41.11
54.68
54.61
p I imptim 17 3 9 .2 1 - 48.33 39.92 - 49.04 40.63 - 49.74 4 1.33 - 50.45
51.15
18 36.53 - 47.79 37.29 - 48.54 38.05 - 49.30 38.81 - 50.06
■ 50.82
50.48
-51.42
-49.81
49.66
■ 48.66
■ 48.97
• 48.95
■ 48.97
rl 39.61 - 47.28 40.41 - 48.08 41.21 - 48.88 42.01 - 49.68
r2 37.91 - 48.28 38.69 - 49.06 39.48 - 49.85 40.27 - 50.64
r3 38.50 - 46.72 39.27 - 47.49 40.04 - 48.27 40.81 - 49.04
r4 39.77 - 4 7 .13 40.40 - 47.76 4 1.04 - 48.39 4 1.67 - 49.02
r5 37.68 - 45.61 38.44 - 46.37 39.20 - 47.13 39.97 - 47.90
r6 37.09 - 46.08 37.81 - 46.80 38.54 - 47.53 39.26 - 48.25
rl 37.94 - 46.09 38.66 - 46.80 39.37 - 47.52 40.09 - 48.23
r8 37.93 - 45.79 38.73 - 46.59 39.52 - 47.38 40.32 - 48.17
data cl50 cl55 cl60 cl65 cl70
42.74 - 5 1.86 43.45 - 52.56 4 4 .15 - 53.27 44.86 - 53.98 45.57
40.32 - 5 1.58 4 1.08 - 52.34 4 1.84 - 5 3 .10 42.60 - 53.86 43.36 -
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54.47
55.36
53.67
52.81
52.48
52.59
52.53
52.94
43.61 - 51.28 44.41 - 52.07 45.21 - 52.87 46.01 - 53.67 46.80 -
41.84 - 52.21 42.63 - 53.00 43.41 - 53.78 44.20 - 54.57 44.99
42.36 - 50.58 4 3 .13 - 5 1.36 43.90 - 52 .13 44.68 - 52.90 45.45 -
42.93 - 50.29 43.56 - 50.92 4 4 .19 - 5 1.55 44.83 - 52 .18 45.46 -
4 1.49 - 49.42 42.26 - 5 0 .19 43.02 - 50.95 43.78 - 5 1.7 1 44.55 -
40 .71 - 49.70 4 1.43 - 50.42 4 2 .16 - 5 1. 15 42.88 - 5 1.87 43.60 -
41.52 - 49.67 42.23 - 50.38 42.95 - 51.10 43.67 - 5 1.8 1 44.38
4 1.9 1 - 49.76 42.70 - 50.56 43.50 - 5 1.35 44.29 - 52 .15 45.08 -
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The pilot data from the mfVEP is as detailed in Table A.2.2 below. This data was not 
divided into custom sectors but analysed in the conventional annuli. The mean 
experience score (and SD) as rated by the normal controls were 2.8 (1.5) and 3.6 (0.9) 
for the camera and monitor system respectively. All individuals rated the monitor 
system more highly.
Table A2.2 mfVEP Pilot Data For 20 Norm al C ontro ls Detailing Mean Raw Amplitude Values 
and Standard Deviation (SD)
Annulus
Location
1
nV (SD)
2
nV (SD)
3
nV (SD)
4
nV (SD)
5
nV (SD)
Group (n)
Camera
(20)
54.5 (20.3) 40.3 (17.2) 37.4(15.7) 35.2(18.2) 31.5(14.9)
Monitor
(20)
38.3 (15.2) 27.3 (15.3) 28.2(13.2) 26.7 (12.4) 22.5 (11.4)
A.2.3 Publications And Presentations
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BRIEF C O M M U N I C A T I O N
In utero exposure to  vigabatrin: No indication of visual 
field loss
•Charlotte Lawthom, •Philip E. M. Smith, and fjohn M. Wild
'W elsh Epilepsy Unit, University Hospital of Wales, Cardiff, U nited Kingdom; and fCardiff School of O ptom etry  
and Vision Sciences, Cardiff University, Cardiff, United Kingdom
SUMMARY
The purpose of the study was to determine 
whether in utero exposure to vigabatrin caused vi­
sual field loss.
Three mothers with four children who had been 
exposed to vigabatrin in utero and who were sub­
sequently formula fed were identified. All seven in­
dividuals underwent perimetry and imaging of the 
retinal nerve fiber layer (RNFL).
All individuals yielded reliable outcomes to  
perimetry and RNFL images of acceptable qual­
ity. Two of the three mothers exhibited vigabatrin-
attributed visual field loss and an abnormally at­
tenuated RNFL. The third exhibited an upper left 
quad ran tanopia, consistent with previous temporal 
lobe surgery, and a normal RNFL. All four children 
yielded normal visual fields and RNFL thicknesses.
The presence of the normal findings for the chil­
dren is reassuring and, if representative, suggests a 
lack of vigabatrin visual toxicity and therefore ob­
viates the need for ophthalmological examination 
of those exposed to vigabatrin prenataliy.
KEY WORDS: Vigabatrin, Visual field loss, Retinal 
nerve fiber layer thinning, Prenatal exposure.
The antiepileptic drug vigabatrin is associated with irre­
versible visual field loss (Eke et al., 1997). The prevalence 
of vigabatrin-attributed visual field loss is at least 30% 
(Kalviainen & Nousiainen, 2001) and increases with dura­
tion and extent of exposure to the drug (Wild et al., 2007). 
Vigabatrin-attributed visual field loss manifests as a bilat­
eral concentric constriction. In the mild to moderate stages, 
the field loss for static perimetry within the central visual 
field (i.e., within a radius of 30° from fixation) manifests 
as an annular defect at the extremities of the nasal field, ex­
tending to varying amounts above and below the horizontal 
midline, and also centripetally, with relative sparing of the 
temporal field. In the advanced stages, the defect is concen­
tric within the central field (Wild et al., 1999). Vigabatrin- 
attributed visual field loss is initially asymptomatic: the vi­
sual acuity remains normal or near-normal, and the nasal 
field loss is compensated by the relatively well-preserved 
temporal field in the contralateral eye.
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Perimetry is the “gold standard” for detecting vigaba­
trin toxicity. However, a developmental age of 9 years is 
usually necessary to understand the requirements of the 
examination, thereby excluding many children. In addi­
tion, 20%-25% of adults with epilepsy are unable to pro­
duce a reliable outcome. Fortunately, a structural mea­
sure, namely, attenuation of the retinal nerve fiber layer 
(RNFL) thickness as estimated by optical coherence to­
mography (OCT), identifies vigabatrin toxicity with seem­
ingly excellent sensitivity and specificity (Wild et al., 
2006). OCT is a noninvasive imaging technique that pro­
vides high-resolution cross-sectional images of the retina 
and is already used in the management of glaucoma and, 
increasingly, of multiple sclerosis. Vigabatrin toxicity has a 
characteristic pattern of RNFL attenuation: the nasal quad­
rant is seemingly universally affected, with or without su­
perior and/or inferior quadrant involvement, while the tem­
poral quadrant is spared. This appearance thus differs from 
the temporal quadrant atrophy seen in optic neuritis and in 
optic nerve head hypoplasia.
It can be surmised that, worldwide, a substantial number 
of women of childbearing age will have received vigaba­
trin. Uncertainty persists regarding the potential for visual 
dysfunction in individuals exposed in utero to vigabatrin. 
To our knowledge, only one report has described the out­
come of systematic visual field examination of prenataliy
1
2C. Lawthom e t al.
Table I. The dem ographics and results for the three families
Family I Family 2 Family 3
M other 1 D aughter l.l D aughter 1.2 M other 2 D aughter 2.1 M other 3 Son 3.1
Age a t assessm ent (years) 44.3 6.8 10.3 39.8 8.6 39.2 15.8
Vigabatrin gestational dose  (kg) 0.560 0.560 0.560 0.662 0.662 0.287 0.287
Vigabatrin dose  mg/kg/day equivalent 1200 1200 1410 600
Visual Field VAVFL N orm al N orm al VAVFL N orm al N orm al N orm al
Mean RNFLT (pm) 55 109 106 70 no 104 115
A bnorm al A bnorm al
Nasal quad ran t RNFLT (/xm) 31 102 81 34 71 74 76
A bnorm al A bnorm al
Bold type indicates an abnormal finding. VAVFL, vigabatrin-attributed visual field loss.
exposed individuals; two children, unrelated to each other, 
each yielded inconclusive visual field examinations (Sorri 
et al., 2005). However, many children exposed to vigaba­
trin prenataliy are now reaching the age where complete 
ophthalmological examination is possible. The aim of this 
case series was to assess whether vigabatrin-attributed vi­
sual field loss was present in children with in utero expo­
sure to vigabatrin.
M e t h o d s
Three families (four children) were identified in which 
each mother completed one or more successful pregnancies 
while receiving vigabatrin for refractory partial epilepsy. 
All four children were born at term and were exclu­
sively formula fed. Vigabatrin placental transfer, which 
may reach 100% (Tran et al., 1998; Abdulrazzaq et al., 
2001), represented the only mechanism of vigabatrin 
exposure.
The three mothers were aged 44.3, 39.8, and 39.2 years 
at the time o f the study. The duration of the refractory par­
tial epilepsy was 26, 17, and 24 years, and the duration 
of vigabatrin exposure was 8.5, 9.8, and 6.7 years, respec­
tively. The cumulative vigabatrin doses were 8.75, 10.50, 
and 7.32 kg, respectively, and the mean daily dose was 
2.82, 2.74, and 2.99 g, respectively. Two mothers (M2 and 
M3) had taken one other antiepileptic drug (carbamazepine 
in both cases) within the conception period which was con­
tinued throughout the pregnancy in the case of mother M3.
Three o f the four children were female. The ages of the 
children at the time of the study were 6.8, 10.3, 8.6, and 
15.8 years, respectively. Cumulative vigabatrin gestational 
dosage was recorded, and all three mothers reported com­
pliance with medication before and during pregnancy. The 
estimated in utero exposure to vigabatrin using area under 
the curve estimates for fetal growth is shown in Table 1.
Perimetry
Each o f the mothers underwent two-level (three zone) 
suprathreshold perimetry of the full field and threshold
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The appearance o f the central visual field o f the left 
eye (left) and o f the right eye (right) by threshold static 
automated perimetry fo r m other M l, exhibiting the 
typical binasal annular defect of vigabatrin-attributed 
field loss, illustrated in terms o f the gray scale (top) 
and o f the height (middle) and shape (bottom ) deviation 
probability maps. Abnormality is indicated by increasing 
levels o f gray and by the increasing darkness o f the 
symbols indicating the level o f probability associated 
w ith the measured value lying w ithin the normal range. 
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The printout of the abnormal peripapillary RNFL thickness (solid black line) displayed in terms of Cartesian coordi­
nates (left) for the right eye of mother MI (top left) and for the normal thickness of the right eye of her daughter 
(D I.2) (bottom left) and in terms of the various segmental displays (right). The associated percentiles for the normal 
range are indicated in color (yellow and red represent abnormality).
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perimetry o f the central field, as recommended by the mar­
keting authorization holder (Aventis Pharma, 2001), us­
ing the Humphrey Field Analyzer (Carl Zeiss Meditec, 
Dublin, CA, U.S.A.). Reliable outcomes to the visual field 
examination, in terms o f incorrect responses to the false- 
negative, false-positive, and fixation-loss catch-trials, were 
obtained in all three mothers. Each o f the children under­
went perimetry of the full field in an identical manner to 
that o f their mother. Reliable results were obtained in all 
four children.
Im aging  w ith O C T
The RNFL thickness was determined for each mother 
and child, using the RNFL Thickness 3.4 Protocol o f the 
StratusOCT (Carl Zeiss Meditec, Dublin, CA, U.S.A.). 
All scans exhibited the requirements o f a signal-to-noise 
ratio greater than 25 dB and at least 90% good quality 
A-scans.
The study had approval from the South East Wales 
Ethics Committee, and informed consent was obtained 
from each adult and, in the case of the children, from their 
legal guardians.
R e s u l t s
The three mothers and the four children were visually 
asymptomatic. The visual acuity and the fundus, examined 
through dilated pupils, were normal in each individual.
Two o f  the three mothers each exhibited bilateral 
vigabatrin-attributed visual field loss and an abnormally at­
tenuated RNFL thickness. The third mother exhibited a left 
upper temporal partial quadrantanopia, secondary to an an­
terior temporal lobectomy, and a RNFL thickness within 
the normal range.
All four children manifested normal visual fields. The 
mean and nasal quadrant RNFL thickness for each child 
were well within the normal range for young adults (the 
StratusOCT software does not contain a database for chil­
dren, although children are considered to exhibit compara­
ble RNFL thicknesses to adults).
The appearance o f the central visual field for mother 
M l, exhibiting typical vigabatrin-attributed field loss, is 
given in Fig. 1. The printout of the abnormal RNFL 
thickness for mother M l and o f the normal thickness of 
her daughter D1.2 is given in Fig. 2, top and bottom, 
respectively.
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D i s c u s s i o n
This is the first report of definitively normal visual fields 
in children exposed prenataliy to vigabatrin across a range 
of placental doses. The four children also each manifested 
a normal RNFL thickness.
Infants treated with vigabatrin for infantile spasms nor­
mally receive dosing regimens of 100-150 mg/kg/day. It is 
noteworthy that the estimates of the maximum fetal daily 
dosing of the four children were up to 10  times this amount 
(Table 1). However, infants exposed to vigabatrin after 6  
months of age are approximately 2.5 times more likely to 
exhibit vigabatrin toxicity compared with those exposed 
before 6  months of age (Westall et al., 2007), suggest­
ing a possible physiological immaturity effect. A possible 
explanation for the lack of visual dysfunction following 
high in utero exposure may reflect the lack of placental 
metabolism of vigabatrin, suggested by equal amounts 
of active and inactive enantiomers, in contrast to the 
maternal excess of active enantiomer (Challier et al., 
1992). The pathogenesis of retinal toxicity in vigabatrin 
is still not understood. It is speculative, but plausible, 
that the mechanism of toxicity requires vigabatrin metabo­
lites that may be absent in utero and relatively under­
produced in neonates. All children were exposed via pla­
cental transfer alone. No assertion can therefore be made 
regarding the safety of maternal breastfeeding while on 
vigabatrin.
In terms of the possible visual toxicity of vigabatrin, 
the findings are clinically reassuring and, if representa­
tive, obviate the need to identify and then ophthalmo- 
logically examine the children exposed to vigabatrin in 
utero. Furthermore, for women of childbearing age re­
ceiving vigabatrin, the findings can aid informed dis­
cussion about potential visual aspects of vigabatrin tox­
icity. The latter should also be placed in the context 
of possible unplanned pregnancy in women treated with 
vigabatrin as an antiaddiction drug (Fechtner et al., 
2006).
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Nasal Retinal Nerve Fiber Layer Attenuation: 
A Biomarker for Vigabatrin Toxicity
Charlotte Lawthom, M RCP ,1 Philip E. M. Smith, M D , FRCP,1 John M. Wild, PhD2
Purpose: To investigate whether nasal peripapillary retinal nerve fiber layer (RNFL) attenuation is associated i;
with visual field loss attributed to the anti-epileptic drug vigabatrin. j!
Design: Prospective cross-sectional observational study. j
Participants: Twenty-seven individuals with focal-onset epilepsy exposed to vigabatrin and 13 individuals 
with focal-onset epilepsy exposed to non-GABAergic anti-epileptic drug monotherapy. 1'
Methods: At one visit, suprathreshold perimetry of the central and peripheral field (3-zone, age-corrected \\
Full Field 135 Screening Test) and threshold perimetry of the central field (Program 30-2 and the FASTPAC j«
strategy) were undertaken for the right eye using the Humphrey Field Analyzer (Carl Zeiss Meditech, Dublin, CA). 2<
At a second visit, ocular coherence tomography was undertaken for the same eye using the 3.4 RNFL thickness 2
protocol of the StratusOCT (Carl Zeiss Meditech). 2 :
Main Outcome Measures: The magnitude, for each individual, of the RNFL thickness, averaged across the 2 :
4 oblique quadrants, and for each separate quadrant. 2
Results: Of the 27 individuals exposed to vigabatrin, 1 1  (group I) exhibited vigabatrin-attributed visual field 2
loss, 15 exhibited a normal field, and 1 exhibited a homonymous quadrantanopia (group II). All 13 individuals %
exposed to non-GABAergic therapy had normal fields (group ill). All individuals in group I exhibited abnormal 2
average and nasal quadrant RNFL thicknesses in the presence of a normal temporal quadrant thickness. Most 2 :
also exhibited additional RNFL attenuation in either the superior or inferior quadrant, or both. Four individuals in 2
group II exhibited an identical pattern of RNFL attenuation suggesting that nasal RNFL thinning is a more 3*
sensitive marker for vigabatrin toxicity than visual field loss. None of the 13 individuals in group III exhibited nasal 3
quadrant RNFL attenuation. 3:
Conclusions: Vigabatrin-attributed visual field loss is associated with a characteristic pattern of RNFL 3 ;
attenuation: nasal quadrant thinning and normal temporal quadrant thickness with or without superior or inferior 3.
quadrant involvement. Nasal attenuation may precede visual field loss. Ocular coherence tomography of the 3 ;
peripapillary RNFL should be considered in patients previously exposed to vigabatrin and at baseline and 3 ,
follow-up in those commencing vigabatrin for treatment of epilepsy or in trials for anti-addiction therapy. The y
pattern of RNFL thinning seems to be a useful biomarker to identify vigabatrin toxicity. 3 :
Financial Dlsdosurefs): Proprietary or commercial disclosure may be found after the references. y
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Vigabatrin is a highly effective antieplleptic drug1,2 li­
censed outside of the United States for the adjunctive 
therapy of focal-onset epilepsy. The first of the new 
generation of antiepileptic drugs, vigabatrin is a selective 
and irreversible inhibitor of the enzyme y-aminobutyric 
acid (GABA)-transaminase, which catalyzes the inacti­
vation of GABA. The increase in concentration of pre- 
synaptic GABA is thought to produce the anticonvulsant 
effect. Vigabatrin has been widely used beyond the initial 
licensing to include idiopathic generalized epilepsies, 
monotherapy prescription, and pediatric use. It is also of 
considerable benefit in West syndrome3 and seizures 
secondary to tuberous sclerosis.4 Vigabatrin, adminis­
tered over a short duration and at a low cumulative dose, 
has also been studied as an anti-addiction therapy for 
misuse of stimulant drugs;5 the elevated levels of GABA 
in the cortex reduce the extracellular dopamine increase, 
which is responsible for the heightened stimulatory effect 
in substance misuse.6
Eight years after its introduction, vigabatrin was found to ^
be associated with visual field loss.7 The prevalence of the ^
field loss is at least 30%8 and increases with the duration ^
and extent of exposure to the drug.9 Vigabatrin-attributed 4 .
visual field loss presents as a severe, bilateral/symmetric, 4 ,
“concentric” constriction of sudden/rapid, but variable time 4 ,
to, onset that affects the peripheral field (i.e., beyond a 5 ,
radius of 30 degrees from fixation) more nasally than tern- 5
porally. The field loss encroaches on the central field where 5 ;
it manifests, in varying extent of severity, as a characteristic 5 :
deep and steeply bordered bilateral nasal annulus with a 5 .
relative sparing of the temporal field. 10 In the severest 5:
manifestation, the defect is completely concentric to within 5 '
approximately 15 degrees from fixation. The field loss is 5'
usually asymptomatic: The predominandy nasal loss in the 5:
ipsilateral eye is compensated by the comparatively well- 5'
preserved temporal field in the contralateral eye, and the 61
visual acuity always remains normal or near-normal. 10 6
Once manifest, the field loss remains stable on with- &
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63 drawal of the drug11 and seemingly does not progress12
64 or progresses very slowly13 with continued vigabatrin
65 therapy. The visual electrophysiology14,15 and histopa-
6 6  thology16 of vigabatrin-attributed visual field loss indi-
67 cates a retinal origin. The nasal predominance of the field
6 8  loss is less obvious by kinetic perimetry.
69 As a consequence of the emerging reports of visual field
70 loss attributable to vigabatrin and the variable time to onset
71 of the defect, many patients were withdrawn from the drug;
72 however, a substantial number are still receiving treatment.
73 Vigabatrin is now only prescribed, de novo, for children,
74 learning-disabled adults, and the small number of adults
75 whose epilepsy is refractory to all other antiepileptic drugs.
76 At least 25% of adults with epilepsy and particularly those
77 exposed to vigabatrin are unable to perform perimetry be-
78 cause of their associated cognitive limitations. In addition,
79 noncompliance to perimetry is a problem in those children
80 and learning-disabled adults for whom treatment with viga-
81 batrin is particularly useful, thereby creating an ethical
82 dilemma. In other patients exposed to vigabatrin, the out-
83 come of the visual field examination is frequently inconclu-
84 sive and often requires 1 or more confirmatory examina-
85 tions, even after which the results often remain equivocal.
8 6  Thus, there are substantial numbers of patients in whom the
87 presence or absence of vigabatrin toxicity cannot be estab-
8 8  lished by perimetry.
89 The fundal abnormalities associated with vigabatrin-
90 attributed visual field loss are subtle when viewed by
91 fundoscopy. The field loss can occur in the presence of a
92 seemingly normal retina or normal optic nerve head. 17,18
93 However, field loss can also occur with optic nerve atro-
94 phy10,19-21 with or without 1 or more of a variety of retinal
95 abnormalities, including surface wrinkling retinopathy,21,22
96 peripheral retinal arterial narrowing, 10,22 peripheral retinal
97 hypopigmentation,23 irregular sheen at the macula,22 and thin-
98 ning of the retinal nerve fiber layer (RNFL) .20,21,24 The atten-
99 uation of the RNFL, by both fundoscopy21 and image enhance-
1 0 0  ment of fundus photographs,20 can show a nasal predilection
101 that can frequently be associated with corresponding secondary
1 0 2  nasal optic atrophy.
103 The subtlety and variation of the associated optic nave
104 head and retinal abnormalities preclude the use of fundal
105 examination by ophthalmoscopy as a biomarker of vigabatrin-
106 attributed field loss. Visual electrophysiology has identified
107 biomarkers of vigabatrin-attributed field loss, particularly the
108 30 Hz flicker electroretinogram;14,15 however, no one stand-
109 alone electroretinogram criterion possesses a clinically accept-
1 1 0  able sensitivity and specificity.
111 Measurement of the RNFL thickness using scanning laser
1 1 2  ophthalmoscopy,25,26 optical coherence tomography, 28 or
113 nerve fiber layer polarimetry29 shows considerable potential as
114 a biomarker for vigabatrin toxicity. However, such potential
115 is based on case histories,25,27 retrospective case analysis,28
116 or uncontrolled studies of small numbers of individuals with
117 field loss.29 Only 1 case-controlled prospective study has
118 been undertaken.26
119 Our case-controlled prospective study26 measured RNFL
120 thickness using ocular coherence tomography (OCT) with
121 the StratusOCT (Carl Zeiss Meditech, Dublin, CA) and the
1 2 2  proportional circle scan set at a scan radius corresponding to
the vertical diameter of the individual optic nerve head. At 
100% specificity, based on the 90% confidence interval 
from 2 0  age-matched normal individuals, the mean of the 
RNFL thickness over the circular scan yielded 100% sen­
sitivity for 13 individuals with vigabatrin-attributed visual 
field loss. However, 3 of 8  individuals exposed to vigabatrin 
but with normal fields and 2 of 14 individuals receiving 
carbamazepine monotherapy (a non-GABAergic antiepilep­
tic drug) and exhibiting normal fields also manifested mean 
RNFL thicknesses outside the apparent normal range. The 
former raises the possibility of an earlier manifestation of 
vigabatrin toxicity than the predominantly nasal field loss, 
whereas the latter questions the validity of the confidence 
intervals.
The Proportional Circle Scan is used with a scan diam­
eter based on a function of the vertical diameter of the 
individual optic nerve head. This is in contrast with the 
more commonly used alternative: a fixed scan radius that 
does not account for variation in the optic nerve head size. 
The former has die advantage of overcoming the between- 
individual differences in the topographic variation of the 
normal nerve fiber layer thickness, inherent with thq use of 
a fixed scan radius, and arising from between-individual 
variations in the size of the optic nerve head. However, only 
the fixed scan radius protocol benefits from the manufac­
turer's standardized and substantive generic database of 
normal values contained within the instrument software and 
available to all users. Thus, there is a pressing need to 
validate the previous findings of RNFL attenuation, ob­
tained with the Proportionate Circle Scan and the small 
proprietary database, 6 against the fixed scan radius and the 
corresponding generic database of normal values as a bi­
omarker of vigabatrin-attributed visual field loss, particu­
larly for the nasal quadrant
The purpose of the study was 2-fold: (1) to investigate 
the validity of retinal nerve fiber attenuation measured by 
OCR as a biomarker of vigabatrin-attributed visual field 
loss, with particular reference to a standardized set of ge­
neric normal values (i.e., those of the 3.4 RNFL thickness 
protocol of the StratusOCT); and (2) to determine whether 
retinal nerve fiber attenuation within the nasal quadrant is a 
more sensitive marker of vigabatrin-attributed visual field 
loss than that for the remaining quadrants.
Materials and Methods
The study used a cross-sectional prospective observational design.
Cohort
The cohort comprised 27 consecutively presenting individuals 
with focal-onset epilepsy (7 male and 20 female) and exposure to 
vigabatrin who had volunteered to take part in the study and 13 
consecutively presenting volunteers with focal-onset epilepsy (4 
male and 9 female), no exposure to vigabatrin or other GABAergic 
antiepileptic drugs, and current treatment with non-GABAergic 
monotherapy, primarily carbamazepine.
The mean age of the individuals exposed to vigabatrin was 39.6 
years (standard deviation, 14.1). This latter group included 3 
learning-disabled adults and 3 adolescents aged 13 years, 13 years,
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and 15 years. The individuals with no exposure to vigabatrin 
(designated as belonging to group HI) served as a control. The 
mean of this group was 47.8 years (standard deviation, 14.2).
Adults were recruited from the Welsh Epilepsy Unit, Univer­
sity Hospital of Wales, Cardiff, and adolescents were recruited 
from the Pediatric Neurology and Adolescent Services at the 
University Hospital of Wales, Cardiff. All individuals conformed 
to rigid inclusion criteria in each eye, including a distance refrac­
tive error of ^ 5  diopters mean sphere and <2.5 diopters cylinder, 
open angles, clear ocular media; no fundal or optic nerve head 
abnormalities characteristic o f known disease other than possible 
vigabatrin toxicity; no previous ocular surgery or trauma; and no 
history of diabetes mellitus and no family history of glaucoma. All 
individuals exhibited a visual acuity of 20/30 or better in each eye.
The individuals attended for 2 visits. Visual field examination 
of the right eye was undertaken at 1 visit, and RNFL imaging of 
the same eye was undertaken at a second visit The order of the 
perimetry and imaging visits was randomized between individuals.
Perimetry
Perimetry comprised 2 examinations: 3-zone, age-corrected su- 
prathreshold perimetry undertaken with the Full Field 135 Screen­
ing Test followed by threshold perimetry undertaken with Program 
30-2  and the FASTPAC strategy of the Humphrey Field Analyzer 
750 (Carl Zeiss Meditec). Distance refraction corrected, where 
appropriate, for the viewing distance of the perimeter bowl was 
used for examination of the central field. No correction was used 
for examination of the peripheral field (i.e., that beyond 30 degrees 
eccentricity). The left eye was covered with an opaque occluder. 
Individuals were given frequent rest periods, both throughout and 
between perimetric examinations, and occasionally required more ; 
than 1 visit to provide a conclusive visual field outcome.
Imaging «
Measurement of the RNFL thickness was undertaken using OCR 
with the Stratus OCT (Carl Zeiss Meditec) and the 3.4 RNFL 
thickness protocol. This approach undertakes 512 sequentially 
obtained A-scans in 1.3 seconds along a circle 3.4 mm in diameter 
positioned at the center of the optic nerve head. The contralateral 
eye was occluded, and individuals viewed the internal fixation 
target. The z-offset and polarization were obtained before each 
scan. Three scans were obtained, and the mean o f  the 3 scans was 
calculated by the instrument software. All scans exhibited a signal 
to noise ratio >25  dB and at least 90% good quality A-scans. The 
mean image was analyzed by Stratus OCT software Version 3.0. In 
addition, a single representative image was analyzed by Stratus 
OCT software Version 3.0 to produce an RNFL Thickness Aver­
age Analysis Report. The pupil o f the right eye was dilated, using 
tropicamide 1%, for all 10 individuals aged 55 years or more.
Analysis
The visual fields for each individual were evaluated by one of the 
authors (JMW), who was masked to the antiepileptic drag status and 
the results for the RNFL thickness and has 25 years of experience of 
interpreting the results of automated perimetry and 10 years of expe­
rience in interpreting vigabatrin-attributed visual field loss. In all 
cases, but particularly for those in whom the loss was concentric 
within the central field, the evaluation was confirmed by exclusion of 
all other potential or confounding ophthalmologic or neurologic 
causes determined at examination by the corresponding lead clini­
cians and based on standard investigative techniques, as appropriate, 
including ocular electrophysiology and brain im a g in g
Vigabatrin-attributed visual field loss was defined before the 
onset o f the study as a bilateral, symmetric, “concentric,” steeply 
sided absolute defect in the peripheral field, recorded by 2-level 
3-zone suprathreshold perimetry, consistent with the field loss in 
the central field recorded by threshold perimetry and with an 
appearance characteristic of that attributable to vigabatrin. In mild 
to moderate cases, the field loss characteristic o f vigabatrin in the 
central field extends, to varying amounts, in an annulus above and 
below the horizontal midline at the nasal extremities o f the central 
field and centripetally with varying amounts of sparing of the 
temporal field: In the most severe cases, the defect is completely 
concentric within the central field.
The RNFL thickness for each individual was analyzed in terms 
of the absolute values of thickness displayed in the RNFL Thick­
ness Average Analysis Report (i.e., the average thickness of all 4 
oblique quadrants and the thickness for each individual oblique 
quadrant) and in terms of the corresponding percentile (< ls t ,  
:£5tb, ^lOOth percentile) of the result within the manufacturer’s 
generic database of age-corrected normal values. The adolescents 
were compared with the percentiles for an 18-year-old because the 
StratusOCT software does not contain a database for individuals 
aged less than 18 years. Descriptive statistics of the magnitudes of 
the RNFL were used as appropriate.
Written informed consent was obtained from each individual 
after an explanation had been given o f the nature and possible 
consequences of the study. In the case of the adolescents and 
learning-disabled adults, written informed consent was obtained 
from the parent or legal guardian, as appropriate. The study had 
approval from the local institutional review board. The study 
adhered to the tenets of the Declaration of Helsinki.
Results
Of the 27 individuals exposed to vigabatrin, 11 exhibited vigabatrin- 
attributed visual field loss (group I), 15 exhibited normal fields, and 1 
exhibited a superior homonymous quadrantanopsia secondary to tem­
poral lobectomy (group H). Four individuals were receiving viga­
batrin at the time of the study (1 in group I and 3 in group II). Four
Table 1. Summary Measures of the Demographic Characteristics for Each of the 3 Groups
Group 
(No. of Individuals)
Gender
Male . Female
Mean Age (y) 
(SD; Range)
Mean Duration of 
Epilepsy (y) (SD)
Mean Duration of 
Vigabatrin (y) (SD)
Cumulative Dose of 
Vigabatrin (kg) (SD)
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Kl l )
II ( 1 6 )
III (1 3 )
4  7 4 1 .5  (1 1 .1 ;  2 0 .1 - 5 6 .4 )  2 5 .0 ( 6 .0 )
3  13 3 8 .3  (1 6 .1 ;  1 3 .4 - 6 2 .3 )  2 0 .1  (8 .4 )
4  9  4 7 .7  (1 4 .2 ;  2 2 .8 - 6 7 .4 )  2 2 .7  (1 1 .4 )
8 .8  (2 .3 )  
7 .6  (2 .8 )
9 .8  ( 2 .7 )
6.8 (2.6) 
0
S D  =  stan d ard  d e v ia t io n . t
G roup I com p r ises  in d iv id u a ls  e x h ib it in g  v ig a b a tr in -a ttr ib u ted  v isu a l fie ld  lo ss . G ro u p  II com p r ises  in d iv id u a ls  ex p o sed  to  v ig a b a tr in  b u t  w ith  n o  
vig ab a tr in -attr ib u ted  v is u a l fie ld  loss. G ro u p  III co m p r ise s  in d iv id u a ls  r e c e iv in g  n o n -G A B A e r g ic  a n t i-e p ile p t ic  drug th erap y  a n d  w ith  n o r m a l field s.
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Table 2. Summary Measures of the Retinal Nerve Fiber Layer Thickness Averaged Across the 4 
Quadrants and for Each Individual Quadrant
R e tin a l N e r v e  F ib er  L a y e r  T h ic k n e s s  ( m ic r o n s )  (G r o u p  M e a n , S D )
Group 
(No. of Individuals) Average Nasal Superior Temporal Inferior
Kl l ) 6 4 .0  ( 7 .6 ) 3 7 .1  ( 4 .8 ) 7 3 .9 ( 1 5 .4 ) 6 8 .5  (9 .7 ) 7 6 .2 ( 1 9 .4 )
1 1 (1 6 ) 9 1 .1  (1 1 .9 ) 6 2 .0 ( 1 4 .5 ) 9 8 .6  (2 1 .6 ) 7 9 .9 ( 1 6 .1 ) 1 0 3 .6 ( 1 7 .0 )
III (1 3 ) 9 3 .2 ( 1 1 .0 ) 7 4 .8 ( 1 5 .1 ) 1 0 7 .0  (2 0 .4 ) 7 1 .4 ( 1 3 .9 ) 1 1 7 .9 ( 1 7 .3 )
S D  =  stan d ard  d e v ia tio n .
G ro u p  I co m p r ises  in d iv id u a ls  e x h ib it in g  v ig a b a tr in -a ttr ib u ted  v isu a l f ie ld  loss. G ro u p  II co m p r ises  in d iv id u a ls  
e x p o se d  to  v ig a b a tr in  bu t w ith  n o  v ig a b a tr in -a ttr ib u ted  v isu a l field  loss. G ro u p  III co m p r ises  in d iv id u a ls  r ec e iv in g  
n o n -G A B A e r g ic  a n t i-e p ile p t ic  drug th erap y  an d  w ith  n o r m a l field s.
individuals in group I and 4 individuals in group II had taken part 
in the previous study of RNFL thickness using the Proportionate 
Circle scan.26 All 13 individuals in group III exhibited normal 
fields. The summary measures of the demographic characteristics 
ti for each of the 3 groups are given in Table 1.
All 27 individuals exposed to vigabatrin were able to undertake 
suprathreshold perimetry, and all exhibited incorrect responses 
within the normal range to each of the 3 types of catch trials. Two 
adolescents and 1 adult could not perform threshold perimetry. For 
threshold perimetry, 1 individual, exposed to vigabatrin but with 
normal fields, exhibited incorrect responses to the fixation loss 
catch trials that were outside of the normal range, although fixation 
mediated by the gaze tracker was considered stable. Two individ­
uals, both with vigabatrin-attributed visual field loss, exhibited 
incorrect responses to the false-negative catch trials that were 
outside of the normal range. Of these latter 2 individuals, 1 also 
exhibited incorrect responses to the fixation loss catch trials that 
were outside of the normal range, although fixation mediated by 
the gaze tracker was considered stable.
The summary measures (group mean, standard deviation, and 
range) of the RNFL thickness, as a function of quadrant, for each 
T2 of the 3 groups are given in Table 2.
The frequency, across individuals, of the magnitude of the 
percentile (<  1 st, ^5th, <  100th) associated with the measured 
value of the RNFL thickness for each quadrant in each of the 3 
T3 groups is given in Table 3.
All 11 individuals with vigabatrin-attributed visual field loss 
(group I) exhibited an abnormally attenuated RNFL (i.e., ^  1st or 
^5th percentile) when averaged across the 4 quadrants. All 11 
individuals also manifested an abnormal nerve fiber layer thick­
ness in the nasal quadrant; 7 of the 11 individuals exhibited 
additional abnormal thinning in the superior or inferior quadrant. 
All 11 individuals exhibited a normal RNFL thickness for the
temporal quadrant. An example, from an individual in group I, of 
the nasal attenuation and temporal sparing of the RNFL together 
with the appearance of the central visual field is given in Figure 1. fi
Twelve of the 16 individuals in group II (i.e., those exposed to 
vigabatrin but with normal visual fields and the individual with the 
temporal lobectomy but otherwise normal fields) exhibited a nor­
mal RNFL thickness when averaged across the 4 quadrants and for 
each individual quadrant. The remaining 4 individuals all exhibited 
abnormally attenuated average and nasal RNFL thicknesses in the 
presence of a normal temporal nerve fiber layer. Two of these 4 
individuals were 2 of the 3 individuals who had exhibited an 
abnormal nerve fiber layer in the previous study from our group 
using the variable scan protocol.
Ten of the 13 individuals in group III (i.e., those exposed to 
non-GABAergic anti-epileptic drugs) exhibited a normal RNFL 
thickness when averaged across the 4 quadrants and for each individ­
ual quadrant However, 3 of the 13 individuals each exhibited a 
normal average thickness but an abnormal thickness in only one of the 
superior, inferior, or temporal quadrants, respectively. The RNFL 
thickness in the nasal quadrant was normal for all 13 individuals.
A moderate correlation (r =  -0.47, P<0.01) was present 
between the RNFL thickness in the nasal quadrant and the cumu­
lative dose of vigabatrin (Fig 2). The magnitude of the correlation F2 
is limited by the floor effect of the retinal nerve fiber thickness 
measurement at approximately 35 to 40 /im, which presumably 
arises from glial cell hypertrophy replacing the nerve fiber layer30 
and from the finite thickness o f the internal limiting membrane.
Discussion
T his study confirm s that attenuation o f  the R N FL thickness, 
relative to  the m anufacturer’s generic database o f norm al
Table 3. Frequency, Across Individuals, of Magnitude of the Percentile (^  1 st, ^5th) of Measured Value of Retinal Nerve Fiber 
Layer Thickness, Averaged Across the 4 Quadrants and for Each Individual Quadrant
P e r c e n t ile
G r o u p  
( N o .  o f  I n d iv id u a ls )
A verage R N F L Nasal RNFL Superior RNFL Temporal RNFL Inferior R N F L
N  < 5 %  <=/% N ^5%  < 1 %  N  ^ 5 %  < 1 % N  < 5 % < 1 % N  < 5 %  < 1 %
Kl l ) 0  3  8 0  3  8 4  5 2 11 0 0 3 5 3
1 1 (1 6 ) 12 4  0 12 4  0 15 1 0 16 0 0 15 1 0
1 1 1(13 ) 13 0  0 13 0  0 11 2 0 12 1 0 12 1 0
R N F L  =  r e t in a l n e r v e  fiber layer th ick n ess ;  N  =  a n orm a l v a iu e y y  ( i .e . ,  > 5 t h  p e r c e n t ile ) .
G ro u p  I c o m p r ise s  in d iv id u a ls  e x h ib it in g  v ig a b a tr in -a ttr ib u ted  v isu a l field  lo ss . G ro u p  II com p rises in d iv id u a ls  e x p o se d  to  v ig a b a tr in  b u t w ith  n o
v ig a b a tr in -a ttr ib u ted  v isual field  loss. G ro u p  III com p r ises  in d iv id u a ls  r e c e iv in g  n o n -G A B A e r g ic  a n t i-e p ile p t ic  drug th erap y  an d  w ith  n o r m a l fields.
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F ig u r e  1 . V igab atrin -attribu ted  v isual field loss record ed  b efore  th e  stu d y  w ith  P rogram  2 4 -2  an d  th e  S I T A  Fast a lgor ith m  o f  th e  H u m p h rey  F ield  A n a ly zer  
(C a rl Z eiss M e d ite c h , D u b lin , C A )  (to p ), w ith  Program  3 0 -2  a n d  th e  F A S T P A C  a lg o r ith m  (m id d le  to p ) , an d  as part o f  th e  stu d y  for  o n ly  th e  r ight ey e  
w ith  P rogram  3 0 -2  an d  th e  F A S T P A C  algorith m  (m id d le  b o t to m ) . T h e  c o r r esp o n d in g  R N F L  a tten u a tio n  for o n ly  th e  right ey e  record ed  w ith  S tra tu sO C T  
(C arl Z eiss M e d ite c h )  (b o tto m ) an d  illustrated in  term s o f  th e  h e ig h t  p rofile  ( le f t )  a n d  qu ad ran t an d  sec to r  d istr ib u tion s (r ig h t).
values, is associated with vigabatrin-attributed visual field  
loss. Moreover, it shows that the toxicity is particularly 
associated with RNFL thinning in the nasal quadrant and 
preservation in the temporal quadrant.
The predilection for attenuation of the RNFL in the nasal 
quadrant with temporal quadrant sparing is in agreement 
with a characteristic pattern of peripheral RNFL atrophy, 
sparing of the central region, and corresponding secondary 
optic atrophy that has been found in some individuals with 
vigabatrin toxicity and labeled, variously, as “C-shaped” or 
“temporal sparing atrophy”20 or “inverse atrophy.”21 Such a 
pattern o f optic atrophy is distinct from that o f  acquired and 
congenital optic neuropathies. However, the inverse retinal 
nerve fiber atrophy o f vigabatrin toxicity is seemingly dif­
ficult to recognize using fundoscopy alone, and, when vis­
ible, probably indicates an advanced stage o f atrophy. Rec­
ognition can also be further confounded by the presence of  
coexisting optic nerve hypoplasia in some patients treated
with vigabatrin. Temporal quadrant nerve fiber layer atten­
uation is likely to be present only when the field loss is 
concentric within the central field.
The attenuation of the nasal quadrant RNFL and the pres­
ervation of temporal quadrant nerve fiber layer are compatible 
with the characteristics of the field loss attributable to vigaba­
trin, that is, a concentric constriction that, in the mild to 
moderate levels of severity, exhibits a nasal predominance and 
relative sparing of the temporal field. The attenuated nerve 
fiber layer in the nasal quadrant of the retina accounts for the 
temporal field loss. The retinotopic correspondence at the optic 
nerve head with the visual field is such that the retinal nerve fibers 
in the unaffected temporal quadrant largely originate from the 
papillomacular bundle and the fovea, whereas the temporal fibers 
corresponding to those locations that exhibit nasal vigabatrin- 
attributed visual field loss enter the optic nerve head immediately 
on either side of the superior pole (but with a slightly greater 
preponderance superior nasally) and nasally to the inferior pole.31
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Nasal Quadrant Retinal Nerve Fiber 
Layer thickness (pm) as a function of 
cumulative dose of vigabatrin (kg)
6 0
0 . 0  5 . 0  1 0 . 0  1 5 . 0
Cumulative dose of vigabatrin (kg)
20.0
F ig u r e  2 .  N a sa l R N F L  th ick n ess (m icrom eter) as a fu n ctio n  o f  cu m u lative  
dose o f  vigab atrin  (k ilogram s) for th e  16 patien ts exp o sed  to  v igabatrin  but  
w ith  n o  vigabatrin-attributed  visual field loss (open circles) and  th e  11 p atien ts  
m an ifestin g  vigabatrin-attributed  v isu al field  loss (r =  —0 .4 7 , P < 0 .0 1 ) .
A similar temporal quadrant nerve fiber layer preservation/sparing 
is also present in retinitis pigmentosa.32
The predilection for nasal quadrant nerve fiber layer 
thinning in vigabatrin toxicity, measured here by optical 
coherence tomography, is also compatible with that found 
by nerve fiber layer polarimetry.29
The mechanism of vigabatrin toxicity in the retina is 
unknown, and the etiologic agent may be vigabatrin itself, 
the resulting elevated level of GABA within the retina, or a 
combination thereof. The presence and pattern of nerve fiber 
layer atrophy may represent primary or secondary, ganglion 
cell body or nerve fiber, damage.
All 13 patients treated with non-GABAergic drugs mani­
fested a normal nerve fiber layer averaged across the quad­
rants. Such a finding is in agreement with the presence of a 
normal RNFL thickness in patients treated with the non- 
GABAergic anti-epileptic drug carbamazepine26 33 and the 
mildly GABAergic drug sodium valproate.26 33 However, 3 of 
the 13 individuals manifested an abnormally thin nerve fiber 
layer (<5th percentile) in the superior or inferior quadrant. No 
clinical reason was found for this mild attenuation. It is pos­
sible that the attenuation in these 3 cases may have arisen from 
transsynaptic degeneration because of a longstanding preexist­
ing cerebral lesion. It is also conceivable that transsynaptic 
degeneration may also be a confounding factor in the 
vigabatrin-exposed groups. However, as part of their 
ongoing care for epilepsy, all 40 individuals had under­
gone epilepsy protocol brain magnetic resonance imaging 
to identify intracerebral lesions. Only one individual, with 
the homonymous superior quadrantanopia secondary to a 
temporal lobectomy, had visual field loss attributable to an 
intracerebral lesion. She had received vigabatrin, but there 
was no visual field loss attributable to vigabatrin and her 
RNFL thickness was normal. We have also recorded a 
normal RNFL thickness in all 9 cases of a consecutive series 
of 9 individuals manifesting visual field loss from a cortical 
lesion. This suggests that transsynaptic degeneration of the
retinal ganglion cell axons is not present at all or is not 
identifiable with the resolution of the StratusOCT. A more 
likely explanation for the 3 cases of abnormally thin supe­
rior or inferior quadrant nerve fiber layer in the non- 
GABAergic group is inadvertent vertical misalignment of 
the patient or scan circle leading to an apparent reduction in 
the nerve fiber layer thickness in the region of the corre­
sponding vertical pole.
On the basis of the various findings, it would seem that 
an attenuated RNFL, measured by OCT, in at least the nasal 
quadrant combined with a normal nerve fiber layer in the 
temporal quadrant is a highly sensitive and specific indica­
tor of vigabatrin-attributed visual field loss. Because of the 
small numbers of individuals exposed to vigabatrin man­
aged at any one center, including our own, it will be difficult 
to estimate accurately the magnitude of the sensitivity and 
specificity. More precise estimates of the magnitudes will 
only become available as a consequence of a pooling of 
experiences between centers.
Four of the 16 individuals exposed to vigabatrin but exhib­
iting normal visual fields exhibited abnormally attenuated av­
erage and nasal quadrant RNFL thicknesses in the presence of 
a normal temporal quadrant thickness. This pattern of nerve 
fiber layer thinning is identical to that encountered in the 
individuals with vigabatrin-attributed visual field loss and sug­
gests that measurement of RNFL thickness, at least by OCT, is 
a more sensitive measure of vigabatrin toxicity than perimetry. 
The finding is not surprising given that structural abnormality 
manifests before functional abnormality in, for example, open 
angle glaucoma34 and multiple sclerosis.35
The proposed use of vigabatrin as an anti-addiction ther­
apy is based on short-term exposure (9 weeks and a total 
dose of 0.137 kg). Nevertheless, it would be advisable for 
such patients to undergo regular ocular examination, includ­
ing RNFL assessment.
The presence of nasal quadrant RNFL attenuation deter­
mined by OCT with the 3.4 RNFL thickness protocol can be 
used as biomarker of vigabatrin toxicity. The technique 
should be considered as a baseline and follow-up measure to 
augment perimetry in all patients commencing treatment with 
vigabatrin for epilepsy or substance abuse.5 It should also be 
considered to supplement the examination routine of those 
patients already exposed to vigabatrin. It is suitable for the 
assessment of vigabatrin toxicity in learning-disabled adults. 
For optimum interpretation of the findings in children, normal 
values will be required for the OCT generic database. In the 
absence of a definitive visual field result, the development of 
nasal RNFL attenuation should be considered as a clinical 
indicator for the evaluation of withdrawal of vigabatrin.
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